Entries |
Document | Title | Date |
20080206787 | Process to determine enzyme activity - The present invention provides for various processes for determining enzyme activity. In one embodiment, a process for detecting an enzyme activity includes contacting a blood component with a substrate comprising a cleavage site of the enzyme and a tag moiety to produce a sample comprising a cleavage product having a known mass, and placing the sample in contact with a SELDI sample chip which has surface moieties which bind to the cleavage product. In another embodiment, the process further includes subjecting the SELDI sample chip to SELDI mass spectrometry to identify the cleavage product. The present invention also provides for a kit which includes a SELDI sample chip having surface moieties capable of binding to an enzyme cleavage product. | 08-28-2008 |
20080213800 | Method for Examing Interstitital Cystitis - It has been found that the urine from an IC patient shows a high value in amount and the existence of activity of an azurophilic granular substance, thereby to establish a method for examining IC. The present invention relates to a method for examining interstitial cystitis using the kinetics of an azurophilic granular substance in urine as a marker. Also, the present invention relates to a kit for examining interstitial cystitis for use in the examination method, a use of an azurophilic granular substance as a test marker for examining interstitial cystitis or evaluating pharmacological effects of a drug, and a method for examining therapeutic effects on a patient with interstitial cystitis using an azurophilic granular substance as a marker. | 09-04-2008 |
20080227115 | Inhibition of cancer metastasis - The present invention relates to compositions and methods for cancer diagnosis, treatment and drug screening. In particular, the present invention provides compositions and methods for targeting the nuclear translocation of IkB kinase-α (IKKα) and the IKKα-mediated suppression of Maspin expression observed in metastatic prostate cancer cells. | 09-18-2008 |
20080227116 | Histaminase Determination - Disclosed is a method for determining histaminase (DAO; EC 1.4.3.6) activity in a sample. Said method comprises the following steps: an aqueous solution is supplied which contains a predefined amount of a diamine; the aqueous solution is mixed and incubated with the sample for a given period of time in conditions in which the diamine can be reacted with a DAO possibly present in the sample; the diamine is derivatized; the amount of derivatized diamine is determined; the predefined amount of diamine is compared to the amount of derivatized diamine; and the activity of histaminase possibly present is determined. | 09-18-2008 |
20080254485 | Methods And Compositions For Monitoring And Risk Prediction In Cardiorenal Syndrome - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function. | 10-16-2008 |
20080261238 | Method for Differentiation of Factor XIII Deficiency States in Relation to Fibrinogen Deficiency States Using Thrombelastographic Techniques - The invention relates to a method for determining a factor XIII deficiency, a method for determining a fibrinogen deficiency, and a method for differentiating between a factor XIII deficiency and a fibrinogen deficiency by means of thrombelastographic techniques. On the basis of the evaluation of the thrombelastographic parameters, a rapid and a selective substitution of factor XIII and/or of fibrinogen in deficiency states is possible. | 10-23-2008 |
20080261239 | DETECTING MOLECULAR INTERACTIONS - The present disclosure features a variety of compositions, kits, and methods that are useful for, inter alia, detecting and/or analyzing an interaction between two molecules, a target molecule and a target-specific binding agent which can be, e.g., proteins, nucleic acids, saccharides or polysaccharides, small molecules, or combinations of any of the foregoing. The compositions, kits, and methods can also be used, e.g., to detect the presence or absence of an enzymatic activity (e.g., a kinase activity, a protease activity, or a phosphatase activity) in a sample; to identify a compound that modulates an interaction between two molecules; or to identify compounds that modulate the activity of an enzyme. | 10-23-2008 |
20080261240 | METHOD - A method for attenuating a microorganism which comprises inhibiting in the microorganism a metabolic pathway essential for viability, by promoting use of the substrate of the pathway in a different metabolic pathway which is non-essential to the microorganism whereby the substrate is unavailable to the essential pathway and the micro organism is attenuated. | 10-23-2008 |
20080274476 | Assay Method - There is disclosed a method for determining the activity of gamma-secretase in a text subject, using a biological sample from the subject. | 11-06-2008 |
20080274477 | Forms of Factor Xiia - A 53 Kd novel form of factor XIIa and related products, including nucleic acid molecules, monoclonal and polyclonal antibodies and hybridoma cell lines. Also assays for a 53 Kd form of factor XIIa and uses of said assays in diagnostic and prognostic methods, for example in the prediction of survival following myocardial infarction. | 11-06-2008 |
20080274478 | NOVEL AROMATIC PRENYLTRANSFERASES, NUCLEIC ACIDS ENCODING SAME AND USES THEREFOR - In accordance with the present invention, a novel aromatic prenyltransferase, Orf2 from | 11-06-2008 |
20080293078 | Method For the Detection of Atp in a Sample With the Aid of Luminescene and a Computer Programme For That Purpose - The present invention relates to a method for detecting ATP in a sample by using luminescence, wherein a luminescence reagent is added to the sample that has not undergone any pre-treatment with an extractant in order to effect the formation of an ATP complex, wherein the luminescence of the ATP com lex thus formed is measured. | 11-27-2008 |
20080299584 | ONCOPROTEIN PROTEIN KINASE ANTIBODY KIT - An isolated polypeptide (JNK) characterized by having a molecular weight of 46 kD as determined by reducing SDS-PAGE, having serine and threonine kinase activity, phosphorylating the c-Jun N-terminal activation domain and polynucleotide sequences and method of detection of JNK are provided herein. JNK phosphorylates c-Jun N-terminal activation domain which affects gene expression from AP-1 sites. | 12-04-2008 |
20080299585 | METHODS FOR DETECTION AND MEASUREMENT OF SECRETORY PHOSPHOLIPASE A2 LEVELS (sPLA2) IN BIOLOGICAL FLUIDS - Elevated levels of secretory phospholipase A | 12-04-2008 |
20080311591 | Differential Immunoassay - The invention provides assay methods and kits that in general measure the level of a first analyte in a sample reduced by the level of a second analyte present in the same sample. In one embodiment, where levels of a first analyte from a first source is desirably determined and first analyte in the sample released from a second source is accompanied by proportional co-release of a second analyte, the assay identifies the level of first analyte released only from the first source. For analytes within bodily fluids, the assay can differentiate between elevated levels of analyte specific to the particular physiological or pathological state and elevated levels not specific to the particular state, providing single tests with diagnostic utility. | 12-18-2008 |
20090004675 | Method of Identifying Compounds for Bacterial Growth Modulation - The present invention relates to a method of identifying a candidate compound for modulating bacterial growth. This the method involves providing a β clamp peptide from a bacterial replicase, providing a second peptide that binds to at least one amino acid of SEQ ID NO:9 that is not designated X, wherein the second peptide does not exhibit polymerase activity, and providing a test compound. The β clamp peptide and the second peptide are contacted with the test compound, and the level of binding between the β clamp peptide and the second peptide in the presence of the test compound is determined. The level of binding between the β clamp peptide and the second peptide in the presence of the test compound is then compared to a control that does not contain the test compound. A test compound that alters the level of binding between the β clamp peptide and the second peptide compared to the control is a candidate compound for modulating bacterial growth. | 01-01-2009 |
20090011431 | Diagnosis of Sepsis by the Selective Determination of the Concentration of Cu/Zn Superoxide Dismutase (Cu/Zn Sod) in Patient Samples - The present invention relates to a method for the early determination of the risk of mortality of patients in intensive care units or emergency care units during which the concentration of Cu/Zn superoxide dismutase (Cu/Zn SOD) in a serum sample or plasma sample of the patient is selectively determined, and quantitatively or semi-quantitatively measured concentrations, which exceed a predetermined threshold value are correlated with a high risk of mortality. | 01-08-2009 |
20090011432 | Detecting and Profiling Molecular Complexes - Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex. | 01-08-2009 |
20090017467 | COMPOSITION EXHIBITING A VON WILLEBRAND FACTOR (vWF) PROTEASE ACTIVITY COMPRISING A POLYPEPTIDE CHAIN WITH THE AMINO ACID SEQUENCE AAGGILHLELLV - The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production. | 01-15-2009 |
20090035789 | MONITORING ENZYME MIXTURES - This invention provides a method for simultaneously detecting the presence of at least two enzymes in a sample, said method comprising the steps of; i) providing a first substrate for a first enzyme, said first substrate being labeled with a first fluorophore, ii) providing a second substrate for a second enzyme, said second substrate being labeled with a second fluorophore, iii) exposing the labeled substrates to the sample to allow the first and second enzymes present in the sample to interact with respective first and second fluorophore-labeled substrates to form respective first and second fluorophore-labeled substrate fragments; and, detecting the presence of said fluorophore-labeled substrate fragments. | 02-05-2009 |
20090053735 | Vector expressing n-deacetylase/n-sulfotransferase 2 - An object of the present invention is to provide an expression vector that allows for stable production of N-deacetylase/N-sulfotransferase 2 in large amounts and a process for production of N-deacetylase/N-sulfotransferase 2 using the same. The present invention provides a recombinant baculovirus expression vector obtained by incorporating into baculovirus DNA, a DNA fragment having lobster L21 DNA, DNA encoding gp67 signal peptide and DNA encoding the 79th to 883rd amino acids of human N-deacetylase/N-sulfotransferase 2 in this order in the 5′ to 3′ direction. | 02-26-2009 |
20090053736 | Homogeneous Chemiluminescent Immunoassay for Analysis of Iron Metalloproteins - The present invention relates to assays and kits for detecting or quantifying iron metalloprotein in test samples. | 02-26-2009 |
20090053737 | Monoclonal Antibody Which Binds Met In Formalin-Fixed and Paraffin-Embedded Tissues and Related Methods - In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided. | 02-26-2009 |
20090053738 | PROTEASE DETECTION - A method of detecting a protease in a sample. The method comprises providing an analyte degradable by the protease. The analyte is contacted with the sample. The degradation products of the analyte or the residual undegraded analyte is detected in a binding assay. | 02-26-2009 |
20090075298 | METHOD OF ANALYZING ENZYME - A method of analyzing an enzyme, comprising (1) bringing a sample suspected of containing an enzyme to be analyzed into contact with an enzyme substrate which is immobilized on an insoluble carrier and can be cleaved by the enzyme, in a liquid, (2) separating the insoluble carrier from the liquid, and (3) analyzing a substrate or a fragment thereof which remains on the insoluble carrier and/or a fragment of the substrate which is released from the insoluble carrier into the liquid; and a kit for analyzing an enzyme, comprising at least an enzyme substrate which is immobilized on an insoluble carrier and can be cleaved by the enzyme, are disclosed. | 03-19-2009 |
20090075299 | Diagnostic Methods - The present invention relates to methods of diagnosing cancerous conditions in a patient, as well as methods of monitoring the progression of a cancerous condition and/or methods of monitoring a treatment protocol of a therapeutic agent or a chemotherapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. | 03-19-2009 |
20090081702 | DISCRIMINATON OF CARDIAC DYSFUNCTION IN PREGNANT FEMALES - The present invention relates to a method for diagnosing if a pregnant woman suffers from a cardiac dysfunction, comprising the steps of a) measuring the level of a natriuretic peptide in a sample b) measuring the level of placental growth factor and/or sFlt-1 or a variant thereof in a sample, wherein an increased level of a natriuretic peptide and a decreased level of placental growth factor and/or an increased level of sFlt-1 or a variant thereof indicates the presence of a placenta-associated cardiac dysfunction, and wherein an increased level of a natriuretic peptide and a not decreased level of placental growth factor and/or a not increased level of sFlt-1 or a variant thereof indicates the presence of a cardiac dysfunction related to heart disease. The present invention also relates to an array, to an immunological rapid test, to the use of corresponding kits, and to methods for a decision support for the possible treatment of a pregnant woman suffering from a cardiac dysfunction. | 03-26-2009 |
20090081703 | METHOD FOR DETECTING DEEP VENOUS THROMBOSIS - A method for detecting deep vein thrombosis (DVT) in humans includes the steps of assaying a collected blood sample and measuring the amount of Lp-PLA | 03-26-2009 |
20090081704 | COMPOSITIONS, METHODS AND KITS FOR REAL-TIME ENZYME ASSAYS USING CHARGED MOLECULES - Compositions, methods and kits useful for, among other things, detecting, quantifying and/or characterizing enzymes. | 03-26-2009 |
20090087864 | Procedure for the determination of the activity of the protease which activates factor VII from protein solutions - A procedure for the determination of the activity of the protease which activates blood clotting factor VII from protein solutions is describes, in which
| 04-02-2009 |
20090098575 | The Human E3alpha Ubiquitin Ligase Family - The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3α ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products. | 04-16-2009 |
20090098576 | Feline Pancreatic Lipase - Isolated nucleic acid molecules having a nucleotide sequence encoding feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Isolated feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Host cells comprising a vector containing the polynucleotide sequences and methods for expressing the polypeptides. The generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of feline pancreatic lipase in a biological sample. The methods include using standards or calibrators of recombinant feline pancreatic lipase to quantify the lipase in a sample. Devices and kits for performing methods for detecting feline pancreatic lipase in biological samples. | 04-16-2009 |
20090098577 | METHOD OF IDENTIFYING COMPOUNDS THAT MODULATE CASPASE 9 ACTIVITY VIA USE OF A KOSMOTROPIC SALT - The present invention discloses methods for activating Caspase 9 in such a way that it can be used in assays to discover modulators of Caspase 9. | 04-16-2009 |
20090104627 | METHOD FOR DETERMINATION OF ENZYMATIC ACTIVITY - A novel modified polysaccharide, a solid phase to which the polysaccharide is adhered, methods for detecting N-deacetylase activity, N-sulfotransferase activity and N-deacetylase/N-sulfotransferase activity in a sample which utilizes said solid phase, and detection kits thereof. | 04-23-2009 |
20090104628 | Method for quantifying phosphokinase activity on proteins - The invention involves a method for measuring phosphorylation of proteins at specific sites and, as such, is an indicator of the protein kinase activity of enzymes capable of phosphorylating those sites. The method involves the in vitro or in vivo phosphorylation of a target protein at a specific serine, threonine or tyrosine residue, subjecting that protein (non-phosphorylated) to reaction mixture containing all reagents, including phosphokinase which allow the creation of a phosphorylated form of protein. The phosphorylated protein is measured by contacting it with an antibody specific for the phosphorylation site(s). The invention includes antibodies useful in practicing the methods of the invention. The invention particularly relates to all proteins modified by phosphorylation and dephosphorylation as illustrated by Tau, Rb and EGFR proteins and antibodies specific for the site of phosphorylation of the Tau, Rb or EGFR proteins. | 04-23-2009 |
20090111124 | Kinase peptides and antibodies - The invention relates to novel kinase peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of a kinase-mediated disease, as well as for determining or monitoring the efficacy of treatment. | 04-30-2009 |
20090117591 | Fibrosis Markers - The invention relates to the use of a combination of at least two markers that are selected from among Uromodulin, MAC2BP, AGP1 and Cathepsin A, for the in vitro detection of fibrotic alterations. In addition, the invention relates to a kit for determining the levels of said markers in a biological sample. | 05-07-2009 |
20090117592 | Altered Intracellular Localization of BRK/Sik Protein Tyrosine Kinase in Human Prostate Tumors - The invention provides methods for detecting abnormal prostate conditions, such as benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), and adenocarcinoma, in an animal by comparing the amount of the Breast Tumor Kinase (BRK) tyrosine kinase in the nuclei of prostate luminal epithelial cells in a test sample with an amount of nuclear BRK protein in epithelial cells of normal prostate glands. | 05-07-2009 |
20090123941 | METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents. | 05-14-2009 |
20090136969 | Lipoprotein Associated Phospholipase A2, Inhibitors Thereof and Use of the Same in Diagnosis and Therapy - The enzyme Lp-PLA | 05-28-2009 |
20090142776 | ANTIBODY FOR ASSAYING ADAMTS13 ACTIVITY AND METHOD FOR ASSAYING THE ACTIVITY - The subject of the present invention is to provide a useful antibody for measuring ADAMTS13 activity, in particular, a monoclonal antibody and a method for measuring ADAMTS13 activity. Further, another subject of the present invention also is to provide a monoclonal antibody which has specific reactivity to an antigenic determinant site produced by reacting ADAMTS13 with VWF that is a substrate or a partial peptide of VWF that is a potential substrate, but has no specific reactivity to the complete VWF molecule, and a use of the antibody of interest. Those subjects were achieved by succeeding in obtaining a monoclonal antibody (anti-N-10 monoclonal antibody) which has specific reactivity to a cleavage site that is cleavable by ADAMTS13 in the partial peptide of VWF, and further by finding a method for measuring ADAMTS13 activity using the monoclonal antibody of interest. | 06-04-2009 |
20090142777 | Reagents for the detection of protein phosphorylation in leukemia signaling pathways - The invention discloses 424 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Cytoskeletal proteins, Cellular Metabolism enzymes, G Protein/GTPase Activating/Guanine Nucleotide Exchange Factor proteins, Immunoglobulin Superfamily proteins, Inhibitor proteins, Lipid Kinases, Nuclear DNA Repair/RNA Binding/Transcription proteins, Serine/Threonine Protein Kinases, Tyrosine Kinases, Protein Phosphatases, and Translation/Transporter proteins. | 06-04-2009 |
20090148866 | Antibodies and Improved Test Sample Handling Methods for Use in Assays for Myeloperoxidase - The present disclosure relates to isolated antibodies that can be used in an assay to determine the concentration levels of myeloperoxidase (MPO) in a test sample. Additionally, the present disclosure also relates to the use of improved test sample handling methods in assays in order to preserve the original MPO levels in the test sample. | 06-11-2009 |
20090155814 | PROTEINS IN TYPE 2 DIABETES - The present invention relates to the use of naturally occurring compounds and derivatives thereof as markers for predisposition of diabetes related diseases. The invention also relates to a pharmaceutical composition for treatment of diabetes related diseases. | 06-18-2009 |
20090162870 | FATTY ACID SYNTHASE IN LIVER DISEASE - Methods and compositions for detecting elevated fatty acid synthase (FAS) expression in the liver of a subject are disclosed. The detection may be of expression in liver cells per se or in a bodily fluid of a subject. Also disclosed are methods for identifying the presence or absence of liver disease or pathology in relation to elevated FAS. The disclosed methods may be practiced with various compositions comprising reagents for detecting FAS expression as described herein. | 06-25-2009 |
20090162871 | Mutants of the factor VII-activating protease and detection methods using specific antibodies - Mutants of the DNA sequence coding for the protease (FSAP) which activates blood clotting factor VII and single-chain plasminogen activators, the mutants comprising a G/C base exchange at nucleotide position 1177 and/or a G/A base exchange at nucleotide position 1601, are described. The corresponding protease has a Glu/Gln exchange at amino acid position 393 and/or a Gly/Glu exchange at amino acid position 534. Diagnostic methods which are used for detecting FSAP in body fluids or tissue cells and also for identifying patients with genetic heterozygous or homozygous FSAP expression are also described. In addition, antibodies against FSAP and its mutants are disclosed and diagnostic methods which can be used to detect antibodies against FSAP and its mutants are specified. | 06-25-2009 |
20090170125 | Cellular assay method for identifying pkc-0 inhibitors - The invention relates to a method for investigating the modulating effect of a test substance on a PKCθ-dependent signal transduction pathway or for finding a PKCθ modulator in a human or animal cell, including the steps
| 07-02-2009 |
20090170126 | Prostasin Partial Peptide and Anti-Prostasin Antibody - An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen. | 07-02-2009 |
20090186367 | DIAGNOSIS OF FERTILITY CONDITIONS USING A SERINE PROTEASE - The present invention relates to a method of diagnosing an infertility condition in a human female subject, the method comprising detecting pregnancy-related serine protease (PRSP) protein in a test sample taken from said subject at between 7 and 20 weeks into pregnancy; detecting PRSP protein in a test sample from a fertile control mammal taken within the same period; and comparing the PRSP protein in the test sample with the PRSP protein detected in the control sample, wherein a change in PRSP protein in the sample compared to the control sample is indicative of an infertility condition. | 07-23-2009 |
20090203043 | Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways - The invention discloses 142 novel phosphorylation sites identified in insulin signaling pathways, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 08-13-2009 |
20090203044 | SPHINGOSINE-1-PHOSPHATE LYASE POLYPEPTIDES, POLYNUCLEOTIDES AND MODULATING AGENTS AND METHODS OF USE THEREFOR - Compositions, methods and kits for diagnosing and treating cancer are provided. Therapeutic compositions may comprise agents that modulate the expression or activity of a sphingosine-1-phosphate lyase (SPL). Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous SPL. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided. | 08-13-2009 |
20090215080 | METHODS FOR IDENTIFICATION OF INHIBITORS OF ENZYME ACTIVITY - The invention discloses compositions and methods of synthesis to create novel ligands and drugs and identifying such compounds as inhibitors of enzyme targets for use in the treatment of clinical disorders, including cancer, infectious diseases, parasitic infestations, neurological disorders, reproductive disorders, inflammatory disorders, circulatory disorders, and metabolic disorders. | 08-27-2009 |
20090220990 | METHOD AND KIT FOR DETECTING CONDITION IN PATIENT WITH DISTURBANCE OF CONSCIOUSNESS - A method for detecting a condition in a patient with disturbance of consciousness, by analyzing an amount and/or activity of a von Willebrand factor-cleaving protease, and a kit for detecting a condition in a patient with disturbance of consciousness, comprising an antibody or a fragment thereof which specifically binds to a von Willebrand factor-cleaving protease, or a von Willebrand factor or a fragment thereof, are disclosed. Examples of the detection of a condition include a detection of cerebrovascular disease, a detection of arteriosclerotic vascular disease, and a detection or prediction of severity. | 09-03-2009 |
20090233316 | Protein, An Antibody and Measurement of the Protein - A novel mammalian protein related to human hypothetical protein FLJ22662 (SEQ ID NO: 1) and homologous hypothetical proteins from mammal species other than | 09-17-2009 |
20090239242 | Method for the early identification and prediction of kidney injury - A method for the early identification and prediction of elevated blood creatinine levels resulting from a reduction in kidney function in a subject, comprises contacting a urine sample from the subject with a capture molecule for a biomarker specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of elevated blood creatinine levels resulting from a reduction in kidney function. The method can be used to detect Acute Kidney Injury (AKI) caused by many conditions or diseases or through the administration of drugs. The method can indicate and/or predict a reduction in kidney function significantly earlier than the current standard creatinine test. Methods for predicting a need for renal replacement therapy (RRT) are also disclosed. | 09-24-2009 |
20090253149 | Novel Chemistry Used in Biosensors - The invention relates to novel compositions and methods for the detection of analytes using the nuclear reorganization energy, λ, of an electron transfer process. | 10-08-2009 |
20090258374 | Multisignal Labeling Reagents, and Processes and Uses Therefor - The present invention provides multisignal labeling reagents and these are useful in a number of biochemical applications, including the manufacture of biomolecular probes and their use in detecting or amplifying analyte-specific moieties. | 10-15-2009 |
20090258375 | ASSAYS FOR DETECTING PREGNANCY-ASSOCIATED GLYCOPROTEINS - Disclosed are methods and compositions for detecting pregnancy in an animal by means of assaying peptidase activity of one or more Pregnancy Associated Glycoproteins (PAGs). In certain aspects, methods also comprising use of an antibody that binds immunologically to a PAG that displays proteolytic activity are provided. Substrates of proteolytic PAGs are also provided, as are kits, and methods of use. Further, methods of purifying PAGs based on their proteolytic activity are also provided. | 10-15-2009 |
20090263829 | ALZHEIMER'S DISEASE BIOMARKERS AND METHODS OF USE - The invention encompasses biomarkers for AD, a method for detecting AD, a method of monitoring AD, and a kit for quantifying biomarkers for AD. | 10-22-2009 |
20090263830 | VISUALIZATION AND QUANTITIATION OF CELLULAR CYTOTOXICITY USING CELL-PERMEABLE FLUOROGENIC PROTEASE SUBSTRATES AND CASPASE ACTIVITY INDICATOR MARKERS - This invention provides a non-radioactive assay to monitor and quantify the target-cell killing activities mediated by cytotoxic T lymphocytes (CTLs). This assay is predicated on the discovery that apoptosis pathway activation and, in particular, caspase activity, provides a measure of cytotoxic effector cell activity. In one embodiment, measurement of CTL-induced caspase activation in target cells is achieved through detection of the specific cleavage of fluorogenic caspase substrates. This assay reliably detects antigen-specific CTL killing of target cells, and provides a more sensitive, more informative and safer alternative to the standard | 10-22-2009 |
20090269784 | PROTEIN ENGINEERING OF MONOACYLGLYCEROL LIPASE (MGLL) - A number of soluble engineered forms of MGLL that are suitable for high-throughput screening and protein crystallization, as well as a crystallized form of monoacylglycerol lipase protein (MGLL) and descriptions of the X-ray diffraction patterns are disclosed. The engineered constructs of MGLL permit the expression and purification of protein suitable for crystallography or high-throughput screening and identification of ligands, which can function as active agents to MGLL. The X-ray diffraction patterns allow the three dimensional structure of MGLL to be determined at atomic resolution so that ligand binding sites on MGLL can be identified and the interactions of ligands with MGLL amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of MGLL. | 10-29-2009 |
20090286260 | MYELOPEROXIDASE DETECTION IN DIAGNOSIS AND PROGNOSIS OF HEMATOPOIETIC DISORDERS - The present invention relates to the diagnosis of hematopoietic disorders and to determining the prognosis of patients affected by such disorders. The methods generally comprise determining a level of myeloperoxidase in a body fluid sample from the individual and using the level as a factor for diagnosing the disorder in the mammal or as a factor for determining the prognosis of a patient diagnosed with such a disorder. Myelodysplastic syndrome, acute myeloid leukemia and chronic myeloid leukemia are exemplary disorders. Also provided are method of cancer therapy involving reducing the level of myeloperoxidase in the body fluid of the individual. | 11-19-2009 |
20090311719 | IN VITRO METHOD FOR DIAGNOSING NEURODEGENERATIVE DISEASES - Disclosed is an in vitro method for the detection, for the determination of the severity and for the assessment of the progress and prediction of neurodegenerative diseases, in which the presence and/or concentration of carbamoyl phosphate synthetase 1 (CPS 1) is determined in a biological fluid of a patient who suffers from a neurodegenerative disease or is suspected of suffering from such a disease, and conclusions about the presence, progression, severity or success of a treatment of the neurodegenerative disease are drawn on the basis of the determined presence and/or concentration of CPS 1 or the non-detectability of a CPS 1 immune reactivity. | 12-17-2009 |
20090317830 | HEPATITIS C VIRUS NS2/3 ASSAY - The present invention provides an assay for the detection of the NS2/3 cleavage products NS2 or NS3 in the presence of uncleaved NS2/3. Following self-cleavage of NS2/3 to generate NS2 and NS3 cleavage products, a sample is incubated with a ligand specific for the recognition of NS2 or NS3 cleavage product in the presence of uncleaved NS2/3. There is provided a method for detecting a NS2/3 autocleavage product in a sample containing NS2/3 protease, whereby the amount of bound ligand detected correlates with the NS2/3 autocleavage activity. A further aspect of the present invention concerns ligands selectively recognizing one of the NS2 cleavage product or the NS3 cleavage product with minimal cross-reactivity with the uncleaved NS2/3 and the other cleaved product. The present invention provides antibodies that selectively recognize one of cleaved NS2 product or cleaved NS3 product with minimal cross-reactivity with the uncleaved NS2/3 and the other cleaved product. | 12-24-2009 |
20090325193 | Diagnostic Test For The Detection Of A Molecule Or Drug In Whole Blood - The invention provides methods of preparing a test sample for use in an assay for detecting an analyte bound by an intracellular ligand. The methods typically involve contacting the test sample with an assay reagent comprising: a lysis reagent; and a protease that has proteolytic activity for said intracellular ligand; to form a mixture compatible for use in an immunoassay without subsequent extraction steps. Other aspects of the invention include related immunoassays and test kits. | 12-31-2009 |
20100015635 | IMMOBILISATION OF FLUORESCENT PROTEINS - The present invention concerns a method of detection of an analyte in which a protein capable of binding the analyte and comprising a fluorescent energy label and an energy acceptor moiety capable of accepting energy emitted by the label or protein by Forster energy transfer (FRET), is exposed to incident electromagnetic energy to excite the protein or label, and the fluorescent emission of the label is measured; characterised in that the protein is encapsulated in a biocompatible, optically transparent matrix which is permeable to the analyte, and in that the protein undergoes no substantial conformational change during the method; further characterised in that the energy acceptor moiety has a more active and less active state, which is determined by the presence of analyte, and the emission from the label is indicative of the presence of analyte. A biocompatible optically transparent matrix in which a protein capable of binding an analyte is also provided. | 01-21-2010 |
20100021939 | PROCESS FOR DETECTING ENZYME ACTIVITY IN AN IMMUNOASSAY - The invention relates to a process for detecting enzyme activity in an immunoassay comprising the following steps: | 01-28-2010 |
20100028907 | Novel Antigens and Antibodies Associated to Pancreatic Ductal Adenocarcinoma - The present invention provides novel human protein antigens and related antibodies that have been identified as being specifically expressed in association to human Pancreatic Ductal Adenocarcinoma (PDA). In particular, novel phosphorylated isoforms of alpha-enolase have been identified in transformed cell lines of pancreatic origin and antibodies binding such isoforms are specifically present in the sera of PDA patients. These proteins and antibodies can be useful for the diagnosis and the treatment of PDA and other cancers having common molecular features. | 02-04-2010 |
20100028908 | NOVEL DETECTION SYSTEM - The present invention relates to methods of making nanoarrays for use in detecting species formed on the surface of the array using SE(R)RS. The methods can involve nanolithographic printing of a compound by dip pen nanolithographic printing. A SE(R)RS substrate can be used for the array and which can be selected from surfaces roughened by the oxidation-reduction cycle (ORC), island films, colloidal nanoparticles and surface-confined nanostructures. A coating or intermediate layer, such as a layer formed of nitrocellulose, can be provided between the compound and the SE(R)RS substrate. There are also provided arrays themselves and methods of using such arrays. | 02-04-2010 |
20100041068 | DEEPLY QUENCHED ENZYME SENSORS AND BINDING SENSORS - Sensors for detecting enzyme activity are provided that include a substrate module comprising a substrate for the enzyme of interest and a fluorescent label, a quencher, and a detection module. The detection module binds to the substrate module either before or after the enzyme acts on the substrate and sequesters the label from the quencher, resulting in an increased signal from the label. Sensors for detecting protein-protein interactions are also provided that include a quencher and a labeled first polypeptide. Binding of the first polypeptide to a second polypeptide sequesters the label from the quencher, resulting in an increased signal from the label. Methods using the sensors to detect enzyme activity and to screen for compounds affecting enzyme activity or to detect protein-protein interactions and to screen for compounds affecting protein-protein interactions, respectively, are also described. | 02-18-2010 |
20100041069 | METHODS FOR DIAGNOSING AND MONITORING LIVER DISEASES - A method of diagnosing a liver disorder in a subject is disclosed. The method comprises determining a level of sH2A and at least one additional liver marker in a sample of the subject wherein a change beyond a predetermined threshold in both the sH2A and the at least one additional marker with respect to a sample from a healthy individual is indicative of the liver disorder. Kits for diagnosing a liver disorder are also disclosed. | 02-18-2010 |
20100047824 | CITRUS FRUIT PEELING PROCESS - An efficient process for enzymatically peeling citrus fruit applies a vacuum to perforated fruit and, while maintaining that vacuum, introduces an enzyme solution to the perforated fruit. The fruit is infused with the enzyme by releasing the vacuum pressure. After incubating the enzyme, the albedo of the fruit is weakened and the citrus peel can be readily removed. The peeled fruit may be divided into sections and the encompassing membrane removed. | 02-25-2010 |
20100055715 | Nucleic and amino acid sequences of prokaryotic ubiquitin-like protein and methods of use thereof - The present invention relates to prokaryotic ubiquitin-like protein (Pup) nucleic acid sequences and Pup amino acid sequences encoded therefrom. Also encompassed are antibodies that are immunologically specific for Pup. Methods directed to isolation and identification of pupylated substrates that utilize the conjugated Pup as an affinity tag are also included. Pupylated substrates that are identified using the method and reagents of the present invention provide tools useful for the identification of additional components of prokaryotic proteasomal machinery. Modulators of Pup activity and methods for identifying such modulators are also encompassed herein. | 03-04-2010 |
20100075342 | Biomarker for ovarian cancer CTAP3-related proteins - The present invention provides a protein-based biomarker that is useful in qualifying ovarian cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarker can be detected by SELDI mass spectrometry. | 03-25-2010 |
20100081147 | HUMAN CATECHOL-O-METHYLTRANSFERASE (COMT) ASSAY - Disclosed is an assay (method) to quantify the amounts of catecholamine-O-methyltransferase (COMT) protein in samples, such as extracts from cell cultures, body fluids, tissues, and environmental samples. It uses novel agents (anti-NE, COMT-NE, or COMT-epitope-NE) in combination with two previously described agents (anti-COMT and COMT) in a competitive ELISA system to achieve this aim. | 04-01-2010 |
20100086944 | Methods and Compositions for Diagnosis and Prognosis of Renal Artery Stenosis - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects in the context of renal artery stenosis (RAS). In particular, the invention relates to using assays that detect NGAL, their use to diagnose RAS in subjects suffering from hypertension, and their use in prognosis, particularly of mortality and worsening renal function. | 04-08-2010 |
20100099118 | METHODS OF DETERMINING TOTAL PON1 LEVEL - A method of determining an amount of total PON1 in a sample of a subject is disclosed. The method comprises:
| 04-22-2010 |
20100099119 | Detecting a Bacterial Process in Chronic Rhinosinusitis - The present invention provides a method for identifying bacterial induced rhinosinusitis. The method comprises obtaining a nasal or paranasal mucus sample and detecting the presence of neutrophil degranulation in the mucus sample. Degranulation of neutrophils can be determined by morphological analysis of the cells in the mucus or by detection of released (i.e., “free”) granule content markers such as neutrophil elastase or myeloperoxidase. Based on an accurate determination of the cause of sinusitis as described herein, an appropriate treatment can be instituted. | 04-22-2010 |
20100105076 | ANALYSIS KIT COMPRISING AT LEAST TWO MOLECULARLY IMPRINTED POLYMERS AND AT LEAST ONE MARKER, AND METHOD OF ANALYSIS USING SAME - The present invention relates to a kit for analysing at least one target molecule comprising at least a first molecularly imprinted polymer and a second molecularly imprinted polymer which are chemically identical or different, capable of interacting with the target molecule(s), and at least one marker, wherein said marker is either a competitive marker or marker capable of (i) of interacting with all or part of the recognition sites for the target molecule(s) of the second molecularly imprinted polymer and (ii) of being displaced from said recognition site(s) by the target molecule(s) when said molecularly imprinted polymer is placed in the presence of said target molecule(s), or an intrinsic marker or a constitutive unit of the second molecularly imprinted polymer, capable (i′) of interacting with all or part of the target molecule(s) when the latter interact(s) with all or part of its recognition sites for said target molecule(s) and (ii″) of consequently emitting a detectable signal. | 04-29-2010 |
20100112598 | Novel Assay for Inositol Phosphorylceramide Synthase Activity - Disclosed is a simple and reproducible method for assaying inositol phosphorylceramide synthase activity that employs a fluorescence resonance energy transfer pair for measuring enzyme activity. The invention also includes a novel method for identifying IPC synthase inhibitors. | 05-06-2010 |
20100120064 | ANTIBODY SPECIFIC TO INTACT HUMAN AUTOTAXIN, METHOD OF SCREENING THE SAME AND METHOD AND REAGENT FOR EXAMINING MALIGNANT LYMPHOMA BY ASSAYING AUTOTAXIN - A screening method is provided for antibody specifically recognizing naturally-occurring form of human autotaxin in a state in which it is present in the body without being denatured, comprising the steps of: binding a binding factor capable of capturing a candidate antibody of the antibody to a solid phase; binding the candidate antibody of the antibody to the binding factor; allowing naturally-occurring form of human autotaxin to react on a system in which the candidate antibody has reacted; and selecting an antibody that specifically recognizes the naturally-occurring form of human autotaxin by using as an indicator thereof the binding strength of the naturally-occurring form of human autotaxin to the antibody. Moreover, a detecting method for malignant lymphoma is provided comprising: measuring the concentration of autotaxin in a human specimen, and judging to be a malignant lymphoma in the case that value exhibits a significantly higher value than normal values comprised of measured values from normal healthy subjects. | 05-13-2010 |
20100120065 | METHOD FOR DETERMINING ENDOGLYCOSIDASE (HEPARANASE) ENZYME ACTIVITY - The present invention provides a method for determining endoglycosidase activity, and in particular of the heparanase type, in a sample, and also a method for detecting compounds that modulate the activity of endoglycosidases and in particular endoglycosidases of the heparanase type. | 05-13-2010 |
20100120066 | METHOD FOR DETECTING INTERACTIONS BETWEEN TWO AND MORE BIOLOGICAL MACROMOLECULES - Methods for detecting interactions of biomolecules include (a) preparing a cell comprising (i) a first construct comprising a bait, a first labeling material and a translocation module; and (ii) a second construct comprising a prey and a second labeling material; (b) detecting the distribution of the first construct and the second construct in the cell. The methods are simplified and show significantly high accuracy. | 05-13-2010 |
20100129832 | DETECTION METHOD AND DETECTION REAGENT FOR AUTOIMMUNE PANCREATITIS OR FULMINANT TYPE-1 DIABETES - By detecting an antibody which immunologically reacts with amylase α2-A in a sample, AIP or FT1DM is examined or the possibility of developing FT1DM is determined. Detection of this antibody is for instance carried out by an immunological method using an antigen which immunologically reacts with this antibody. The antigen is preferably a partial fragment containing the amino acid sequence of amino acid numbers 299 to 512 of human amylase α2-A. | 05-27-2010 |
20100136576 | In Vitro Method for Diagnosing Prostate Cancer - The invention relates to an in vitro method for diagnosing prostate cancer and to antibodies and fragments thereof directed against CK2-α and their use for the diagnosis and prognosis of prostate cancer. | 06-03-2010 |
20100136577 | COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF PROLIFERATIVE ABNORMALITIES ASSOCIATED WITH OVEREXPRESSION OF HUMAN TRANSKETOLASE LIKE-1 GENE - Methods for in vitro diagnosis of carcinoma are disclosed. In one aspect the invention relates to methods such as detecting the level of transketolase like-1 polypeptide, which are especially useful for the detection of tumors and their precursory stages based on the detection of overexpression of human transketolase like-1 gene in biological samples. In another aspect the invention relates to methods for treatment of disorders associated with the overexpression of human transketolase like-1 gene. Methods for treatment may include gene therapeutic approaches as well as methods for inhibiting or reducing the activity of transketolase like-1 polypeptides. | 06-03-2010 |
20100136578 | METHOD OF MEASURING THE ACTIVITY OF LIPID-MODIFIED ENZYME - It is intended to provide an assay method whereby the activity of a lipid-modifying enzyme can be conveniently measured over a wide range and a drug capable of controlling a lipid-modifying enzyme with the use of this assay method. The above problem can be solved by, for example, a method of measuring the activity of a lipid-modifying enzyme which comprises the steps of (I) preparing a lipid micelle containing a biotinylated lipid and a substrate for the lipid-modifying enzyme; (II) bringing the lipid micelle prepared in the above step (I) into contact with the lipid-modifying enzyme; and (III) evaluating the activity of the lipid-modifying enzyme by applying an evaluation method using the proximity effect to the product obtained in the above step (II). | 06-03-2010 |
20100136579 | BIOMARKERS USEFUL IN LIVER FIBROSIS DIAGNOSIS - Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and β-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis. | 06-03-2010 |
20100143940 | (3R)-HYDROXYACYL-ACP DEHYDRATASE ENZYMES USED IN THE BIOSYNTHESIS OF MYCOLIC ACIDS AND USE OF SAME FOR SCREENING ANTIBIOTICS - The invention relates to (3R)-hydroxyacyl-ACP dehydratase enzymes involved in the biosynthesis of mycolic acids, and to the use of same for screening antibiotics, medicaments that can be used to treat infections in humans or in animals, caused by | 06-10-2010 |
20100151494 | FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS - The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor. | 06-17-2010 |
20100159477 | Reagents for the detection of protein phosphorylation in signaling pathways - The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, adhesion/extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding/repair/replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G/regulator proteins, inhibitor proteins, motor/contractile proteins, phosphatase, protease, Ser/Thr protein kinases, Protein kinase (Tyr)s, receptor/channel/cell suface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function. | 06-24-2010 |
20100159478 | BIOMARKERS FOR CHRONIC VASCULAR DYSFUNCTION - Materials and methods for using biomarkers to determine prognosis and response to treatment in subjects having chronic vascular dysfunction. | 06-24-2010 |
20100159479 | TIMP-1 AS A MARKER FOR COLORECTAL CANCER - The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein TIMP-1 (tissue inhibitor of metalloproteinase 1) as a marker molecule in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual, the method involving measuring TIMP-1 in the sample. Measurement of TIMP-1 can, e.g., be used in the early detection or diagnosis of colorectal cancer. | 06-24-2010 |
20100159480 | BIOSENSORS, METHOD FOR OBTAINING THE SAME AND USES THEREOF - The invention relates to biosensors, methods for obtaining them and their use for detecting, assaying or locating, in direct immunofluorescence, a ligand such as an antigen or hapten, in a heterogeneous population. The biosensor includes (i) at least one fragment of a receptor which is protein in nature, capable of binding to a ligand via an active site, where at least one amino acid residues of the fragment located in the proximity of the active site is naturally present in the form of a cystein (Cys) residue, or is substituted with a Cys residue, and (ii) a fluorophore coupled to the Cys residue. | 06-24-2010 |
20100159481 | DETECTION OF HYPERTENSION USING GLUCURONIDATED METABOLIC PRODUCTS - A method of assessing arachidonic acid (AA) metabolites-dependent hypertension by measuring glucuronidated dihydroxyeicosatrienoic acids (DHETs) and DHET metabolites in a biological sample which contains the epitopes unique to DHET (using any methods including GC/MS, LC/MS or ELISA). An example of the glucuronidated DHET metabolite is DHET-alcohols such as omega or omega-1 oxidated DHET and DHET esterified glycerol. The method further includes determining the amount of glucuronidated molecules containing a DHET-specific epitope which is immunoreactive with antibodies produced against DHETs. | 06-24-2010 |
20100167310 | Reagent for Measuring Agglutination and Method of Measuring Agglutination - [PROBLEMS] To provide a reagent for measuring agglutination by using a reaction accelerator, which causes no spontaneous agglutination of receptor-sensitized carrier particles in the coexistence of these carrier particles, and a measurement method. | 07-01-2010 |
20100167311 | Oxidoreductases and Processes Utilising Such Enzymes - In Cu-containing nitrite reductase from | 07-01-2010 |
20100167312 | METHOD FOR ASSAYING A TARGET ANALYTE WHILE REDUCING INTERFERENCE IN AN IMMUNOSENSOR SYSTEM - An electrochemical immunosensor system with reduced interference, comprising: a first immunosensor that generates an electrochemical signal based on the formation of a sandwich between an immobilized antibody, a target analyte and a labeled antibody, wherein a portion of the signal arises from non-specific binding of the labeled antibody in the region of the first immunosensor, and
| 07-01-2010 |
20100184088 | METHODS OF IDENTIFYING AGENTS THAT MODULATE METHYLATION OF VEGFR1 BY SMYD3 - The present invention relates to methods for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of VEGFR1 by SMYD3. The invention further provides methods and pharmaceutical compositions for treating and preventing colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified. | 07-22-2010 |
20100184089 | DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL - A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF. | 07-22-2010 |
20100196926 | Combined Method And Kit For The Sequential Measurement of (1) The Enzymatically Active Fraction And (2) The Total Amount Of An Enzyme - The present invention is related to a combined method and kit (or device) for the sequential measurement of the enzymatically active fraction and the total amount of an enzyme [(such as myeloperoxidase (MPO)] in a sample, and that find improved applications in veterinary and human health fields. | 08-05-2010 |
20100203553 | Histochemical and biomarker for liver fibrosis - The histochemical and biomarker for liver fibrosis is a technique for determining the existence and extent of liver fibrosis by evaluating the extent of peptidylarginine deiminase (PAD) activity by immunological methods. The method is illustrated using liver biopsy. A small section of tissue from a liver biopsy is incubated overnight with a monoclonal antibody specific to PAD, stained, and examined microscopically. The number of hepatocytes that positively express PAD activity per one hundred hepatocytes is counted and expressed as a percentage. The percentage of PAD activity is then correlated with a METAVIR fibrosis score according to results from a statistically significant reference population. The degree of liver fibrosis and an appropriate treatment regimen may then be determined. | 08-12-2010 |
20100203554 | GENERIC KINASE/PHOSPHATASE ASSAY WITH SINGLE READOUT - The present invention relates to a generic method for detecting a kinase or phosphatase activity. The method comprises the following steps: incubating a kinase or phosphatase activity sample with a kinase or phosphatase substrate molecule comprising either a fluorophore having a detectable readout or molecule with an aromatic group which serves as a quencher of the fluorophore, incubating the mixture of step a) with a detection entity comprising either a fluorophore or a molecule with an aromatic group and a binding partner, wherein the substrate molecule and the detection entity are capable of binding to the binding partner and the binding of the substrate molecule and the detection entity to the binding partner lead to an altered readout of the fluorophore, and measuring the readout of the fluorophore in the mixture of step b), wherein an altered readout of the fluorophore compared to a blank is indicative for the presence of a kinase or phosphatase activity in the sample. | 08-12-2010 |
20100203555 | Wild-Type Receptor Assays - A method for determining ligand activation of receptors using cells expressing genetic constructs of a fusion protein of at least a binding domain of an auxiliary protein and a fragment of β-galactosidase, a fusion protein of an endosome-associated protein and a complementary fragment of β-galactosidase, and a wild-type receptor. The receptors are characterized by binding to the auxiliary protein-binding domain upon activation by an agonist and then endocytosing associated with an endosome to which the endosome-associated protein binds. Cells are incubated with a candidate ligand followed by lysis with a lysing medium comprising a substrate for the β-galactosidase. The enzyme product is then detected as a measure of the activation of the receptor. | 08-12-2010 |
20100209941 | METHOD, DEVICE AND KIT FOR DETERMINING CONDITIONS RELATED TO A DYSFUNCTION OF THE RENAL PROXIMAL TUBULE - A method, device and kit are disclosed for determining a condition related to dysfunction of the Renal Proximal Tubule (RPT) by detecting the presence of type III Carbonic Anhydrase, CAIII, in a urine sample of a subject. The method is used for diagnosis and to monitor the progress of a condition, and to determine the efficacy of a treatment. | 08-19-2010 |
20100209942 | NEW BIOMARKER FOR MONITORING DEVELOPMENT OF DISEASES AND ASSESSING THE EFFICACY OF THERAPIES - The invention concerns a method for monitoring the development of a disease in a patient, or for assessing the efficacy of a cytokine therapy or a statin therapy in a patient, in which methods CD73 in a tissue fluid drawn from said patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid. | 08-19-2010 |
20100209943 | Measurement Of Protease Activity In Post-Mortem Meat Samples - The present methods and systems relate to the placement on meat surfaces of a dye-linked protease substrate bonded in a defined location to a solid, porous support. Proteases in the meat hydrolyze the substrate, which then releases the dye, which diffuses away so that the extent of diffusion can be determined by imaging. Alternatively, the amount of dye released can be determined by its mobilization into a liquid medium. The present methods and systems also relates to determining the amount of hydrolyzed protein that is present in post-mortem meat samples. Agents which bond to hydrolyzed proteins, but not to unhydrolyzed proteins, are generated, wherein such agents comprise antibodies or aptamers. Such agents are then used in quantitative assays comprising ELISA tests or lateral flow tests. | 08-19-2010 |
20100216160 | METHOD FOR THE SCREENING PROTEASOME OF ACTIVITY-MODULATING AGENTS AND MEANS FOR CARRYIING OUT SAID METHOD - An in cellulo method for the screening of proteasome activity-modulating agents, includes the following steps of:
| 08-26-2010 |
20100216161 | Method for identifying protease inhibitors - The invention describes a method for assaying HCV NS3 protease activity using an NS3•4A protease molecule. The invention also provides a method for screening and identifying modulators of NS3 protease. | 08-26-2010 |
20100221747 | IMMUNOCHROMATOGRAPHY DETECTION OF MULTIDRUG-RESISTANT STAPHYLOCOCCUS AND DIAGNOSTIC KIT - It is intended to provide an immunochromatographic detection device which detects PBP2′ specifically produced by a multidrug-resistant | 09-02-2010 |
20100221748 | AMPK modulation as a method of regulating stem cell and cancer stem cell proliferation, self-renewal and differentiation - Methods are disclosed for decreasing stem cell proliferation, including cancer stem cell proliferation. These methods comprise administering to stem cells inhibitors of AMP activated protein kinase (AMPK). Methods for promoting stem cell growth by increasing stem cell proliferation, self-renewal and/or differentiation are also disclosed. These methods comprise administering AMPK activators to stem cells. Methods of achieving selective differentiation of stem cells are also disclosed. These methods comprise administering small molecules to stem cells that modulate AMPK activity. Applications of these methods are also disclosed, such as methods of increasing numbers of neuronal progenitor cells. These methods can be used therapeutically, such as for repair of spinal cord injuries, or for stimulating neurogenesis in the hippocampus, and other cell-based therapies. The methods can also be used for screening of compounds that can be activators or inhibitors of AMPK activity. | 09-02-2010 |
20100221749 | THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF - The invention relates to a three-functional pseudo-peptidic reagent, to the various uses thereof, in particular for preparing bioluminescent reagents or optionally luminescent bio-conjugates, to the use of said reagents and bio-conjugates for functionalising solid substrates, and to the use of solid substrates thus functionalised in the detection of molecules of interest. | 09-02-2010 |
20100227335 | MATRIX METALLOPROTEINASE-7 (MMP-7) MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF OVARIAN CANCER - Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MMP-7. Monoclonal antibodies having the binding characteristics of an MMP-7 antibody of the invention and monoclonal antibodies that bind to an MMP-7 epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce an MMP-7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed MMP-7 monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MMP-7 epitope of a disclosed monoclonal MMP-7 antibody and methods of using these polypeptides in the production of MMP-7 antibodies are also encompassed by the present invention. | 09-09-2010 |
20100233729 | DETECTING INTERACTIONS AT BIOMIMETIC INTERFACES WITH LIQUID CRYSTALS - A method of forming a liquid crystal device, includes: contacting an aqueous solution comprising a surfactant and a receptor molecule with a top surface of a liquid crystal. The liquid crystal is in a holding compartment of a substrate, and the receptor molecule is adsorbed on the top surface of the liquid crystal forming an interface between the liquid crystal and the aqueous solution. The receptor molecule is different than the surfactant. A method of detecting a compound in a flowing stream includes passing an aqueous solution over a top surface of a liquid crystal in a holding compartment of a substrate. The method also includes determining whether a change in the orientation of the liquid crystal occurs as the aqueous solution is passed over the top surface of the liquid crystal. A change in the orientation of the liquid crystal indicates the presence of the compound in the flowing stream. | 09-16-2010 |
20100240067 | APPARATUS AND METHOD FOR ASSAYING COAGULATION IN FLUID SAMPLES - This invention is a disposable cartridge for use at the patient side to perform traditional coagulation assays on fresh whole blood or blood derivative samples. The cartridge, in use with an electronic analyzer allows a fluid sample to be metered and quantitatively mixed with reagents which activate the coagulation cascade. An artificial substrate for thrombin, the enzyme whose action results in clot formation is also provided. Clot formation is subsequently detected using a microfabricated sensor also housed within the cartridge which detects electrochemically the product of the thrombin reaction upon the synthetic substrate. | 09-23-2010 |
20100240068 | MARKER PANEL FOR COLORECTAL CANCER - The present invention relates to a method for assessing colorectal cancer (CRC) in vitro including measuring in a sample the concentration and/or activity of a seprase polypeptide and/or fragments thereof and of either anti-p53 and/or osteopontin and/or ferritin, of optionally one or more other marker of CRC, and using the combined measurement result in the assessment of CRC. Furthermore, it especially relates to a method for assessing CRC from a liquid sample, derived from an individual by measuring seprase and at least anti-p53, ferritin and/or osteopontin in the sample. The method according to the present invention can, e.g., be used in the early detection of cancer by screening of asymptomatic individuals or in the surveillance of patients who undergo surgery. | 09-23-2010 |
20100248263 | BIOMARKERS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION - The invention relates to proteins associated with age-related macular degeneration (AMD). These proteins, which are present in blood, are expressed in individuals with AMD at either elevated or reduced levels compared to healthy individuals. The invention provides methods for diagnosing AMD. The invention provides methods for assessing the efficacy of treatment of AMD. The invention provides methods for monitoring the progression of AMD. | 09-30-2010 |
20100248264 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions - Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Automated systems for performing the methods also are provided. | 09-30-2010 |
20100261198 | METHODS OF DETECTION OF FACTOR XIA AND TISSUE FACTOR - The invention provides compositions and methods for the detection of Factor XIa or Tissue Factor (TF) activity in a sample using an antibody based clotting time prolongation assay. The invention provides methods for detection of FXIa or TF activity in a sample using a fluorogenic substrate. Further provided herein is a correlation between elevated levels of FXIa and/or TF with inflammation, acute coronary syndrome (ACS), myocardial infarction, coronary artery disease (CAD), heart failure, aortic stenosis, stroke, or transient ischemic attack. The frequency of FXIa and TF activity was substantially lower in individuals with stable coronary artery disease and no history of myocardial infarction. No FXIa or TF activity was observed in healthy individuals. | 10-14-2010 |
20100267054 | Measuring The Activity Of Proteases - A method and apparatuses for determining the total content of proteases by means of measuring their enzyme activity after previous deinhibition is disclosed. In biological samples, lysosomal proteases are completely (e.g. in blood serum) or partly (e.g. in tissue homogenates) inhibited. A method proposed for the deinhibition entails immersing a solid support material (e.g. nylon or nitrocellulose) as plastic strip to which is linked, covalently or by adsorption, an inhibitor-binding substance which binds the inhibitor corresponding to the protease more strongly than the protease in the sample for measurement. After the deinhibition has taken place, the plastic strip is removed from the liquid sample for measurement, and the sample for measurement is passed on for measurement of the enzyme activity. Fluorogenic substrates from which the fluorogen 7-amino-4-trifluoromethylcoumarin is eliminated proved to be particularly advantageous for the activity measurement. These substrates make it possible for the sensitivity on measurement in microtitre plates with a fluorescence reader to be at least 10 times higher compared with conventional AMC substrates in blood serum, and thus for the fluorimetric determination of such enzyme activities in blood serum to be efficient with this measuring arrangement which is widely used in clinical laboratories. | 10-21-2010 |
20100273186 | SPLIT MUTANT HYDROLASE FUSION REPORTER AND USES THEREOF - The invention provides polynucleotides encoding and polypeptides corresponding to split hydrolase fusion proteins, wherein the hydrolase sequence may include at least one substitution, and use of the split hydrolase fusion proteins. | 10-28-2010 |
20100273187 | ANTIBODIES AGAINST DELTA-5 DESATURASE AND USES THEREOF - Disclosed are antibodies that specifically recognize Δ5-desaturase, methods of producing the antibodies, nucleotides and polypeptides for producing the antibodies, and methods of using the antibodies. The Δ5-desaturase-specific antibodies provide improved methods of detecting Δ5-desaturase in a sample. | 10-28-2010 |
20100285502 | NOVEL AROMATIC PRENYLTRANSFERASES, NUCLEIC ACIDS ENCODING SAME AND USES THEREFOR - In accordance with the present invention, a novel aromatic prenyltransferase, Orf2 from | 11-11-2010 |
20100291590 | METHODS FOR THE DIAGNOSIS AND THE PROGNOSIS OF A BRAIN TUMOR - The present invention relates to methods for the diagnosis of a brain tumor and for the estimation of a prognosis for patients having a brain tumor using the presence/absence of a particular IDH1 mutation as a marker. | 11-18-2010 |
20100291591 | NOVEL PLATING MEDIA - Plating media contains enzyme substrates (ES) used to detect enzyme activity associated with a target organism and that include a binding motif (BM) that serves to bind detectable enzymes (DE) (also called marker enzymes in this disclosure). A signalogenic substructure (SG) produces detectable signals and an enzyme labile group (ELG) is labile to the action of a marker enzyme and it typically includes the binding motif. The enzyme labile group links to the signalogenic substructure via a labile bond (LB) which is cleaved by the action of the marker enzyme separating the signalogenic substructure and the enzyme labile group. In some embodiments a linker is inserted between the signalogenic substructure and the enzyme labile group. Presence of the enzyme and thus the organism is detected by presence of a fluorogenic, precipitate that can be detected in single colonies. | 11-18-2010 |
20100297665 | METHOD FOR TESTING AND SCREENING P38 MAP KINASE MODIFIERS - This invention provides methods for treating diseases associated with elevated p38 mitogen-activated protein kinase activity. Moreover, the invention provides methods for testing a candidate compound for a p38 mitogen-activated protein kinase modifying activity by calculating the level of relocalization of an SMN complex component from the cytoplasm to the nucleus of a cell. Additionally, the invention provides a kit and a system for calculating the same. | 11-25-2010 |
20100297666 | METHODS FOR DETERMINATION OF PROTEIN PHOSPHATASE ACTIVITY, AND USES IN PREDICTING THERAPEUTIC OUTCOMES - One aspect of the present disclosure encompasses methods for determining a protein kinase or phosphatase activity in a biological sample, comprising: contacting in a reaction mix a first test sample and a fluorescently-labeled peptide substrate capable of being modified by a protein phosphatase or a protein kinase, contacting the reaction mix with a TiO | 11-25-2010 |
20100297667 | METHOD FOR DIAGNOSIS OF DISEASE USING QUANTITATIVE MONITORING OF PROTEIN TYROSINE PHOSPHATASE - The present invention relates to a method for quantifying protein tyrosine phosphatase (referred as PTP hereinafter) in biosamples, precisely a diagnostic method for disease by quantifying PTP using mass spectrometry and profiling of comparative PTP levels. By quantifying PTP in biosamples and profiling thereof according to the method of the present invention, disease can be diagnosed and diverse disease conditions and health conditions can be confirmed via profiling. | 11-25-2010 |
20100297668 | HUMAN E3ALPHA UBIQUITIN LIGASE FAMILY - The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3α ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products. | 11-25-2010 |
20100304404 | MOLECULAR MODIFICATION ASSAYS - Systems for detecting molecular modifications and the presence and/or activity of enzymes and/or other agents involved in facilitating or otherwise regulating such modifications. | 12-02-2010 |
20100304405 | COMBINATORIAL DISCOVERY OF ENZYMES WITH UTILITY IN BIOMASS TRANSFORMATION - Methods for the cell-free identification of polypeptide and polypeptide combinations with utility in biomass transformation, as well as specific novel polypeptides and cell-free systems containing polypeptide combinations discovered by such methods are disclosed. | 12-02-2010 |
20100311081 | PREDICTING CANCER PROGRESSION - A method of predicting the likelihood of cancer relapse in a patient undergoing treatment for cancer is provided. The binding response level of an immunoreactive material (IM) comprising thymidine kinase 1 (TK1) protein is determined in a body fluid sample of a patient and the likelihood of relapse of the cancer disease is predicted based on this determined IM binding response level. Those patients that run a risk of cancer progress and relapse 1-15 years after the cancer treatment may be identified directly by the IM binding response level within a few months following initiation of the treatment. | 12-09-2010 |
20100317029 | Nasopharyngeal cancer malingancy biomarker and method thereof - The present invention discloses a nasopharyngeal cancer malignancy biomarker and a method thereof, wherein relative TP expression is used to evaluate the malignancy of nasopharyngeal cancer. The biomarker of the present invention assists the currently-existing inspections to find out cancer in the early stage and achieve early diagnosis and early therapy. The present invention also functions as an effective indicator to monitor the metastasis and relapse of nasopharyngeal cancer. | 12-16-2010 |
20100317030 | METHODS AND COMPOSITIONS FOR DETERMINING ENZYMATIC ACTIVITY - The present invention comprises crystalline polyketide synthases, isolated non-native polyketide synthases having the structural coordinates of said crystalline polyketide synthases, and nucleic acids encoding such non-native polyketide synthases. Also disclosed are methods of predicting the activity and/or substrated specificity of putative polyketide synthase, methods of identifying potential polyketide synthase substrates, and methods of identifying potential polyketide synthase inhibitors. | 12-16-2010 |
20100317031 | ULTRA-SENSITIVE CHEMILUMINESCENT SUBSTRATES FOR ENZYMES AND THEIR CONJUGATES - New chemiluminescent compounds, stable in aqueous buffers, for use in biological assaying include acridane-based compounds and 1,2-dioxetanes. Among the new acridane-based compounds are water-soluble acridanes, enhancer coupled acridanes, bis and tris-acridanes as well as acridane-1,2-dioxetanes. Among the new 1,2-dioxetanes are electron deficient group-containing dioxetanes and tethered bis-1,2-dioxetanes. The 1,2-dioxetanes are useful as substrates for various enzymes. The acridanes can be admixed with an oxidizing agent an aqueous buffer and, optionally, a stabilizer to form a substrate or reagent formulation useful for assaying, inter alia, HRP. | 12-16-2010 |
20100330588 | METHOD TO QUANTIFY METHYLTRANSFERASE ACTIVITY - The related disclosure pertains to a method to quantify methyltransferase activity. In an exemplar embodiment, the method may be carried out by the following steps: i) incubating a mixture comprising a methyltransferase, a substrate, and radiolabeled S-adenosylmethionine for a period of time sufficient for the protein methyltransferase to methylate and transform at least some of the substrate into a methylated product of the substrate, then ii) at one or more times removing an aliquot of the mixture, then iii) contacting the aliquot of the mixture to a resin capable of binding the methylated product of the substrate, followed by iv) a washing step to remove the unreacted radiolabeled S-adenosylmethionine, followed by v) an elution step to elute and isolate the methylated product, then vi) measuring the amount of radiolabel in the methylated product. | 12-30-2010 |
20110003312 | LINKED PEPTIDE FLUOROGENIC BIOSENSORS - Biosensors, compositions comprising biosensors, methods of producing biosensors, and methods of using biosensors are disclosed. The biosensors comprise a fluorogen-activating peptide and a blocking peptide. The fluorogen-activating peptide and blocking peptide are covalently linked through a peptide linker. The blocking peptide associates with the fluorogen-activating peptide thereby blocking an active domain of the fluorogen-activating peptide when the linker is in an unmodified state. The peptide linker may contain an amino acid sequence that is specifically recognized as a modification substrate by a cognate enzyme. The fluorogen-activating peptide and the blocking peptide at least partially disassociate when the linker is modified by an enzyme, thereby allowing the fluorogen-activating peptide to bind a cognate fluorogen and modulate a fluorescence signal. | 01-06-2011 |
20110014631 | METHOD FOR DIAGNOSING ACUTE CORONARY SYNDROME - This invention concerns a bioaffinity assay for quantitative determination in a sample of free PAPP-A, defined as the pregnancy associated plasma protein A (PAPP-A) that is not complexed to the proform of major basic protein (proMBP), wherein
| 01-20-2011 |
20110020839 | METHODS AND COMPOSITIONS FOR DETECTING THE ACTIVATION STATE OF MULTIPLE PROTEINS IN SINGLE CELLS - The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state. | 01-27-2011 |
20110027801 | EphA KINASE CANCER DIAGNOSTIC - A method of detecting malignant progression of neoplastic cells in an animal includes obtaining a sample of neoplastic cells from the animal, determining a level of S897-EphA2 phosphorylation in the neoplastic cells of the samplem, and comparing the determined level of S897-EphA2 phosphorylation in the sample to a control value, wherein an increased level of S897-EphA2 phosphorylation compared to the control value is indicative of malignant progression of the neoplastic cell in the animal. | 02-03-2011 |
20110045494 | CANCER DETECTION METHODS AND TECHNIQUES - A method is provided for detecting and/or measuring the occurrence of an enzyme in the form of CYP1B1 in a patient for the detection of cancer in said patient. The method includes the steps of administering a reporter substrate to a patient; taking a bodily fluid and/or tissue sample from the patient after one or more pre-determined periods of time; and analyzing the bodily fluid and/or tissue sample in vitro for the occurrence and/or measurement of a metabolite of the reporter substrate caused as a result of metabolism of the reporter substrate by said enzyme in said patient during said pre-determined period of time. | 02-24-2011 |
20110053178 | Methods and Compositions for Detection of Lethal Cell and Uses Thereof - The present invention relates to methods and compositions for identifying and detecting lethal cell useful for monitoring disease status and therapy response in various types of cancer patients regardless of the etiological origin of the cancer and uses thereof. | 03-03-2011 |
20110053179 | Biomarkers For Prediction Of Major Adverse Cardiac Events And Uses Thereof - The present invention relates to combinations of biomarkers and levels thereof that may be used, for example, in the determination of risk associated with the occurrence of a major adverse cardiac event (MACE) in a patient. | 03-03-2011 |
20110053180 | KINASE SENSORS - The present invention generally relates to compositions and methods for determining kinase activity. In some cases, the compositions comprise a triazole heterocycle. In some embodiments, the compositions comprise a quinoline moiety. In one aspect, the present invention is directed to compositions that undergo chelation-enhanced fluorescence (CHEF). In some cases, the compositions may have fluorescence emission spectra with peak maxima greater than 490 nm. The compositions of the present invention can be used, in certain embodiments, to detect phosphorylated substrates and biological processes such as phosphorylation events. | 03-03-2011 |
20110059465 | SCREENING ASSAYS FOR AGENTS THAT ALTER INHIBITOR OF APOPTOSIS (IAP) PROTEIN REGULATION OF CASPASE ACTIVITY - The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP. In addition, the invention provides methods of modulating the ability of a population of cells to survive ex vivo by contacting the cells with an agent that alters the caspase inhibitory activity of an IAP in the cells. | 03-10-2011 |
20110065127 | Detection of Degradative Enzymes and Biomolecules in Bodily Fluids - Provided herein are methods, kits and compositions useful in detecting degradative enzymes and biomolecules in bodily fluid samples. | 03-17-2011 |
20110070594 | Method for Detecting Escherichia coli - Described herein are methods of detecting an infection and for detecting the presence or absence of microorganisms, for example, wound pathogens in a sample, by contacting a sample with an enzyme produced and/or secreted by the bacteria, and detecting modification or the absence of modification of the substrate, as an indicator of the presence or absence of the enzyme in the sample. The present invention also features a biosensor for detecting the presence or absence of bacteria in a sample. | 03-24-2011 |
20110070595 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS - The present invention relates to immobilization compounds and methods useful for the identification of PARP interacting compounds or for the purification or identification of PARP proteins. | 03-24-2011 |
20110076692 | Detection of Cardiac Markers on a Droplet Actuator - The present invention provides for the detection of cardiac markers on a droplet actuator. An aspect provides a method of assaying a cardiac marker in a biological sample from a subject, the method including providing a droplet actuator, loading the biological sample and assay reagents on the droplet actuator, executing droplet operations to create sample droplets from the sample and reagent droplets from the reagents on the droplet actuator, and executing droplet operations using the sample droplets and reagent droplets to produce a detectable signal indicative of the quantity of the cardiac marker in the biological sample. Still other aspects are provided. | 03-31-2011 |
20110076693 | METHOD FOR DETECTION AND QUANTIFICATION OF PLK1 EXPRESSION AND ACTIVITY - Isolated peptide substrates of Plk1 and nucleic acids encoding these peptides are disclosed. The peptides include two to ten repeats of the amino acid sequence set forth as X | 03-31-2011 |
20110081659 | SUBSTRATES FOR GLYCOGEN SYNTHASE KINASE 3 ENZYMES AND METHODS OF USE - Methods and compositions for glycogen synthase kinase 3 assays continue to be required for detection of glycogen synthase 3 kinase, assessment of glycogen synthase 3 kinase activity and identification of modulators of glycogen synthase 3 kinase. Methods and compositions for glycogen synthase kinase 3 assays are provided herein based on the discovery of a previously unknown interaction between glycogen synthase 3 kinase and eukaryotic translation initiation factor 4E-binding protein 1 which serves as a substrate for glycogen synthase kinase 3-alpha and glycogen synthase kinase 3-beta. | 04-07-2011 |
20110097736 | METHODS OF DETERMINING LEVELS OF FREE AMINO ACID AND DIPEPTIDES AND DIAGNOSING ALZHEIMER'S DISEASES - Provided herein are methods of diagnosing Alzheimer's disease (“AD”) based on characteristic changes of the levels of certain free amino acids or dipeptides (collectively termed as “AD diagnosis markers”) in the body fluid sample of an individual, carnosine synthesis activities in the plasma, and dopamine synthesis activities in the plasma. Also provided are methods of simultaneously determining the levels of at least two free amino acids or dipeptides in the biological fluid sample of an individual. | 04-28-2011 |
20110097737 | Methods and Compositions for Targeting Proteins of Interest to the Host Cell Envelope - Methods and compositions are provided for producing membrane proteins or toxic proteins from recombinant DNA introduced into a prokaryotic host cell by targeting the expressed proteins to the envelope of the host cell. The methods and compositions utilize a protein vehicle fused to a protein of interest. The fusion protein may contain one or more protease cleavage sites to separate the protein of interest from the protein vehicle either in vivo or in vitro. The protein vehicle is characterized by a membrane-tar peptide and a trans-membrane segment separated by a cytoplasmic amino acid sequence that includes a cytoplasmic affinity-binding domain. | 04-28-2011 |
20110097738 | PLASMA BIOMARKER TOOL FOR THE DIAGNOSIS OF LIVER CANCER COMPRISING LIVER CARBOXYLESTERASE 1 AND LIVER CANCER SCREENING METHOD - The present invention relates to a plasma biomarker for diagnosing hepatocellular carcinoma (HCC), in particular to the discovery of a protein in plasma using 2-D fluorescence differential gel electrophoresis (2-D DIGE), immunoprecipitation and Nano-liquid chromatography mass spectrometry (Nano-LC-MS/MS) system that was unknown on the basis of conventional techniques. By demonstrating the presence of liver carboxylesterase 1 (hCE1) in human plasma and confirming that its secretion level is higher in patients with HCC than in healthy volunteers, this invention may be used as a screening method to diagnose HCC at an early stage. | 04-28-2011 |
20110104712 | Method for Assaying Plasma Enzymes in Whole Blood - The present invention relates to a method for assaying catalytic plasma enzymes, such as transaminases and NADH-dependent enzymes, in a sample of whole blood, by measuring, in a microfluidic chamber, the decrease in the fluorescence of NADH consumed during the enzymatic reactions catalyzed by the NADH-dependent enzymes. | 05-05-2011 |
20110111427 | BIOMARKER FOR THE ESTIMATION OF ACUTE RENAL DISORDER AND PROGNOSIS OF THE DISORDER, AND USE OF THE BIOMARKER - To provide a novel biomarker that is useful for prediction of early onset of acute kidney injury, estimation of prognosis associated with a renal function, and differentiation of acute kidney injury. Furthermore, to provide use of the novel biomarker. Midkine is used as a biomarker. The determination of a possibility of the onset of acute kidney injury, estimation of prognosis associated with a renal function or differentiation of an acute kidney injury are carried out based on the detection result of the urinary midkine. | 05-12-2011 |
20110124009 | COMPOSITION, KIT AND METHOD FOR ASSAYING NEUROPATHY - The present invention relates to a method for detecting a disease accompanied with neuropathy such as glaucoma, comprising measuring and/or detecting one or more of polypeptides shown in SEQ ID NOS: 1 to 15, mutants thereof, or fragments thereof in a biological sample from a subject, and also to a composition or kit for diagnosis of a disease accompanied with neuropathy such as glaucoma. | 05-26-2011 |
20110136137 | SERUM PROTEOMIC FOR FINDING DIAGNOSTIC MARKERS AND FOR MONITORING THERAPEUTICAL INTERVENTION IN TREATMENT OF HEPATOCELLULAR CARCINOMA - The invention is directed to biomarkers for determining the EGFR kinase activity in a subject, and the use thereof for predicting and monitoring therapeutic intervention in cancer patients. Areas of application are the life sciences: biology, biochemistry, biotechnology, medicine and medical technology. | 06-09-2011 |
20110136138 | METHOD FOR PREDICTING A NEED FOR RENAL REPLACEMENT THERAPY (RRT) - A method for predicting a need for Renal Replacement Therapy (RRT) in a patient comprises: determining a concentration of pi glutathione S transferase-(πGST) in a first urine sample from the patient; and wherein a need for RRT is predicted when the πGST concentration is determined to be elevated in comparison to a patient without kidney injury. The method according to the invention can further comprise detecting for the presence of risk factors for RRT in a patient, the risk factors including elevated serum creatinine concentration, type I diabetes, type II diabetes, hypertension, dyslipidemia, hyperglycaemia, proteinuria and hypoalbuminemia. | 06-09-2011 |
20110143368 | Tyrosine phosphorylation sites - The invention discloses 142 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 06-16-2011 |
20110143369 | METHOD FOR DETERMINING TREATMENT OF DISSEMINATED INTRAVASCULAR COAGULATION - A method for determining an appropriate treatment option for a patient who has been diagnosed with disseminated intravascular coagulation (DIC) but who may have thrombotic thrombocytopenic purpura (TTP), by analyzing the amount and/or enzyme activity of a von Willebrand factor (vWF)-cleaving protease (ADAMTS13) and the amount of vWF in a patient that has been diagnosed with DIC is disclosed. Using the method of the present invention, a differential diagnosis of patients with thrombotic thrombocytopenic purpura (TTP) can be made from among patients diagnosed with DIC, which could not previously be distinguished on the basis of only clinical findings or known markers. Also disclosed is a kit for determining an appropriate treatment option, the kit comprising an antibody or a fragment thereof which specifically binds to ADAMTS13. | 06-16-2011 |
20110151481 | BETA-2 MICROGLOBULIN AS A BIOMARKER FOR PERIPHERAL ARTERY DISEASE - The present invention provides β2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject. | 06-23-2011 |
20110159521 | METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The invention provides an ELISA assay for the determination of serum mast cell β-tryptase levels using rabbit anti-tryptase as the capture antibody and alkaline phosphatase conjugated G3 as the detecting antibody. Luminescent substrate CPSD was used to enhance the assay sensitivity. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of β-tryptase, histamine and/or prostaglandin E | 06-30-2011 |
20110165593 | Mutants of 06-Alkylguanine-DNA Alkyltransferase - The invention relates to AGT mutants showing, when compared to the wild type human AGT, two or more advantageous properties selected from (a) reduced DNA interaction; (b) localisation of the expressed protein in eukaryotic cells that is no longer restricted to the nucleus; (c) improved expression yield as soluble protein and improved stability in various hosts; (d) improved stability under oxidising conditions; (e) improved stability within cells after reaction with a substrate; (f) improved stability outside cells before and after reaction with a substrate; (g) improved in vitro solubility; (h) improved reactivity against O | 07-07-2011 |
20110165594 | SYSTEMIC MARKERS FOR ASTHMA AND ANALOGOUS DISEASES - Provided herein are diagnostic and prognostic methods, diagnostic and prognositic markers, and methods for evaluating anti-inflammatory agents or drugs in subjects with asthma and/or an analogous disease associated with high oxidative and nitrative stress at the disease site. In certain embodiments, the methods comprise a step of assaying for decreased levels of superoxide dismutase activity in the blood, serum, or plasma of the subject. In certain embodiments, the methods comprise a step of assaying for elevated levels of one or more oxidatively-modified SOD isoforms or species in the blood, serum or plasma of the subject. Also provided are diagnostic kits for use in the present invention. In certain embodiments, such kits comprise at least one binding reagent that specifically binds to at least one oxidatively-modified SOD species. | 07-07-2011 |
20110183357 | DEVICE AND METHODS FOR LIQUID CRYSTAL-BASED BIOAGENT DETECTION - The present invention provides liquid crystal-based devices and methods for bioagent detection. In certain aspects, the present invention is directed to devices and methods utilizing liquid crystals and membranes containing polymerized targets that can report the presence of bioagents including, but not limited to, enzymes, antibodies, and toxins. | 07-28-2011 |
20110189697 | RECOMBINANT CELLS AND PLANTS FOR SYNTHESIS OF VERY LONG CHAINS FATTY ACID (VLCFA) - The present disclosure is relative to a method for the production of Very-Long-Chain Fatty Acids (VLCFA) into a plant cell, including culturing a recombinant plant cell in an appropriate medium, wherein said plant cell is transformed with an heterologous gene encoding for an hydroxyacyl-CoA dehydratase. The disclosure is also relative to a method for producing vegetable oil including high levels of VLCFA. | 08-04-2011 |
20110189698 | Protein Biomarkers and Methods for Diagnosing Kawasaki Disease - A method, kit and device for diagnosing Kawasaki Disease are provided. The invention provides detecting an expression level of at least two Kawasaki Disease diagnostic biomarkers in a biological sample from a patient with a capture agent and diagnosing the patient as having Kawasaki Disease when the expression levels of the at least two diagnostic biomarkers in the patient biological sample are higher than the normal expression levels of the same biomarkers in a biological sample from a control subject. The first Kawasaki Disease diagnostic biomarker disclosed in the present invention is a cardiomyocyte biomarker, and the second Kawasaki Disease diagnostic biomarker is an inflammatory biomarker. The invention further provides detecting an expression level of a third biomarker, interferon type-I biomarker, in the patient biological sample with a capture agent and diagnosing the patient as having Kawasaki Disease when the expression level of interferon type-I biomarker is lower than the expression level in a control subject. | 08-04-2011 |
20110195432 | METHODS FOR THE SELECTION OF THERAPEUTIC TREATMENTS FOR CANCER - Methods are disclosed for identifying subjects that would benefit from treatment with an inhibitor of HDAC6 deacetylase activity. The methods can include contacting a sample obtained from the subject with an of HDAC6 deacetylase activity detecting the amount of HDAC6 protein present in the tumor sample in comparison with a control. Such methods can be used to determine if a tumor in a subject is sensitive to treatment with an inhibitor of HDAC6 deacetylase activity. Also disclosed are methods for monitoring a response to a cancer treatment. Such methods are particularly useful in selecting a compound or multiple compounds for the treatment of cancer in a subject. Methods are also disclosed for identifying agents that inhibit cancer. The methods can include contacting at least one cell with a test agent and detecting an amount of HDAC6 protein in the cell in comparison to a control. | 08-11-2011 |
20110201021 | USE OF THE IRAP PROTEIN FOR IMPLEMENTING METHODS OF DIAGNOSIS AND OF PROGNOSIS - The use of the IRAP protein for implementing methods of diagnosis and of prognosis. | 08-18-2011 |
20110201022 | ASSAYS FOR DETECTION OF PHENYLALANINE AMMONIA-LYASE AND ANTIBODIES TO PHENYLALANINE AMMONIA-LYASE - Provided herein are methods of detecting the presence of a pegylated enzyme, an enzyme-specific antibody (e.g., a neutralizing antibody or of a particular isotype), or a polyethylene glycol (PEG)-specific antibody in a sample, such as a bodily fluid or tissue of a patient. In certain embodiments, the enzyme is phenylalanine ammonia-lyase (PAL), such as | 08-18-2011 |
20110201023 | MANNOSE 6-PHOSPHATE-BINDING ANTIBODIES AND THEIR USES - The present invention relates to an isolated antibody or antigen-binding fragment thereof which specifically binds to mannose 6-phosphate and methods for preparing such antibody or antigen-binding fragment thereof. The invention further relates to a nucleic acid molecule encoding such antibody or antibody fragment, an expression vector comprising such nucleic acid molecule and a host cell comprising such nucleic acid molecule or expression vector. The invention also relates to a method for purifying or concentrating a target molecule comprising at least one mannose 6-phosphate residue from a sample. In another aspect, the invention relates to a method for diagnosing a disease which is characterized by an absent or reduced modification of molecules with mannose 6-phosphate residues. Finally, the invention relates to the use of an antibody or antibody fragment of the invention for use in medicine, in particular for the diagnosis of a disease which is characterized by an absent or reduced modification of molecules with mannose 6-phosphate residues. | 08-18-2011 |
20110212465 | ARMET AS A MARKER FOR CANCER - Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery. | 09-01-2011 |
20110217719 | METHODS AND KITS FOR DIAGNOSING OBSTRUCTIVE SLEEP APNEA - The presently-disclosed subject matter provides methods and kits for diagnosing obstructive sleep apnea (OSA) in a subject, such as a human child, wherein a biological sample is provided from the subject and the amount of a Urocortin III peptide is determined from the sample. Further provided are methods for diagnosing OSA in a subject wherein the amount of a Urocortin III peptide and one or more peptides selected from a Uromodulin peptide, an Orosomucoid 1 peptide, and a Kallikrein 1 peptide are determined in a biological sample from a subject. | 09-08-2011 |
20110223616 | HuR-Associated Biomarkers - The present invention relates to methods of identifying gene targets, including methods of using ribonucleoprotein (RNP) immunoprecipitation-microarrays to identify cancer gene targets, such as subsets of RNP-associated mRNAs in breast cancer cell lines. Also presented, are ribonucleotide binding protein-associated biomarkers, panels or sets of ribonucleotide binding protein-associated biomarkers, methods and compositions comprising ribonucleotide-binding protein, associated nucleotides, nucleotide arrays, and kits to facilitate the diagnosis of and monitoring the disease status or progression of treatment of breast cancers, including drug-resistant breast cancers. | 09-15-2011 |
20110229911 | AZUROPHILIC GRANULE PROTEASES AS MARKERS IN CARDIOLOGICAL DISEASES - The present invention is concerned with an assay for detecting and/or determining the level of a protease from azurophilic granules of polymorphonuclear neutrophils or a complex thereof with an endogenous inhibitor for risk stratification and/or prognosis and/or therapy control and/or monitoring of a patient having a cardiological disease or condition. | 09-22-2011 |
20110236908 | TOTAL PLASMA FVII/FVIIA LEVELS AS INDICATORS OF PRE-ECLAMPSIA OF PREGNANT FEMALES - Raised total plasma FVII protein, including activated FVII (FVIIa) in pregnant females, compared with total plasma FVII protein in normal pregnancy, has been found to be an indicator of the pregnancy complication of pre-eclampsia. | 09-29-2011 |
20110269150 | Compositions and methods for predicting cardiovascular events - The present invention provides compositions, devices, kits, and methods for determining the risk of peri-operative cardiovascular events or predicting cardiovascular events associated with angioplasty. In certain embodiments, the present invention provides methods, compositions, kits, and devices configured for determining the value of at least two markers selected from myeloperoxidase (MPO), an F2-isoprostane (F2-IsoP), C-reactive protein (CRP), urinary micro-albumin (UMA), and lipoprotein-associated phospholipase A2 (Lp-PLAZ), such that a subject's risk of experiencing a cardiovascular event is determined. | 11-03-2011 |
20110281279 | CIRCULATING Epha2 RECEPTOR - Provided are compositions, methods, and kits relating to the detection of a circulating or soluble form of the EphA2 receptor tyrosine kinase. | 11-17-2011 |
20110281280 | Methods and Compositions for Monitoring and Risk Prediction in Cardiorenal Syndrome - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function. | 11-17-2011 |
20110287449 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE - Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from healthy controls. Such comparison characterizes the test subject's risk of developing CVD. | 11-24-2011 |
20110294141 | METHOD FOR ANALYZING PSA AND METHOD FOR DISTINGUISHING PROSTATE CANCER FROM PROSTATIC HYPERTROPHY USING THAT METHOD FOR ANALYZING PSA - A method for distinguishing prostate cancer from prostatic hypertrophy using the method for analyzing PSA and an analysis kit of PSA are provided. | 12-01-2011 |
20110300556 | MONOCLONAL ANTIBODIES DETECTION METHODS FOR ENZYMES THAT CONFER RESISTANCE TO 2,4-DICHLOROPHENOXYACETIC ACID IN PLANTS - Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of an aryloxyalkanoate dioxygenase enzyme. | 12-08-2011 |
20110306058 | METHOD FOR THE FUNCTIONAL MEASUREMENT OF PLASMATIC THROMBODULINE ACTIVITY - A method for the in vitro measurement of the thromboduline functional activity, includes dosing in a biological medium, and from a biological sample, the thrombine-activation of C protein into activated C protein (PCa) in the presence of its co-factor or the thromboduline, the method including adding to the sample plasma the agents necessary for activating the C protein system, adding purified C protein and also adding a fibrin polymerisation inhibitor. Also described is application of the method in the detection of coagulation pathologies. | 12-15-2011 |
20110306059 | COMPOSITIONS AND METHODS FOR MEASURING 3,6-L-AHG TRANSFERASE ACTIVITY AND 3,6-L-AHG - Provided herein are a composition for measuring 3,6-anhydro-L-galactose (3,6-L-AHG) transferase activity by reduction of NADP to NADPH, and a method of measuring 3,6-L-AHG transferase activity using the same. The composition and method are useful for determining 3,6-L-AHG in a material containing 3,6-L-AHG such as algae biomass and industrial applications. | 12-15-2011 |
20110306060 | PCSK9 IMMUNOASSAY - Methods of using PCSK | 12-15-2011 |
20120003665 | Dissolved Protein Arthritis Markers - Methods and kits for diagnosing arthritis are provided. The methods may involve detection of 14-3-3 eta or gamma proteins in a sera or synovial fluid sample. | 01-05-2012 |
20120009592 | ENPP1 (PC-1) GENE HAPLOTYPE ASSOCIATED WITH THE RISK OF OBESITY AND TYPE 2 DIABETES AND THEIR APPLICATIONS - The present invention is directed to a method for determining if a subject is at increased risk to develop obesity or pathology related to obesity by determining the presence of a haplotype comprising three specific SNPs in a DNA or RNA sample of this subject and/or an elevated serum ENPP1 protein concentration. The present invention also relates to a kit and to an isolated nucleic sequence, vector or recombinant cell comprises said ENPP1 gene haplotype. The invention further comprises a method for selecting a compound for the treatment or the prevention of obesity or pathology related to obesity and a method for determining the efficacy of a drug to reduce the risk of obesity or pathology related to obesity in a patient. | 01-12-2012 |
20120009593 | ANALYSIS METHOD FOR THE IN VITRO DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN DOGS BY ASSAYING CANINE PROSTATE SPECIFIC ESTERASE, AND BPH TREATMENT FOLLOW UP - The invention relates to an analysis method for the in vitro diagnosis of benign prostatic hyperplasia (BPH) in a dog, using the CPSE contained in biological fluid samples collected from the dog as well as biological molecules specifically binding CPSE. The invention is characterised in that it includes the following steps: a. collecting a biological fluid sample from a dog; b. measuring the canine prostate specific esterase (CPSE) of said sample; c. comparing said measured CPSE concentration with a reference value, said value being from around 34 ng/ml to around 102.4 ng/ml for serum or plasma, preferably around 61 ng/ml; d. using the CPSE concentration as a BPH marker; and e. diagnosing BPH in a dog when measured CPSE concentrations in said sample exceed said reference value. | 01-12-2012 |
20120009594 | METHOD FOR MEASURING BETA-GLUCAN, AND BETA-GLUCAN-BINDING PROTEIN FOR USE IN THE METHOD - Disclosed are a method for measuring βG comprising the steps of bringing a sample into contact with a βG-binding protein 1 and a βG-binding protein 2, each comprising an amino acid sequence which is identical or substantially identical to an amino acid sequence shown in any one of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20, and having the β-glucan binding activity, to form a complex of the βG-binding protein 1, βG in the sample and the βG-binding protein 2, measuring quantity of the complex, and determining βG concentration in the sample based on the quantity of the complex; a reagent and a kit for use in said method; a novel βG-binding protein; a nucleic acid molecule encoding the βG-binding protein; and a method for producing the aforementioned βG-binding protein. | 01-12-2012 |
20120028274 | PROTEIN KINASE C GAMMA AS A BIOMARKER FOR NEUROPSYCHOLOGICAL AND COGNITIVE FUNCTIONS IN THE CENTRAL NERVOUS SYSTEM - Embodiments of the present invention are directed to a biological marker, the gamma isoform of protein kinase C (PKCg), which surprisingly allows rapid identification of compromised cognitive, behavioral, and neuropsychological functions under conditions associated with acute, transient hypoxia in humans. It was surprisingly discovered that PKCg is released from neural cells and can be detected in peripheral blood after hypoxic events unrelated to the reduction or elimination of blood flow through affected tissues. Embodiments of this invention are also directed to a broad range of clinical applications, particularly in emergency medicine. Other embodiments are related to compositions and methods for distinguishing between hypoxic encephalopathies and conditions arising from neuroanatomical/structural anomalies and/or incidental pathologies, for example, alcohol intoxication. | 02-02-2012 |
20120034624 | OSCILLATING IMMUNOASSAY METHOD AND DEVICE - The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field. | 02-09-2012 |
20120040371 | DIAGNOSIS OF PREECLAMPSIA - The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia. | 02-16-2012 |
20120040372 | RECEPTOR TYROSINE KINASE ASSAYS - Methods for detecting phosphorylation of receptor tyrosine kinases (“RTKs”) upon activation and the modulation of activation by a candidate compound are provided. The method employs cells comprising two fusion products: (1) an RTK fused to a small fragment of β-galactosidase and (2) a phosphotyrosine binding peptide fused to the large fragment of β-galactosidase, where the 2 fragments weakly complex to form an active enzyme, and optionally a construct for a cytosolic RTK phosphorylating kinase, when the RTK does not autophosphoryate. To detect phosphorylation a β-galactosidase substrate is added to the cells, whereby product formation indicates the occurrence of phosphorylation. | 02-16-2012 |
20120045774 | Lipoprotein Associated Phospholipase A2, Inhibitors Thereof and Use of the Same in Diagnosis and Therapy - The enzyme Lp-PLA | 02-23-2012 |
20120045775 | PHOSPHOSPECIFIC PAK ANTIBODIES AND DIAGNOSTIC KITS - The present invention relates to the use of phosphorylated p21-activated protein kinases (PAK), especially PAK4, as biomarkers of tumorogenesis. The present invention contemplates the use of phosphospecific antibodies for detecting phosphorylated PAK from mammalian biopsies, as well as screening assays for identifying compounds that modulate PAK activity. Also contemplated is a method for determining a subset of a given population that is amenable to treatment with a compound that modulates PAK activity. | 02-23-2012 |
20120064542 | MONOCLONAL ANTIBODIES AND DETECTION METHODS FOR ENZYMES THAT CONFER RESISTANCE TO 2,4-DICHLOROPHENOXYACETIC ACID - Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of AAD-1 (aryloxyalkanoate dioxygenase) enzyme. These monoclonal antibodies are surprisingly well suited for detecting AAD-1 transgenic event gene products in a variety of plants and plant tissues. The invention further provides quantitative and qualitative immunoassays using the immunoglobulins of the invention. | 03-15-2012 |
20120077208 | USE OF CARBAMOYL PHOSPHATE SYNTHETASE 1 (CPS) AS A HUMORAL BIOMARKER FOR THE DIAGNOSIS OF TUMOUR DISEASES AND CHRONIC INFLAMMATORY INTESTINAL DISEASES - The invention relates to the use of carbamoyl synthetase 1 (CPS 1) as a humoral biomarker in in vitro methods for early diagnosis and detection, progress prognosis, the evaluation of the severity, and the progress evaluation of tumor diseases and chronic inflammatory intestinal diseases. | 03-29-2012 |
20120077209 | PROTEIN BIOMARKERS AND THERAPEUTIC TARGETS FOR AUTOIMMUNE AND ALLOIMMUNE DISEAES - A method for characterizing the risk a subject will develop an autoimmune and/or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and/or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value. | 03-29-2012 |
20120082999 | NEW ANTIBODY COCKTAIL - The present invention relates to a composition comprising at least three primary antibodies or fragments thereof, wherein the at least three antibodies or fragments thereof binds specifically to at least three different proteins, and wherein the at least three different proteins are AMCAR, CK 5/6, and HMWC. Methods for using the composition in diagnosis, prognosis, and assessing efficacy of treatment is further included as well as kits comprising said composition, and optionally, instructions of its use. | 04-05-2012 |
20120094307 | TUBE FOR MEASURING BIO-RELATED SUBSTANCE AND QUANTIFYING SYSTEM - A bio-related substance assay tube | 04-19-2012 |
20120107833 | Antibody specific for a mammalian sphingosine kinase type 2 isoform protein and methods of use thereof - Polyclonal or monoclonal antibodies which are specific for a mammalian sphingosine kinase type 2 isoform protein and methods for detecting the presence of sphingosine kinase type 2 isoform using the antibodies. | 05-03-2012 |
20120115165 | BIOMARKERS FOR DETECTION AND DIAGNOSIS OF HEAD AND NECK SQUAMOUS CELL CARCINOMA - Novel, sensitive and specific markers and methods for diagnostics and monitoring of head and neck squamous cell carcinoma (HNSCC) are provided. Kits and methods for the use of hyaluronic acid, hyaluronidase and CD44 to diagnose HNSCC are described. | 05-10-2012 |
20120122116 | USE OF LYMPHOCYTES TO MEASURE ANTHRAX LETHAL TOXIN ACTIVITY - It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4 | 05-17-2012 |
20120122117 | SECRETED PHOSPHOLIPASE A2 BIOMARKERS FOR ARTHRITIS - The present invention relates to the use of protein expression profiles of sPLA2 isoforms with clinical relevance to osteoarthritis (OA). In particular, the invention provides methods for diagnosing OA or determining risk factors for development of OA based on expression of sPLA2-IIA. | 05-17-2012 |
20120129185 | METHODS AND COMPOSITIONS FOR DIAGNOSING ANKYLOSING SPONDYLITIS USING BIOMARKERS - The invention provides a method for determining the efficacy of a TNFα inhibitor, such as a TNFα antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and/or a synovitis biomarker. | 05-24-2012 |
20120129186 | DEVICES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF WOUNDS USING BIOMARKERS - The present invention provides for devices and methods for determining the healing phase of a wound. In some aspects, the present invention provides a wound diagnosis device comprising a surface and at least one agent that is specific to a desired biomarker. In another aspect, the present invention provides a method of determining the phase of wound healing. In still other aspects, the present invention provides methods of determining the phase of wound healing using the disclosed devices. | 05-24-2012 |
20120129187 | DIAGNOSTICAL USE OF PEROXIREDOXIN 4 - The present invention relates to a method for the diagnosis or prognosis of a disease or clinical condition in a subject comprising the steps of: (i) providing a sample of bodily fluid of a subject, (ii) determining the level of peroxiredoxin 4 (PRX4) or a fragment thereof having at least 20 amino acids residues in length in said sample, and (iii) correlating the level of PRX4 or a fragment thereof with a disease or clinical condition. | 05-24-2012 |
20120135421 | METHODS FOR THE IDENTIFICATION OF PHOSPHATIDYLINOSITOL KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF PHOSPHATIDYLINOSITOL KINASE PROTEINS - The present invention relates to immobilization compounds of formula (I), immobilization products and preparations thereof as well as methods and uses for the identification of phosphatidylinositol kinase interacting compounds or for the purification or identification of phosphatidylinositol kinase proteins. | 05-31-2012 |
20120149030 | IMMUNOASSAY FOR THROMBIN DETECTION - The invention relates to an in vitro immunoassay for quantifying thrombin in a sample comprising anti-thrombin III (AT-III) and thrombin. The method comprises the following steps: contacting the sample with a small molecule that recognizes the substrate binding site of thrombin; contacting the thrombin with a thrombin specific antibody raised against a thrombin blocked in the active site; and measuring the level of bound antibody. | 06-14-2012 |
20120149031 | ANTI-CMET ANTIBODY AND ITS USE FOR THE DETECTION AND THE DIAGNOSIS OF CANCER - The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to antibodies capable of binding to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding processes, for detecting and diagnosing pathological hyperproliterative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the overexpression of cMet. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers. | 06-14-2012 |
20120156690 | METHOD FOR DIAGNOSING HEMANGIOSARCOMA IN CANINE USING DETECTION OF THYMIDINE KINASE ACTIVITY - The disclosure relates to a method for detecting hemangiosarcoma in canines. The method includes the steps of: (1) obtaining a quantity of blood from the subject canine; (2) separating the quantity of blood into a serum portion and a non-serum portion; (3) contacting the serum portion of the blood with a detector to detect presence of an amount of Thymidine Kinase (TK); and (4) detecting the level of TK in serum and determining whether TK is present in amounts of about 8 units/L or greater. | 06-21-2012 |
20120156691 | COMPOUND - Alternative methods for the detection and measurement of proteases in biological samples and compounds which allow for such detection are required to allow for rapid and selective identification of these enzymes. Compounds which allow for selective identification of these enzymes are provided with assays and kits for their use. | 06-21-2012 |
20120156692 | METHOD FOR SELECTING MARKER FOR DIAGNOSIS OF NUTRITIONAL STATUS OF PLANT, METHOD FOR DIAGNOSING NUTRITIONAL STATUS OF PLANT, AND METHOD FOR DETERMINING GROWTH STATUS - The present invention provides a method for selecting a marker for diagnosis of the nutritional status capable of reflecting the status of a particular nutrient in a plant without being influenced by various stresses in environmental factors, etc., and a method for diagnosing the status of a particular nutrient in a plant using a marker for diagnosis of the nutritional status selected by the method. A metabolite quantitatively changed depending on only the amount of a particular nutrient in a plant is selected as a marker for diagnosis of the nutritional status reflecting the status of the nutrient in the plant. | 06-21-2012 |
20120171696 | Gene Defects And Mutant ALK Kinase In Human Solid Tumors - In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides. | 07-05-2012 |
20120178100 | Serum Markers Predicting Clinical Response to Anti-TNF Alpha Antibodies in Patients with Psoriatic Arthritis - The invention provides tools for management of patients diagnosed with psoriatic arthritis, specifically, prior to the initiation of therapy with an anti-TNFα agent. The tools are specific markers and algorithms of predicting response to therapy based on standard clinical primary and secondary endpoints using serum marker concentrations. In one embodiment the baseline levels of VEGF, prostatic acid phosphatase, and adiponectin are used to predict the response at Week 14 after the initiation of therapy. In another embodiment, the change in a serum protein biomarker after 4 weeks of therapy is used such as MDC, lipoprotein a, and beta2-microglobulin. | 07-12-2012 |
20120178101 | DEVICE, METHOD, AND SYSTEM FOR QUANTITATIVELY MEASURING A SPECIMEN USING A CAMERA - The present invention relates to a device and method for quantitatively measuring an analyte using a camera. More particularly, to capture the identification code required for obtaining an accurate analysis result for the analyte to be analyzed, to capture the result of the reaction of the analyte using a camera without additional equipment, and to read the identification code and the result of the reaction of the analyte, the device of the present invention comprises: a camera for capturing a camera recognition area of an analyte kit, which contains an analyte reaction result obtained by the reaction of the analyte and an identification code for the analyte kit; an image-processing unit for separating the analyte reaction result image and the identification code image from images of the camera recognition area of the analyte kit captured by the camera; a reading unit for reading the analyte reaction result image and the identification code image; and a control unit for enabling the read result of the analyte reaction result image to be processed using the read result of the identification code image. | 07-12-2012 |
20120183973 | BIOMARKER COMPOSITION FOR DETECTING DIABETIC RETINOPATHY AND DIAGNOSTIC KIT THEREFOR - Provided is a biomarker composition for detecting diabetic retinopathy, comprising at least one protein selected from the group consisting of proteins as set forth in SEQ ID NOS: 1 to 169, a method and a kit for diagnosing diabetic retinopathy using the same. The biomarker can provide fundamental information in researching vitreoretinal disorders, such as, diabetic retinopathy and the protein may be used in a method and a kit for diagnosing diabetic retinopathy with a molecule specifically binding thereto. | 07-19-2012 |
20120190042 | PROTEIN BIOMARKERS AND THERAPEUTIC TARGETS FOR OSTEOARTHRITIS - The present invention relates to the identification and use of protein expression profiles with clinical relevance to osteoarthritis. In particular, the invention provides the identity of marker proteins whose expressions are correlated with OA, and/or OA progression. Methods and kits are described for using these protein expression profiles in the study and/or diagnosis of OA, in the determination of the degree of advancement of OA, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that modulate expression of these proteins or nucleic acid molecules encoding these proteins, in particular for the development of disease-modifying OA agents. | 07-26-2012 |
20120190043 | ENZYMATIC SUBSTRATES FOR MULTIPLE DETECTION SYSTEMS - An inventive substrate is provided which includes a substrate compound of formula A-B | 07-26-2012 |
20120190044 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of metalloproteinase inhibitor 2, soluble oxidized low-density lipoprotein receptor 1, interleukin-2, von Willebrand factor, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor receptor superfamily member 11B, neutrophil elastase, interleukin-1 beta, heart-type fatty acid-binding protein, beta-2-glycoprotein 1, soluble CD40 ligand, coagulation factor VII, C—C motif chemokine 2, IgM, CA 19-9, IL-10, TNF-α, and myoglobin as diagnostic and prognostic biomarkers in renal injuries. | 07-26-2012 |
20120196299 | METHOD FOR DETECTION OF INTESTINAL, AND BLOOD-BRAIN BARRIER PERMEABILITY AND TESTING MATERIALS THERETO - Methods, assays, and apparatus are disclosed for testing of antigens associated with intestinal and/or blood-brain barrier permeability. For example, blood, saliva or other bodily fluid can be tested for binding (1) to a bacterial toxin (preferably a lipopolysaccharide), and (2) binding to tissue antigens selected from at least one of (a) a gut-related antigen and (b) a blood brain barrier-related antigen. Analysis of test results can be used to assist in detecting and diagnosing diseases associated with leaky gut syndrome (whether due to paracellular or transcellular pathways, and whether due to bacterial toxins or some other cause) and/or to diseases associated with excessive blood brain barrier permeability, which are contemplated herein to include both neuroinflammation and/or neuroautoimmunity conditions, and especially amyotrophic lateral sclerosis, Parkinsons disease, multiple sclerosis, Alzheimer's, or peripheral neuropathy, and major depression. | 08-02-2012 |
20120202218 | DETECTION METHOD AND DEVICE BASED ON NANOPARTICLE AGGREGATION - A method for determining the presence of a compound in a liquid solution, by admixing the liquid solution with a plurality of nanoparticles; providing conditions effective to cause aggregation of the nanoparticles in the liquid solution in the absence of said compound in the liquid solution; and observing a detectable signal reflecting the amount of aggregation of nanoparticles in the liquid solution, wherein the presence of the compound in the liquid solution results in a detectable signal reflecting a reduced amount of aggregation of nanoparticles in the liquid solution, in comparison to the amount of aggregation of nanoparticles obtained in the liquid solution in the absence of the compound therein. A nanoparticle, a composition, a kit and a for multi-well plate for use in the method are also disclosed. In some embodiments the association is cation-, anion and/or PH induced e.g. by using helix-loop-helix polypeptides as first and second molecules attached to the nanoparticles. The first molecules are directed to the target compound, the second molecules allow for aggregation of the nanoparticles. | 08-09-2012 |
20120202219 | PSA CAPTURE AGENTS, COMPOSITIONS, METHODS AND PREPARATION THEREOF - Disclosed herein are novel synthetic prostate specific antigen (PSA)-targeted capture agents that specifically bind PSA. In certain embodiments, these PSA capture agents are biligand or triligand capture agents containing two or three target-binding moieties, respectively. | 08-09-2012 |
20120208208 | PCSK9 IMMUNOASSAY - Methods of using PCSK9 antagonists. More specifically, methods for measuring circulating PCSK9 levels in a biological sample by means of an immunoassay. | 08-16-2012 |
20120208209 | PCSK9 IMMUNOASSAY - Methods of using PCSK9 antagonists. More specifically, methods for measuring circulating PCSK9 levels in a biological sample by means of an immunoassay. | 08-16-2012 |
20120219963 | DERIVATIVES OF URIDINE PHOSPHATE AND THEIR USES IN PROTEIN BINDING ASSAYS - The present invention relates to compounds and their use in competitive protein binding assays, for example for use with glycosyl transferase and/or glycoprocessing proteins. The present application also provides kits and apparatuses for use in the assays. In particular, the present invention provides a compound of the formula (I): wherein n is 1, 2 or 3; R | 08-30-2012 |
20120237947 | Glutathione S-Transferase Omega 1 Wild Type Specific Antibody - The invention relates to a novel antibody which binds to wild type (wt) Glutathione S-transferase Omega 1 (wtGSTO1) but not to mutant (mut) GSTO1 and methods and uses based on the antibody. The antibody is based on novel haptens and immunogens. | 09-20-2012 |
20120237948 | COLLAGEN NEOEPITOPE ANTIBODY - The present invention provides a novel monoclonal antibody that is specific for a C-terminal neoepitope of a collagen fragment and has substantially equal binding affinity whether proline contained in the neoepitope is in a non-hydroxylated form or in a hydroxylated form, and an immunoassay, a measurement method, a kit and the like using the antibody. The antibody allows for quantification of a collagen fragment generated by digestion of a biological sample with a collagenase present in the sample, regardless of the presence or absence of a hydroxylated form of proline in the neoepitope. | 09-20-2012 |
20120244553 | BIOMARKER OF ALLERGIC DISEASE AND USE OF THE SAME - A biomarker is provided for an allergic disease caused by an allergic reaction that is caused not exclusively by histamine release, such as pruritus, and use of the same. Use of Granzyme A as a biomarker makes it possible to provide an indication for chronic itching skin disease, for which existing antiallergic drugs have little effect, and easily and adequately allow diagnosis of the disease. It is possible to, for example, make a diagnosis of an allergic disease with an IV type allergy-like reaction not depending on the antigen-antibody reaction system. Screening with the use of Granzyme A enables the development of novel remedies for allergic diseases. Moreover, a drug capable of specifically controlling the action of a granzyme enables treatment of allergic disease with little side effect. | 09-27-2012 |
20120244554 | METHOD FOR THE DIRECT MEASURE OF MOLECULAR INTERACTIONS BY DETECTION OF LIGHT REFLECTED FROM MULTILAYERED FUNCTIONALIZED DIELECTRICS - Method and apparatus for the quantitative determination of molecular interactions between ligands in solution and receptors immobilized on the surface of a solid transparent material coated by one or more antireflective dielectric layers, through direct measurement of the light reflected by the interface between the surface and the solution. | 09-27-2012 |
20120258468 | INDICATOR AGENT FOR NONINFLAMMATORY STRESS RESPONSE AND USE THEREOF - A system enabling the molecular biological visualization and quantitative detection of events in a stress-exposed living organism and a means enabling the management of stress are provided. An indicator agent for non-inflammatory stress responses mediated by superoxide, which comprises IL-18, a visualizing agent for non-inflammatory stress responses for detecting the aforementioned indicator agent, a method of measuring the degree of non-inflammatory stress, which comprises using the aforementioned visualizing agent, a method of preventing, ameliorating or predicting a change in immune status based on a non-inflammatory stress response, which comprises applying the aforementioned visualizing agent to an animal, and a therapeutic agent for a change in immune status based on a non-inflammatory stress response for reducing the amount or activity of the aforementioned indicator agent. | 10-11-2012 |
20120258469 | Methods And Devices For Using Mucolytic Agents Including N-Acetyl Cysteine (NAC) - Devices and methods incorporate mucolytic agents into a point-of-care testing device. The sample is loaded, and then the sample travels until it encounters one or more lysis agents and/or mucolytic agents. The mucolytic agent is preferably pre-loaded onto the collection device. In a preferred embodiment, the mucolytic agent is localized between the sample application zone and the conjugate zone. In embodiments with a sample compressor, one or more mucolytic agents may be pre-loaded and dried on the sample compressor, the sample collector, in various locations on the test strip, or in the running buffer. | 10-11-2012 |
20120264138 | METHOD FOR DIAGNOSING AND MONITORING CARDIAC ISCHEMIA IN PATIENTS WITH ACUTE CHEST PAIN AND WITHOUT MYOCARDIAL INFARCTION - The present disclosure relates to a method for diagnosing the ischemic state in a subject suffering from acute coronary syndrome who does not fulfilling the diagnostic criteria for a myocardial infarction. The present disclosure also relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome but does not fulfill the diagnostic criteria for a myocardial infarction. The methods of the present disclosure are based on the determination of fms-like tyrosine kinase-1 (sFLT-1) and, optionally, hepatocyte growth factor (HGF) in a sample of said subject. The present disclosure also relates to kits and/or devices for carrying out the methods disclosed herein. | 10-18-2012 |
20120264139 | METHOD FOR DIAGNOSING ACUTE CORONARY SYNDROME - This invention concerns a bioaffinity assay for quantitative determination in a sample of free PAPP-A, defined as the pregnancy associated plasma protein A (PAPP-A) that is not complexed to the proform of major basic protein (proMBP), wherein | 10-18-2012 |
20120270233 | ASSOCIATION OF BIOMARKERS WITH PATIENT OUTCOME - The present method relates to quantification of prognostic and predictive biomarkers of the PDK/AKT/mTOR pathway, such as GSK3β, S6, CREB, PTEN, AKT and mTOR, using AQUA® analysis to estimate both patient risk and benefit of treatment to patients diagnosed with glioblastoma. Unlike traditional IHC, the AQUA® system is objective and produces quantitative in situ protein expression data on a continuous scale. Taking advantage of the power of the AQUA system, the present method provides a highly robust and standardized diagnostic assays that can be used in the clinical setting to provide physicians with reliable prognostic and predictive information. Glioblastoma multiform (GBM) remains one of the most aggressive human cancers, and biomarkers that provide prognostic and predictive information would be extremely valuable to both the physician and the patient. A patient's risk may be determined using the prognostic biomarkers of the present method. Such a prognostic determination will allow physicians to identify patients with a relatively ‘good’ or a relatively ‘poor’ prognosis. The benefit of treating specific patients with a specific therapy, may be determined usin̂ the predictive markers of the present method. Treatment with the AGC-family kinase inhibitor enzastaurin, for example, identifies patients that will likely benefit from treatment or not. | 10-25-2012 |
20120270234 | DDR2 PROTEIN WITH ACTIVATED KINASE ACTIVITY AND PREPARATION METHOD THEREOF - The present invention relates to a protein containing a modified DDR (Discoidin Domain Receptor) 2 cytosolic tyrosine kinase domain having an increased autophosphorylation and tyrosine kinase activity; a method for preparing a large amount of a protein containing DDR2 cytosolic tyrosine kinase domain, having an increased autophosphorylation and tyrosine kinase activity by inducing phosphorylations of tyrosines by a co-expression with Src or Src related proteins in host cells, or by H2O2 processing of host cells, or a site directed mutation modifying at least one of tyrosines to other amino acid; and a use thereof as a target material in developing medical drugs for treating a disease caused by an excessively activated DDR2 autophosphorylation and tyrosine kinase activity. | 10-25-2012 |
20120276551 | METHODS PREDICTING RISK OF AN ADVERSE CLINICAL OUTCOME - Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation 5 in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 and a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the in the methods described. | 11-01-2012 |
20120276552 | SERUM SPLA2-IIA AS DIAGNOSIS MARKER FOR PROSTATE AND LUNG CANCER - Methods for diagnosing prostate cancer and lung cancer are disclosed. The methods include obtaining a biological sample from a subject, determining a level of serum secretory phospholipase A | 11-01-2012 |
20120282627 | CRYSTAL OF HYPOXIA INDUCIBLE FACTOR 1 ALPHA PROLYL HYDROXYLASE - The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders. | 11-08-2012 |
20120288872 | GENE DEFECTS AND MUTANT ALK KINASE IN HUMAN SOLID TUMORS - Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The invention also provides methods for determining the presence of these mutant polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides. | 11-15-2012 |
20120288873 | BIOMARKERS FOR THE DETECTION AND SCREENING OF DOWN SYNDROME - The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein. | 11-15-2012 |
20120288874 | ENZYMATIC ACTIVITY-BASED DETECTION - Disclosed herein are methods and kits which are useful for detecting presence of an enzyme in a test sample based upon the intrinsic enzymatic activity of such test sample. The present invention provides the ability to evaluate cell culture conditions and optimize the desired glycoform content of recombinantly prepared enzymes. | 11-15-2012 |
20120295280 | CITRULLINATED PEPTIDES FOR DIAGNOSING AND PROGNOSING RHEUMATOID ARTHRITIS - The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (RA), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (ACPAs). The present invention also provides methods for detecting rheumatoid factor (RF) using novel RF detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as RA. Kits comprising at least one of the novel citrullinated peptides and/or RF detection reagents of the present invention are also provided. | 11-22-2012 |
20120295281 | SPECIFIC SALIVARY BIOMARKERS FOR RISK DETECTION, EARLY DIAGNOSIS, PROGNOSIS AND MONITORING OF ALZHEIMER'S AND PARKINSON'S DISEASES - Methods by which specific biomarkers in saliva are used for risk detection, early diagnosis, prognosis and monitoring of Alzheimer's and Parkinson's diseases. | 11-22-2012 |
20120295282 | METHODS OF DIAGNOSING OR TREATING PROSTATE CANCER USING THE ERG GENE, ALONE OR IN COMBINATION WITH OTHER OVER OR UNDER EXPRESSED GENES IN PROSTATE CANCER - The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene. | 11-22-2012 |
20120309018 | CANCER DETECTION MARKERS - Methods and compositions involving molecular markers for the detection and characterization of cancer in a patient are provided. | 12-06-2012 |
20120309019 | DETECTION OF UNHEALTHY BONE MARROW-DERIVED CELL FOR DISEASE PREDISPOSITIONS - Provided herein is a method for detecting the presence of a unique subset of unhealthy bone marrow-derived cell (BMDC) by co-staining the cytoplasmic and/or nuclear expression of PDPK F | 12-06-2012 |
20120309020 | LYSYL OXIDASE-LIKE 2 ASSAY AND METHODS OF USE THEREOF - The present disclosure provides an assay to detect and/or quantify circulating lysyl oxidase-like 2 (LOXL2) polypeptides in an individual. The assay is useful in diagnostic and prognostic applications, which are also provided. | 12-06-2012 |
20120309021 | DETECTION OF ANTIBODY THAT BINDS TO WATER SOLUBLE POLYMER-MODIFIED POLYPEPTIDES - The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative. | 12-06-2012 |
20120315649 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 10B, Cadherin-16, Caspase-9, Bcl2 antagonist of cell death, Caspase-1, Cadherin-1, Poly [ADP-ribose] polymerase 1, Cyclin-dependent kinase inhibitor 1, Cadherin-5, Myoglobin, Apolipoprotein A-II, Mucin-16, Carcinoembryonic antigen-related cell adhesion molecule 5, and Cellular tumor antigen p53 as diagnostic and prognostic biomarker assays in renal injuries. | 12-13-2012 |
20120315650 | DETECTION OF CIRCULATING ADAMTS13-ANTIBODY COMPLEXES - The present invention relates to methods and means for detecting ADAMTS13 immune complexes in a sample. The methods include the steps of capturing and labelling immune complexes of anti-ADAMTS13 antibodies. Capturing and labelling may be achieved by two different binding units targeting the immune complexes. The invention further relates to diagnosing diseases associated with immunologic ADAMTS13 dysfunction like TTP (thrombotic thrombocytopenic purpura). | 12-13-2012 |
20120322080 | Measurement of PKA for Cancer Detection - The present invention relates to a method of detecting the presence of cancer by measuring the level of enzyme activity and autoantibodies in the blood of an individual. In particular the present invention relates to methods for measurement of activated cAMP-dependent protein kinase A (PKA) activity and antibodies to PKA, a kit for activated PKA activity measurement, and the use of the measured levels of these analytes for determining the presence of cancer. | 12-20-2012 |
20120322081 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN - Provided herein is a large immuno-sorbent surface area assay (ALISSA) for rapid and sensitive detection of toxin or enzyme activity. This assay is designed to capture a low number of toxin or enzyme molecules and to measure their intrinsic protease activity via conversion of a fluorigenic or luminescent substrate. The ALISSA is significantly faster and more sensitive than methods routinely utilized in the art. This assay is applicable for use for detection of a variety of toxins or enzymes having proteolytic activity, such as | 12-20-2012 |
20120329070 | BIOMARKER PANELS FOR ASSESSING RADIATION INJURY AND EXPOSURE - Methods and kits are provided for assessing radiation injury and exposure in a subject. The methods comprise measuring the levels of at least two (2) protein biomarkers from different biological pathways and correlating the levels with an assessment of radiation injury and exposure. Additional use of peripheral blood cell counts and serum enzyme biomarkers, evaluated in the early time frame after a suspected radiation exposure, and use of integrated multiple parameter triage tools to enhance radiation exposure discrimination and assessment are also provided. The information obtained from such methods can be used by a clinician to accurately assess the extent of radiation injury/exposure in the subject, and thus will provide a valuable tool for determining treatment protocols on a subject by subject basis. | 12-27-2012 |
20120329071 | PROTEIN BIOMARKERS AND THERAPEUTIC TARGETS FOR RENAL DISORDERS - The present invention relates to a method of diagnosing a renal disorder. The method includes the steps of: (1) obtaining a biological sample from a subject; and (2) determining, in the biological sample, a level of one or more proteins whose abundance in urine change due to the renal disorder, wherein an increase or decrease in the level of one or more of the proteins compared to a control level is indicative of a renal disorder. | 12-27-2012 |
20130004963 | Tyrosine, serine and threonine phosphorylation sites - The invention discloses 155 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 01-03-2013 |
20130004964 | METHOD FOR CARRYING OUT REACTIONS IN AN ANALYTICAL DEVICE - Method and system for carrying out heterogeneous chemical or biological reactions are disclosed. The method comprising providing an analytical device having at least one liquid processing unit having at least one reaction chamber and a first inlet channel in fluid communication with the reaction chamber. The method further comprises supplying to the reaction chamber via the first inlet channel or a second inlet channel analyte capturing particles, supplying to the reaction chamber via the first inlet channel or the second inlet channel a liquid sample containing an analyte of interest, and confining by an equilibrium of forces the analyte capturing particles in a particle rearrangement zone within the reaction chamber. The forces comprise a drag force Fd generated by flowing liquids and a counter-oriented force Fg. The method also comprises capturing analytes present in the liquid sample with the particles in the particle rearrangement zone. | 01-03-2013 |
20130004965 | DETECTING AND COUNTING TISSUE - SPECIFIC STEM CELLS AND USES THEREOF - This invention provides methods of determining the number and percent of tissue specific stem cells (TSSCs) in a sample of cells, a population of cells or a sample of tissue. The methods rely on detecting the pattern-specific asymmetric localization of asymmetric self-renewal associated (ASRA) proteins or cell cycle specific proteins (CSSP) in cell undergoing asymmetrical self-renewal, which is a characteristic of TSSCs. The methods can be applied to any situations in which the percent of TSSC is desired such as laboratory research on adult stem cells, in drug development tests, prognostic indicator and therapeutic index, as a diagnostic and prognostic indicator and in monitoring TSSC expansion, e.g., in cell manufacturing processes. | 01-03-2013 |
20130011857 | COMPLEMENT FACTOR H FOR OXIDATIVE STRESS DISEASE CONDITIONS - The invention relates to complement Factor H for use in the prevention and treatment of oxidative stress disease conditions in a patient, the use of Factor H in the preparation of a pharmaceutical preparation, and methods of determining the specific binding of Factor H to MDA and/or MAA in a sample. | 01-10-2013 |
20130017556 | ASSAYS FOR HDL BIOMOLECULAR INTERACTIONS - The invention relates to methods, compositions and kits for detecting molecular interactions. In one embodiment, the invention relates to methods for quantifying HDL interactions with biomolecules. In still another embodiment, the invention relates to methods for determining HDL function. | 01-17-2013 |
20130017557 | COMBINATION OF sPLA2 TYPE IIA MASS AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENTAANM Mallat; ZiadAACI ParisAACO FRAAGP Mallat; Ziad Paris FRAANM Tedgui; AlainAACI ParisAACO FRAAGP Tedgui; Alain Paris FRAANM Tsimikas; SotiriosAACI La JollaAAST CAAACO USAAGP Tsimikas; Sotirios La Jolla CA USAANM Witztum; JosephAACI La JollaAAST CAAACO USAAGP Witztum; Joseph La Jolla CA US - The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), —combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event. | 01-17-2013 |
20130017558 | ADAM12 AS A BIOMARKER FOR BLADDER CANCER - The invention generally relates to isolated human or humanized antibodies or functional fragments thereof that include an antigen binding region that specifically binds a form of a disintegrin and metalloprotease 12 (ADAM12) present in a tissue or body fluid that is indicative of a cancer. | 01-17-2013 |
20130022992 | IN VITRO ASSAY FOR QUANTIFYING CLOSTRIDIAL NEUROTOXIN ACTIVITY - Novel methods for determining the unknown biological activity of a clostridial neurotoxin in a sample with respect to the known biological activity of a clostridial neurotoxin in a reference sample, comprising the step of comparing the biological activity of a clostridial neurotoxin preparation with the biological activity of a standard preparation of a reference clostridial neurotoxin in certain in vitro systems. | 01-24-2013 |
20130022993 | COMPOUND, PHOSPHORYLATION INHIBITOR, INSULIN RESISTANCE IMPROVING AGENT, PREVENTIVE OR THERAPEUTIC AGENT FOR DIABETES, AND SCREENING METHOD - A new compound inhibiting phosphorylation of Ser727 of STAT3, a phosphorylation inhibitor containing the new compound, an insulin resistance improving agent and a preventive or therapeutic agent for diabetes; and a screening method for at least one of the insulin resistance improving agent and the preventive or therapeutic agent for diabetes. | 01-24-2013 |
20130029351 | A25 BACTERIOPHAGE LYSIN - The invention relates to the identification, sequencing, and isolation of an A25 bacteriophage lysin gene that expresses a protein involved in the lysis of bacterial cells during the phage life cycle. The invention further relates to methods for lysing certain bacteria using lysin, which are useful for example in a diagnostic procedure designed to detect these bacteria. | 01-31-2013 |
20130029352 | METHODS FOR DIAGNOSING AND MONITORING THE PROGRESSION OF CANCER - Methods for measuring c-Met levels in urine and blood samples are provided. Methods for diagnosis and prognosis evaluation for cancer are also provided. | 01-31-2013 |
20130029353 | AUTOANTIBODY ENHANCED IMMUNOASSAYS AND KITS - The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte | 01-31-2013 |
20130034863 | Apparatus and Methods for Detecting Inflammation Using Quantum Dots - Apparatus and methods for detecting an a biomarker indicative of an inflammatory condition, including a capillary tube adapted for one or more biomarkers to adhere to an interior surface thereof, a light source for energizing quantum dots conjugated with the biomarkers within the capillary tube, and a detection system for detecting and quantifying fluorescent energy emitted by the quantum dots in one or more predetermined wavelength ranges, each wavelength range being correlated to one and only one of the biomarkers. A method of stabilizing the fluorescence intensity of quantum dots is also disclosed. | 02-07-2013 |
20130034864 | Protein, An Antibody and Measurement of the Protein - Methods for determining the occurrence or level of a mammalian protein in a sample and methods for determining the capability of a compound to transform or to inhibit the transformation of a selected mammalian protein in pro-phospholipase B form to an enzyme active phospholipase B form employ a pro-phospholipase B (PLB-II) mammalian protein which comprises at least one SU2 subunit comprising SEQ ID NO: 3 and having a molecular weight within the range of 30-60 kDa. Methods for determining the capability of a compound to enhance or inhibit the enzymatic activity of a selected protein having phospholipase B enzyme activity employ a protein comprising an activated form of such a pro-phospholipase B (PLB-II) mammalian protein. | 02-07-2013 |
20130040309 | Methods and Compositions for In-Vivo Enzyme Capture - The invention includes compositions, methods and kits for the in vivo identification of an enzyme that binds to a substrate. The invention comprises, in part, a photoreactive moiety to aid in identification of such an enzyme. | 02-14-2013 |
20130040310 | ULK1 COMPOSITIONS, INHIBITORS, SCREENING AND METHODS OF USE - This disclosure relates to methods and compositions useful for the treatment of cancer and diseases and disorders associated with autophagy. | 02-14-2013 |
20130040311 | MONOCLONAL ANTIBODY AGAINST NECROSIS MARKER ERP29 AND USE THEREOF - [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth. | 02-14-2013 |
20130040312 | DETECTION OF NGAL IN CHRONIC RENAL DISEASE - Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF. | 02-14-2013 |
20130052659 | METHOD FOR MEASURING IgG-MEDIATED COMPLEMENT ACTIVATION - A method for measuring immunoglobulin G-mediated complement activation, includes the following steps:
| 02-28-2013 |
20130059314 | FRET-BASED METHOD FOR THE DETERMINATION OF PROTEIN PHOSPHATASE AND KINASE ACTIVITY - This disclosure relates to methods of determining activities of protein phosphatases and kinases. The disclosure further relates to methods of clinical monitoring of calcineurin activity and immunosuppression in patients and which may be used to predict transplant acceptance in patients. | 03-07-2013 |
20130059315 | Alpha-Amylase Mutants - The present invention relates to a method of constructing a variant of a parent Termamyl-like alpha-amylase, which variant has alpha-amylase activity and at least one altered property as compared to the parent alpha-amylase, comprises
| 03-07-2013 |
20130065246 | METHOD FOR DIAGNOSING MELANOCYTIC PROLIFERATIONS - The invention provides a method for diagnosing a melanocytic proliferation in a subject comprising staining a sample of lesional melanocytes with an antibody against soluble adenylyl cyclase (sAC) and interpreting the sAC staining pattern, which is associated with a diagnosis of a melanocytic proliferation. The sAC staining pattern, which is complex, is discriminatory and distinctive according to the nature of the melanocytic proliferation. The sAC staining pattern comprises one or more of dot-like Golgi staining, broad granular Golgi staining, diffuse cytoplasmic staining, nucleolar staining, incomplete granular nuclear staining, and pan-nuclear staining. The method of the invention is particularly useful in confirming or disaffirming a diagnosis reached through conventional histologic examination of a sample. Additionally, the invention provides a kit for use in interpreting melanocytic proliferations. | 03-14-2013 |
20130065247 | METHODS OF DIAGNOSING LATENT AND ACTIVE MALIGNANCIES - Disclosed are procedures and methods for diagnosing latent and active cancers in a subject. The described methods include the use of sandwich ELISA assays containing antibodies specific for certain epitopes on the A-protein. This enables the assay to discriminate between the monomelic and homopolymeric forms of A-protein. | 03-14-2013 |
20130065248 | REAGENTS AND METHODS FOR SIRTUIN CAPTURE - The invention provides a method of preparing a sirtuin complex. The invention also provides a method of detecting a sirtuin in a sample comprising use of the aforesaid sirtuin complex. | 03-14-2013 |
20130071854 | METHODS FOR THE IDENTIFICATION AND CHARACTERIZATION OF HDAC INTERACTING COMPOUNDS - The present invention relates to methods for the identification and characterization (e.g. selectivity profiling) of HDAC interacting compounds using protein preparations derived from cells endogenously expressing HDACs or cell preparations containing said HDACs. | 03-21-2013 |
20130071855 | FLC AS BIOMARKER - The invention provides a method of identifying a subject likely to have liver disease, or for determining the prognosis of a subject previously identified as having a liver disease comprising detecting an amount of free light chains in a sample from the subject, wherein a higher amount of FLC is associated with an increased likelihood of the subject having a liver disease or an increased likelihood of having a poor prognosis of a liver disease. Assay kits for use in such methods are also provided. | 03-21-2013 |
20130078645 | BIOMARKERS - The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder. The biomarkers used are selected from cyclophilin A, cytosalic non-specific dipepditase, Caoctosin-like protein, Glucose-6-phosphate isomerase, uncharacterized protein KIAA0423, myosin 14, myosin 15, nicotinamide phosphoribosyltransferase, pyruvate kinase isozyme R/L, phosphoglyterate mutase 4. | 03-28-2013 |
20130084582 | SEROLOGICAL MARKERS FOR DETECTING COLORECTAL CANCER AND THEIR APPLICATION FOR INHIBITING COLORECTAL CANCER CELLS - Embodiments relate to serological markers for detecting the colorectal cancer and applications of the serological markers. A phospholipid scramblase1 (PLSCR1), a stomatin-like protein 2 (STOML2) or a transport protein Sec61β (SEC61β) increases expression in the blood at the earlier stage of the colorectal cancer. Detecting the expression of the PLSCR1, STOML2 or SEC61β protein or an induced autoantibody of each protein in a blood sample is used to diagnose the colorectal cancer. Moreover, the serological marker improves the detection efficiency and the sensitivity in detecting the colorectal cancer and is used to predict the prognosis. The serological markers are applied in preparing a detection device or inhibiting the growth of the colorectal cancer cells. | 04-04-2013 |
20130089871 | MARKER FOR DETECTION AND/OR DISCRIMINATION OF NON-ALCOHOLIC STEATOHEPATITIS, METHOD FOR DETECTION AND/OR DISCRIMINATION OF NON-ALCOHOLIC STEATOHEPATITIS, AND KIT FOR USE IN THE METHOD - The detection of a non-alcoholic steatohepatitis patient and the accurate discrimination between a normal person and a non-alcoholic steatohepatitis patient can be achieved by measuring alanine-glyoxylate amino transferase in a sample. | 04-11-2013 |
20130095502 | REAGENTS AND METHODS FOR PHOSPHORYLATION/DEPHOSPHORYLATION ANALYSES - Disclosed herein are reagents that include a moiety that includes a metal such as titanium and that readily binds to phosphorylated molecules the reagents also include at least one moiety that produces a signal or that binds to a molecule that produces a signal. The reagent may also include a moiety that binds to a larger molecule or to a surface. Some forms of the reagent include a dendrimer that can simultaneously bind to multiple metal moieties that include a metal such as titanium and multiple moieties that can be used to detected bound molecules. These reagents can be used in detection and/or measurement and/or at least partial purification of phosphorylated molecules. These reagents and methods using them are used to analyze proteins, polypeptides, nucleic acids, phospholipids and the like. They are readily adapted for use in gels, blots, plate based high through put assays and for mass spectrometry. | 04-18-2013 |
20130095503 | SERUM SPLA2-IIA AS DIAGNOSIS MARKER FOR PROSTATE AND LUNG CANCER - Kits for assessing lung cancer in patients with solitary pulmonary nodules and methods for assessing lung cancer. The kit includes reagents for detection and/or quantification of serum secretory phospholipase A | 04-18-2013 |
20130095504 | DISEASE MARKER DETECTION KIT AND DISEASE MARKER DETECTION METHOD - Provided is a detection kit, which a disease detection kit used together with a secondary ion mass spectrometer in order to detect a disease marker contained in a biological sample, the detection kit including: a base including a noble metal thin film formed thereon; a reactant containing peptide specifically reacting with the disease marker; a first storage unit filled with the reactant; a test substance containing a biological sample of a possible disease carrier; a second storage unit filled with the test substance; a mixing unit mixing the reactant and the test substance with each other to prepare a detection substance containing the specific reactant, which is the peptide specifically reacted with the disease marker contained in the biological sample; and a contact unit contacting the detection substance prepared by the mixing unit with the base to bond the specific reactant to the noble metal film of the base. | 04-18-2013 |
20130102009 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS - Provided are methods and compositions for detecting a compound that activates a sirtuin deacetylase activity on a fluorescent-free activation substrate in vitro. Further provided are sirtuin modulating compounds of the formulas (I)-(XXI), and related compounds (XXXI), (XXXII), (XXXIII), and (XXXIV), including the fluorescent free-substrate SIRT1 activator compounds of formulas (XL), (XI), (XII), and (XIII). | 04-25-2013 |
20130122518 | WELLNESS PANEL - A panel for monitoring levels of biomarkers, including an assay having at least one inflammation monitoring test, at least one oxidative stress monitoring test, and at least one antioxidant activity monitoring test. A method of monitoring an individual's health, by collecting a sample from the individual, applying the sample to an assay panel, performing at least one inflammation monitoring test, at least one oxidative stress monitoring test, and at least one antioxidant activity monitoring test in the panel, and determining levels of biomarkers related to inflammation, oxidative stress, and antioxidant activity and therefore providing information regarding the individual's relative health and/or risk of developing one or more diseases. | 05-16-2013 |
20130130275 | IMMUNOASSAY METHODS AND REAGENTS FOR DECREASING NONSPECIFIC BINDING - Methods and kits for reducing non-specific binding in an immunoassay for PIVKA-II in a test sample are described, in which the test sample is reacted with an anti-prothrombin antibody in the presence of one or more of the following additives: skim milk, saponin, CaCl | 05-23-2013 |
20130130276 | METHOD FOR DETECTING GASTRIC CANCER - The object of the present invention is to provide a method for detecting gastric cancer, and a kit for detecting gastric cancer. The object can be solved by a method for detecting gastric cancer characterized by analyzing β1,4-N-acetylgalactosamine transferase 1. According to the present invention, gastric cancer patients can be detected at high rates, even early stage gastric cancer patients without a subjective symptom. | 05-23-2013 |
20130130277 | REMEDY FOR DIABETES - A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the β subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the β subunit of a trimeric GTP-binding protein, as the active ingredient, etc. | 05-23-2013 |
20130137116 | METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance of NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents. | 05-30-2013 |
20130143232 | METHODS FOR THE DETECTION AND MONITORING OF ACUTE MYOCARDIAL INFARCTION - Disclosed herein are methods of detecting and/or prognosing myocardial infarction by detecting a proteolytic fragment of caspase-3 such as the p17 fragment or the p12 fragment. The myocardial infarction can be STEMI or NSTEMI. | 06-06-2013 |
20130149713 | BIOMARKERS OF HEMORRHAGIC SHOCK - Methods for the use of keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) (KC/GRO), apolipoprotein A2 (APOA2), angiotensinogen r (AGT), thyroglobulin (TG), disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), anionic trypsin-1 (PRSS1), complement C4 (C4A), zona pellucida sperm-binding protein 1 (ZP1), neuropilin-2 (NRP2), solute carrier family 13 member 2 (SLC13A2), glucagon-like peptide 2 receptor (GLP2R), lipoma high mobility group protein isoform I-C (HMGIC) fusion partner-like protein 4 (LHFPL4), and claudin-3 (CLDN3) as biomarkers for diagnosis and prognosis, and for monitoring the efficacy of treatment, in hemorrhagic shock (HS). | 06-13-2013 |
20130149714 | BIO-DIAGNOSTIC TESTING SYSTEM AND METHODS - An implantable diagnostic device in accordance with the present disclosure includes a probe assembly that can be implemented in a variety of ways. A few example implementations include: a needle inside which is located a bio-sensor chip (the needle being insertable into a human being); a compact package containing the bio-sensor chip (the compact package configured for placement inside a catheter); or a silicon-based bio-sensor package configured for insertion into a vein. | 06-13-2013 |
20130157288 | IMMOBILISED-BEAD IMMUNOMULTIPLEX ASSAY - Embodiments of this invention include image-based systems and methods for detection of one or more analytes. A surface has identifiable analyte-specific capture particle(s) immobilised thereto at any point of an assay, to which different analytes attach due to the affinity of analyte-specific capture molecule(s) linked to the surface of the capture particle(s) for the analyte. Analyte-specific detector molecules with conjugated detection moieties are then attached to the analyte, and a computer assisted, image-based detection system captures images of the capture particles with or without attached analytes and detector molecules. By using different subsets of analyte-specific capture molecules, each subset having a characteristic identifiable feature; it is now possible to perform capture particle-based, rapid multiplex assays of biological and non-biological analytes without flow. These image-based systems can be used to aid in diagnosis of disease, evaluation of therapy for disease, or laboratory investigation. | 06-20-2013 |
20130171659 | METHODS OF PROGNOSIS AND DIAGNOSIS OF RHEUMATOID ARTHRITIS - Provided are methods of diagnosing rheumatoid arthritis in a patient by detecting the presence and/or amount of a biomarker of rheumatoid arthritis in a sample from the patient. The methods and biomarkers may be used to develop an accurate prognosis for a patient having rheumatoid arthritis or suspected of having rheumatoid arthritis, or to accurately diagnose a patient having, or suspected of having rheumatoid arthritis. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for a rheumatoid arthritis therapy. | 07-04-2013 |
20130171660 | BLOOD MARKER FOR RENAL CANCER - The present invention provides a blood marker for renal cancer, more specifically, a blood marker that can be practically used for clinical diagnosis of renal cancer. The present invention also provides a blood marker that can be practically used for follow-up after treatment such as surgery and during treatment such as medication for renal cancer. A blood marker for renal cancer selected from the group consisting of Galectin-1, Galectin-3, and α-enolase. Galectin-1 and/or Galectin-3 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging. α-Enolase as a blood marker for renal cancer for use in monitoring during and/or after treatment for renal cancer. | 07-04-2013 |
20130171661 | Assay for Identification of LRRK2 Inhibitors - A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method may comprise or further comprise the step of assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the subcellular location of LRRK2. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems. | 07-04-2013 |
20130177923 | DIAGNOSTIC USE OF INDIVIDUAL MOLECULAR FORMS OF A BIOMARKER - Methods are provided of diagnosing, monitoring or determining the severity of disease or injury by measuring individual molecular forms of neutrophil gelatinase-associated lipocalin (NGAL) in bodily fluids, including the diagnosis and monitoring of acute renal injury leading to acute renal failure in a human or mammalian subject by determining the concentration of the free monomer form of NGAL. | 07-11-2013 |
20130177924 | LINKED PEPTIDE FLUOROGENIC BIOSENSORS - Biosensors, compositions comprising biosensors, methods of producing biosensors, and methods of using biosensors are disclosed. The biosensors comprise a fluorogen-activating peptide and a blocking peptide. The fluorogen-activating peptide and blocking peptide are covalently linked through a peptide linker. The blocking peptide associates with the fluorogen-activating peptide thereby blocking an active domain of the fluorogen-activating peptide when the linker is in an unmodified state. The peptide linker may contain an amino acid sequence that is specifically recognized as a modification substrate by a cognate enzyme. The fluorogen-activating peptide and the blocking peptide at least partially disassociate when the linker is modified by an enzyme, thereby allowing the fluorogen-activating peptide to bind a cognate fluorogen and modulate a fluorescence signal. | 07-11-2013 |
20130183683 | METHODS OF DIAGNOSING ACUTE CARDIAC DISORDERS USING BNP-SP - The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection. | 07-18-2013 |
20130183684 | PROTEIN BIOMARKERS FOR OBSTRUCTIVE AIRWAYS DISEASES - Provided herein are methods for the diagnosis of obstructive airways diseases such as asthma and chronic obstructive pulmonary disease, and the discrimination between such diseases based on the expression profiles of biomarker proteins and combinations of biomarker proteins. In particular embodiments the biomarker proteins are selected from ceruloplasmin, haptoglobin, hemopexin, - | 07-18-2013 |
20130183685 | METHOD OF RECOMBINANT MACROMOLECULAR PRODUCTION - A method for recombinantly expressing a macromolecule in a host cell is disclosed which involves culturing a host cell which contains two nucleic acid sequences, i.e., a first nucleic acid sequence encoding a membrane-permeabilizing agent and a second nucleic acid sequence encoding a desired macromolecule under the operative control of an inducible promoter, to a selected cell density that permits accumulation of the agent. Thereafter the host cell is exposed to an environmental condition that induces the agent to disrupt the integrity of the cell membrane without complete lysis of the cell membrane. The host cell thereby allows transport through the membrane of small molecular weight compounds. These resulting host cells are cultured in the presence of a nutrient cocktail that contains components that can transport through the disrupted cell membrane, e.g., an inducing agent that induces the tightly regulated promoter and metabolic requirements that permit expression of the macromolecule. | 07-18-2013 |
20130189706 | BIOSENSOR USING WHISPERING GALLERY MODES IN MICROSPHERES - A biosensor for detecting the presence of a target analyte is disclosed. The biosensor is formed from microspheroidal particles which have had a binding partner for the target analyte immobilized on their surfaces. The binding partners may be nucleotides; peptides, proteins, enzymes, antibodies and so on. When the analyte binds to its partner, the whispering gallery mode (WGM) profiles of the micro spheroidal particles change such that the profile peaks undergo a red- or blue-shift. The immobilized binding partners may include fluorophores and the like so that they emit fluorescence, phosphorescence, incandescence and the like. These fluorophores may take the form of a nanocrystal or quantum dot. | 07-25-2013 |
20130196342 | Compositions And Methods For Modulating S-Nitrosogluthione Reductase - Disclosed herein are methods and compositions for modulating the levels and/or activity of S-nitrosoglutathione reductase (GSNOR) in vivo or in vitro. Specifically disclosed are GSNOR deletion constructs, host cells and non-human mammals comprising GSNOR deletions, and methods of screening employing GSNOR deletion mutants. Also specifically disclosed are reagents and procedures for measuring, monitoring, or altering GSNOR levels or activity (as well as nitric oxide and S-nitrosothiol levels) in connection with various medical conditions. | 08-01-2013 |
20130196343 | SIGNAL LOCKING LABEL FREE BIOSENSING - A biosensor can include a fluid flow channel ( | 08-01-2013 |
20130203073 | ASSAY FOR ANALYTES BASED ON AGGREGATION - The present invention relates to compositions, assay devices, kits and methods for detecting the presence, amount and/or activity of an analyte in a sample. In particular, the present invention relates to the detection of enzymes. The present invention also relates to methods of diagnosing diseases associated with dysregulation of enzymes, screening for modulators of enzymatic activity, candidate antimicrobial peptides and toxins. | 08-08-2013 |
20130203074 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 as diagnostic and prognostic biomarkers in renal injuries. | 08-08-2013 |
20130210029 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN A NON-SURGICAL ICU POPULATION - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects admitted to a hospital critical care setting for other than a post-surgical or trauma indication. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Insulin-like growth factor IA, soluble Epidermal growth factor receptor, and Leukocyte elastase as diagnostic and prognostic biomarkers in renal injuries. | 08-15-2013 |
20130210030 | IN VIVO METHOD FOR THE EVALUATION OF A COMPOUND-TARGET INTERACTION - The invention relates to a method for evaluation of a compound-target interaction in vivo, comprising the steps of administering the compound to an animal, taking a body fluid sample of the animal, determining the concentration of the compound in the body fluid sample, taking a cellular sample of the animal containing the target, preparing a protein preparation of said cellular sample, providing an immobilised ligand capable of binding to the target, contacting the protein preparation with the immobilised ligand under conditions allowing the formation of a complex between the immobilised ligand and the target, determining the amount of complexes formed in step, and correlating the amount of complexes with the concentration of the compound in the body fluid sample. | 08-15-2013 |
20130210031 | DETECTION OF ADENYLATE CYCLASE - One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result, are rendered unusable after antibiotic use, or are not quantifiable. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, by the time a diagnosis is made a patient may be days beyond the time when treatment would be effective. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax edema factor activity exhibited by the invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines, anti-toxins and edema factor inhibitors. The invention isolates and concentrates edema factor and edema toxin from nearly any sample. By capitalizing on the adenylate cyclase activity of edema factor the invention amplifies output signals producing reliable detection of low concentrations of edema factor previously unachievable. The invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax edema factor, and other adenylate cyclases in biological samples. | 08-15-2013 |
20130217033 | BIOMARKER FOR MONITORING DEVELOPMENT OF DISEASES AND ASSESSING THE EFFICACY OF THERAPIES - The invention concerns a method for monitoring the development of a disease in a patient, and for assessing the efficacy of a therapy influencing on the CD73 level or activity in the patient, in particular a cytokine therapy or a statin therapy. CD73 in a tissue fluid drawn from the patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid. | 08-22-2013 |
20130217034 | PROCESS FOR AVOIDING FALSE POSITIVE RESULTS IN A DETECTING PROCESS OF AN INFLAMMATION INDICATOR IN A RINSE SOLUTION FOR TAKING UP GINGIVAL CREVICULAR FLUID - A process for avoiding false positive results in a detecting process of an inflammation indicator from the matrix metalloproteinase (MMP) family in a gingival crevicular fluid (GCF), wherein said GCF, which is obtained from a mouthrinse or saliva, is filtered before said inflammation indicator from the MMP family is assayed. | 08-22-2013 |
20130217035 | BIOLOGICAL MOLECULE DETECTING APPARATUS AND BIOLOGICAL MOLECULE DETECTING METHOD - A configuration was adopted, in which the orientations of free molecules and binding molecules within a solution are switched by switching the vibration direction of orientation controlling light, thereby switching the amount of light emitted by each free molecule and each binding molecule. There is a difference in the amounts of time required for the orientations of the free molecules and the binding molecules to switch accompanying the switch in the emission direction of the orientation controlling light. Therefore, the timings at which the amounts of light emitted by each type of molecule increase differ. Accordingly, the fluorescence contributed by fluorescent molecules associated with free molecules and the fluorescent molecules associated with binding molecules can be respectively calculated, even if all of the fluorescent molecules within the solution emit fluorescence. Thereby, the concentration of a detection target substance can be accurately measured with a simple structure. | 08-22-2013 |
20130224763 | BIOLOGICAL MOLECULE DETECTING APPARATUS AND BIOLOGICAL MOLECULE DETECTING METHOD - A biological molecule detecting apparatus capable of highly sensitive measurements is provided. A laser was emitted onto a solution, to impart external force onto free molecules and binding molecules within the solution. The external force inhibited Brownian motion of the free molecules and the binding molecules. The concentration of a detection target substance which is associated the binding molecules can be measured with high sensitivity, by measuring the Brownian motion of the free molecules and the binding molecules within the solution irradiated with the laser. | 08-29-2013 |
20130224764 | BIOLOGICAL MOLECULE DETECTING APPARATUS AND BIOLOGICAL MOLECULE DETECTING METHOD - A biological molecule detecting apparatus capable of highly sensitive measurements is provided. The emission direction of an orientation controlling light beam was periodically switched, to periodically switch the orientation direction of binding molecules | 08-29-2013 |
20130224765 | NANO-POROUS MEMBRANE BASED SENSORS - Sensors include nano-porous alumina membranes that are sensitized by immobilization of antibodies in the nano-pores. The nano-membranes can be sensitized to respond to a single target compound, or different portions of the nano-membrane can be differently sensitized. Capture of the target compound can be detected based on a spectral signature associated with electrical conductance in the nano-pores. | 08-29-2013 |
20130230865 | Methods for Monitoring Methotrexate Therapy - The present invention provides methods for assessing efficacy of a methotrexate (MTX) dosing regimen in a patient. | 09-05-2013 |
20130236908 | METHOD FOR PREDICTING A NEED FOR RENAL REPLACEMENT THERAPY (RRT) - A method for predicting a need for Renal Replacement Therapy (RRT) in a patient comprises: determining a concentration of pi glutathione S transferase-(πGST) in a first urine sample from the patient; and wherein a need for RRT is predicted when the πGST concentration is determined to be elevated in comparison to a patient without kidney injury. The method according to the invention can further comprise detecting for the presence of risk factors for RRT in a patient, the risk factors including elevated serum creatinine concentration, type I diabetes, type II diabetes, hypertension, dyslipidemia, hyperglycaemia, proteinuria and hypoalbuminemia. | 09-12-2013 |
20130252254 | Procalcitonin gene expression as a precise biomarker of aging process - The invention relates to a method for diagnosis and/or complications and/or risk assessment of aging, in particular of aging process, wherein a determination of the marker procalcitonin (PCT: SEQ ID No. 1) or a partial peptide or fragment thereof or if contained in a marker combination (Panel, Cluster) is carried out on a patient within normal value ranges of leucocytes under investigation. The invention further relates to invent new drugs, a diagnostic device and a kit for carrying out said method. | 09-26-2013 |
20130252255 | BLADDER CANCER DIAGNOSIS COMPOSITION CONTAINING APE1/REF-1 AND BLADDER CANCER DIAGNOSTIC KIT USING SAME - Provided are a bladder cancer diagnosis composition containing APE1/Ref-1, a bladder cancer diagnostic kit containing an antibody which specifically binds to the APE1/Ref-1, and a method of measuring APE1/Ref-1 concentration in biological samples through an antigen-antibody binding reaction using the antibody which specifically binds to the APE1/Ref-1. According to the invention, the APE1/Ref-1 protein concentration in serum of bladder cancer patients is significantly higher than in healthy subjects, and more particularly, it significantly increases in the serum of patients with stage 2 or later bladder cancer. | 09-26-2013 |
20130260389 | BETA-2 MICROGLOBULIN AS A BIOMARKER FOR PERIPHERAL ARTERY DISEASE - The present invention provides β2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject. | 10-03-2013 |
20130260390 | Methods and Compositions for Highly Sensitive Detection of Molecules - The present invention discloses methods for the detection and monitoring of a condition in a subject using highly sensitive detection of molecules. The invention provides a method for detecting or monitoring a condition in a subject, comprising detecting a first marker in a first sample from the subject and detecting a second marker, wherein the first marker comprises a biomarker, e.g., Cardiac Troponin-I (cTnI) or Vascular Endothelial Growth Factor (VEGF), and wherein the limit of detection of the first marker is less than about 10 pg/ml. The second marker can be a biomarker, physiological marker, a molecular marker or a genetic marker. | 10-03-2013 |
20130260391 | Method Of Determining The Protease Cathepsin B In A Biological Sample - A method for determination of the potentially available activity of cathepsin B in a biological sample, including the activity of the active form of cathepsin B, the form of cathepsin B which can be activated from the pro-form procathepsin B being present in the sample, and the form of cathepsin B which can be activated and which is inhibited in the sample in its activity by protease inhibitor, whereby the procathepsin B being present in the sample is converted into the active form of cathepsin B, the free protease inhibitor for cathepsin B being present in the sample is depleted from the sample or its inhibitor function is suppressed, and the protease inhibitor is withdrawn from the inhibited form of cathepsin B, and subsequently the activity of the active cathepsin B in the sample is determined. | 10-03-2013 |
20130266961 | DIAGNOSIS AND RISK STRATIFICATION BY MEANS OF THE NOVEL MARKER CT-PROADM - The invention relates to a novel diagnostic marker CT-proADM (C-terminal fragment of preproADM, SEQ ID No. 1) for diagnosing and/or stratifying the risk of diseases. Also disclosed is a method for diagnosing and/or stratifying the risk of diseases, particularly cardiovascular diseases, cardiac insufficiency, and infections and/or inflammations of the lungs and respiratory tract. In said method, the CT-proADM (SEQ ID No. 1) marker, or a partial peptide of fragment thereof, or said marker contained in a marker combination (panel, cluster) is determined in a patient who is to be examined. The invention further relates to a diagnostic apparatus as well as a kit for carrying out said method. | 10-10-2013 |
20130266962 | MEANS AND METHODS FOR DIAGNOSING CANCER USING AN ANTIBODY WHICH SPECIFICALLY BINDS TO BRAF V600E - The present invention relates to the field of diagnostic tests and diagnostic tools. Specifically, contemplated is to a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer comprising contacting the sample with an antibody which specifically binds to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide under conditions which allow for binding of said antibody to the epitope and determining binding of the antibody to the epitope, whereby cancer is diagnosed. Further contemplated are antibodies which specifically bind to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide and a device or kit comprising such antibodies. | 10-10-2013 |
20130273562 | 1L1RL-1 as a Cardiovascular Disease Marker and Therapeutic Target - This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure. | 10-17-2013 |
20130273563 | DEVICE FOR PERFORMING AN ENZYME-BASED DIAGNOSTIC TEST AND METHODS FOR USE THEREOF - Enzyme-based diagnostic testing systems for detecting and quantifying at least one of the activity level or the concentration of an enzyme or a biochemical analyte in a biological sample. Such enzyme-based diagnostic testing systems can provide rapid, accurate, affordable laboratory-quality testing at the point of care. An enzyme-based diagnostic testing system may include a lateral-flow chromatographic assay cassette that is configured for assaying an amount or activity of an enzyme in a sample or for enzymatically determining the concentration of an enzyme substrate in a sample. Additionally, the enzyme-based diagnostic testing systems may include testing devices (e.g., a smartphone or a similar remote computing device) having data collection and data analysis capabilities. Such testing devices may also include automated data reporting and decision support. | 10-17-2013 |
20130288269 | Biomarkers For Prediction Of Major Adverse Cardiac Events And Uses Thereof - The present invention relates to combinations of biomarkers and levels thereof that may be used, for example, in the determination of risk associated with the occurrence of a major adverse cardiac event (MACE) in a patient. | 10-31-2013 |
20130288270 | CHEMILUMINESCENT ENZYME ASSAY METHOD AND APPARATUS - A chemiluminescent enzyme immunoassay method for quantifying antigen or antibody using 1,1′-oxalyldiimidazole (ODI) derivative or 1,1′-oxalyldisodium benzoate (ODB) derivative chemiluminescence (CL) detection was developed. Also, various enzymes were quantified using ODI derivative or DOB derivative CL detection. Fluorescent compound formed from a substrate (non-fluorescent compound) through the enzyme assay methods emitted CL when the fluorescent compound received energy from high-energy intermediate formed in ODI derivative or ODB derivative CL reaction. | 10-31-2013 |
20130302819 | METHOD FOR THE EARLY IDENTIFICATION AND PREDICTION OF AN ABRUPT REDUCTION IN KIDNEY FUNCTION IN A PATIENT UNDERGOING CARDIOTHORACIC SURGERY - A method for the early identification and prediction of abrupt reduction in kidney function in a patient undergoing cardiothoracic (CT) surgery, including Cardio-Pulmonary Bypass (CPB), comprises contacting a urine sample from the patient with a capture molecule for a biomarker, especially πGST specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of an abrupt reduction in kidney function, the biomarker being detectable as early as intraoperatively or in the recovery stage post CT surgery, for example prior to transfer of the patient to the Intensive Care Unit (ICU), allowing for immediate corrective medical intervention. The method can be used to detect Acute Kidney Injury (AKI) and a requirement for Renal Replacement Therapy (RRT) namely dialysis, earlier than two hours post CT surgery and as early as zero hours post or during CT surgery or CPB. | 11-14-2013 |
20130302820 | Methods and Compositions for Treating Bleeding Disorders - Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described. | 11-14-2013 |
20130302821 | Method For Evaluating Atherosclerotic Lesion, And Kit - The present invention provides a method and a means for evaluating atherosclerotic lesions by identifying a protein (marker protein) group, the expression level of which varies according to the progression of the atherosclerotic lesion, and using the proteins. Specifically, the present invention relates to a method for evaluating atherosclerotic lesions, comprising the steps of detecting a marker protein exhibiting an expression pattern (expression variation) characteristic at a specific disease stage of atherosclerotic lesions in a subject, and evaluating the atherosclerotic lesions in the subject based on the detection result. | 11-14-2013 |
20130316369 | METHOD FOR DETECTING ESCHERICHIA COLI - Described herein are methods of detecting an infection and for detecting the presence or absence of microorganisms, for example, wound pathogens in a sample, by contacting a sample with an enzyme produced and/or secreted by the bacteria, and detecting modification or the absence of modification or the substrate, as an indicator of the presence or absence of the enzyme in the sample. The present invention also features a biosensor for detecting the presence or absence of bacteria in a sample. | 11-28-2013 |
20130316370 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha as diagnostic and prognostic biomarker assays in renal injuries. | 11-28-2013 |
20130323748 | METHOD OF JUDGING RISK OF CANCER RECURRENCE AND COMPUTER PROGRAM - There is provided a method of judging a risk of cancer recurrence based on the activity value and expression level of the first CDK, the activity value and expression level of the second CDK, and the expression levels of uPA and PAI-1 and a computer program. | 12-05-2013 |
20130323749 | GRANZYME A AND GRANZYME B DIAGNOSTICS - A method for identifying a subject being at risk for or having a chronic Inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin. | 12-05-2013 |
20130323750 | Method for Analyzing Apoptosis Inducing Factor-2 - A method for analyzing apoptosis inducing factor-2 (AIF-2) is disclosed, which has not been found in urine samples of human patients with chronic kidney disease, to establish AIF-2 as a non-invasive biomarker for chronic kidney disease. The method includes: collecting a plurality of urine samples; conducting western blot for each urine sample for detecting the AIF-2 protein content in each urine sample; and conducting statistical analysis of the AIF-2 protein content in each urine sample to establish AIF-2 as a biological marker for chronic kidney disease. | 12-05-2013 |
20130323751 | Urine Biomarkers For Prediction Of Recovery After Acute Kidney Injury: Proteomics - This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal to recovery and/or renal non-recovery. | 12-05-2013 |
20130344503 | METHODS FOR DETERMINING THE RISK OF PRENATAL COMPLICATIONS - The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. | 12-26-2013 |
20130344504 | NNMT AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein NNMT in said sample in vitro. | 12-26-2013 |
20130344505 | APEX1 AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein APEX1 in said sample in vitro. | 12-26-2013 |
20130344506 | SEPRASE AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein Seprase in said sample in vitro. | 12-26-2013 |
20140004530 | METHOD FOR THE EVALUATION OF COMPOUND-TARGET INTERACTIONS ACROSS SPECIES | 01-02-2014 |
20140004531 | Secretory Protein Biomarkers For High Efficiency Protein Expression | 01-02-2014 |
20140011211 | METHOD OF DIAGNOSING THE PRESENCE AND/OR SEVERITY OF A HEPATIC PATHOLOGY IN AN INDIVIDUAL AND/OR OF MONITORING THE EFFECTIVENESS OF A TREATMENT FOR ONE SUCH PATHOLOGY - A method pertains to a diagnosing the presence and/or severity of a hepatic pathology and/or of monitoring the effectiveness of a curative treatment against a hepatic pathology in an individual, comprising the establishment of at least one non-invasive diagnostic score, in particular a diagnostic score for portal and septal fibrosis and/or an estimate score for the fibrosis area and/or an estimate score for the fractal dimension. | 01-09-2014 |
20140017700 | SENSITIVE INTRACAVITY BIOSENSING PLATFORM AND METHODS FOR DETECTION THEREWITH - The present disclosure provides a method of detecting a target analyte, by binding the target analyte and a probe with at least one fluorophore to form a fluid composition. The fluid composition is excited within a laser cavity. The method comprises measuring a laser emission from the fluid composition based on an interaction between the target analyte and the probe. In certain aspects, the method provides hybridizing the target analyte and the probe, prior to the exciting. In certain variations, the methods comprise detecting a target analyte by measuring a laser emission from the fluid composition based on an interaction between the target analyte, where the interaction is probe energy transfer, intercalation, hybridization of the target analyte and the probe, or combinations thereof. The energy transfer can include fluorescence resonance energy transfer (FRET), FRET with a molecular-beacon, or cavity-assisted radiative energy transfer, by way of non-limiting example. | 01-16-2014 |
20140017701 | CHIMERIC PDK1 KINASES - The invention provides chimeric 3-phosphoinositide-dependent protein kinase 1 (PDK1), the PIF-binding pocket of which has mutations to mimic a second protein kinase, its production and use. The invention further provides a method for screening for compounds interacting with the PIF-pocket of an AGC kinase. | 01-16-2014 |
20140017702 | BIOMARKERS FOR ACUTE KIDNEY INJURY - Disclosed is an animal model that can be used, among other things, to generate biomarkers for the prognosis and/or diagnosis of acute kidney injury, more specifically sepsis-induced acute kidney injury. Disclosed are three such biomarkers. The disclosure specifically relates to human chitinase 3-like protein 1 for use as a biomarker. | 01-16-2014 |
20140017703 | BAD PHOSPHORYLATION DETERMINES OVARIAN CANCER CHEMO-SENSITIVITY AND PATIENT SURVIVAL - Despite initial sensitivity BAD-protein phosphorylation were evaluated in patient samples and cell lines as determinants of chemo-sensitivity and/or clinical outcome, and as therapeutic targets. Induced in-vitro OVCA cisplatin-resistance was associated with BAD-pathway expression. Expression of the pathway was also associated with resistance of 7 different cancers cell-types to 8 chemotherapeutic agents. Phosphorylation of the BAD-protein was associated with platinum-resistance in OVCA cells and primary OVCA specimens, and also overall patient survival. Targeted modulation of BAD-phosphorylation levels influenced cisplatin-sensitivity. A 47-gene BAD-pathway signature was associated in-vitro phospho-BAD levels and with survival of 838 patients with ovarian, breast, colon, and brain cancer. The survival advantage associated with both BAD-phosphorylation and also the BAD-pathway signature was independent of surgical cytoreductive status. The BAD apoptosis pathway influences human cancer chemo-sensitivity and overall survival. The pathway is useful as a biomarker of therapeutic response, patient survival, and therapeutic target. | 01-16-2014 |
20140024042 | BIOMARKERS FOR DETECTION AND DIAGNOSIS OF HEAD AND NECK SQUAMOUS CELL CARCINOMA - Novel, sensitive and specific markers and methods for diagnostics and monitoring of head and neck squamous cell carcinoma (HNSCC) are provided. Kits and methods for the use of hyaluronic acid, hyaluronidase and CD44 to diagnose HNSCC are described. | 01-23-2014 |
20140030732 | MICROFLUIDIC HPLC-CHIP FOR GLYCOPEPTIDE ANALYSIS WITH INTEGRATED HILIC ENRICHMENT - A microfluidic device for glycopeptide analysis includes an enrichment column capable of binding carbohydrates; a trapping column capable of binding peptides, wherein the trapping column is configured to be connected downstream of the enrichment column; a separation column, wherein the separation column is configured to be connected downstream of the trapping column; and a plurality of ports configured to work with a switching device to form a plurality of flow paths, wherein one of the plurality of flow paths allows the trapping column to be in fluid communication with the separation column. A method for glycopeptide analysis using a microfluidic device comprising a trapping column and a separation column, the method includes applying a sample of peptides to the microfluidic device; trapping the peptides on the trapping column; eluting the peptides from the trapping column into the separation column; and separating the peptides on the separation column. | 01-30-2014 |
20140030733 | Method for Diagnosing Neurodegenerative Diseases - The present invention relates to a method for diagnosing, in vitro, a neurodegenerative disease in an individual, in which:—the level of the double-stranded RNA-dependent protein kinase (PKR) in a sample of cerebrospinal fluid from the individual is determined,—it is deduced therefrom whether the individual is suffering from a neurodegenerative disease. | 01-30-2014 |
20140030734 | Biomarkers for Diseases of the Central Nervous System - The present invention describes a method of diagnosis and/or progression of a disease based on the detection and quantification of the expression levels of biomarkers preferably selected from the group comprising gelsolin isoforms (SEQ. ID 1 and 2) and Vitamin D binding protein isoforms (SEQ. ID 3 and 4). Said method is applied to central nervous system diseases, preferably to Multiple Sclerosis. | 01-30-2014 |
20140038203 | METHODS FOR DETECTING OR PREDICTING KIDNEY DISEASE - Methods of detecting or predicting the onset or magnitude of kidney diseases such as acute kidney disease (AKI), previously called acute renal failure (ARF), are provided. In various aspects, methods and kits are provided to detect specific urinary proteins associated with AKI diagnosis or prognosis such as, e.g., angiotensinogen. | 02-06-2014 |
20140038204 | SELECTIVE MEASUREMENT OF ACTIVE HUMAN PROTEASE COAGULATION FACTORS - The present invention relates to a method for the selective determination of the concentration of an active human protease coagulation factor in a sample, comprising the steps of binding a specific inhibitor of the human protease coagulation factor to a solid phase, letting the human protease coagulation factor contained in the sample bind to the solid phase-bound inhibitor, and detecting the human protease coagulation factor bound to the solid phase-bound inhibitor with a detection reagent. | 02-06-2014 |
20140051093 | HIGH LEVEL EXPRESSION OF RECOMBINANT TOXIN PROTEINS - The present invention relates to the field of recombinant toxin protein production in bacterial hosts. In particular, the present invention relates to production processes for obtaining high levels of a recombinant CRM197, Diphtheria Toxin, Pertussis Toxin, Tetanus Toxoid Fragment C, Cholera Toxin B, Cholera holotoxin, and | 02-20-2014 |
20140051094 | Method and Compositions for Specifically Detecting Physiologically Acceptable Polymer Molecules - The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition. | 02-20-2014 |
20140057285 | COMPOSITIONS AND METHODS TARGETING FORCE GENERATION IN KINESIN - In some aspects, the invention provides chimeric kinesin proteins. In other aspects the invention provides nucleic acids encoding chimeric kinesin proteins. Compositions and kits are provided that comprise chimeric kinesin proteins and nucleic acids encoding the same. Antibodies and antigen binding fragments that selectively bind kinesin proteins are also provided. | 02-27-2014 |
20140065641 | METHOD OF MEASURING THE DEGREE OF NON-INFLAMMATORY STRESS RESPONSE - A system enabling the molecular biological visualization and quantitative detection of events in a stress-exposed living organism and a means enabling the management of stress are provided. An indicator agent for non-inflammatory stress responses mediated by superoxide, which comprises IL-18, a visualizing agent for non-inflammatory stress responses for detecting the aforementioned indicator agent, a method of measuring the degree of non-inflammatory stress, which comprises using the aforementioned visualizing agent, a method of preventing, ameliorating or predicting a change in immune status based on a non-inflammatory stress response, which comprises applying the aforementioned visualizing agent to an animal, and a therapeutic agent for a change in immune status based on a non-inflammatory stress response for reducing the amount or activity of the aforementioned indicator agent. | 03-06-2014 |
20140065642 | SYSTEMS AND METHODS FOR CHARACTERIZATION OF MOLECULES - The present invention generally provides systems and methods for the detection, identification, or characterization of differences between properties or behavior of corresponding species in two or more mixtures comprised of molecules, including biomolecules and/or molecules able to interact with biomolecules, using techniques such as partitioning. The experimental conditions established as distinguishing between the mixtures of the molecules using the systems and methods of the invention can also be used, in some cases, for further fractionation and/or characterization of the biomolecules and/or other molecules, using techniques such as single-step or multiple-step extraction, and/or by liquid-liquid partition chromatography. The methods could also be used for discovering and identifying markers associated with specific diagnostics, and can be used for screening for such markers once discovered and identified during diagnostics screening. | 03-06-2014 |
20140072982 | SPECIFIC SALIVARY BIOMARKERS FOR RISK DETECTION, EARLY DIAGNOSIS, PROGNOSIS AND MONITORING OF ALZHEIMER'S AND PARKINSON'S DISEASES - Methods by which specific biomarkers in saliva are used for risk detection, early diagnosis, prognosis and monitoring of Alzheimer's and Parkinson's diseases. | 03-13-2014 |
20140080142 | Compositions and Methods of Using Differentiated Cells Sensitized to Botulinum Neurotoxin - Differentiated cholinergic cells having motor neuron-like morphology and increased sensitivity to botulinum neurotoxin are provided herein. Methods of using such differentiated cells for detecting neurotoxin are also provided. | 03-20-2014 |
20140080143 | PSA ASSAY AND REAGENT THEREFOR - Provided is a method for the simple and highly accurate assay of PSA by a one-step reaction that does not use carriers having different average grain sizes. Also provided is a reagent therefor. The PSA assay method comprises sensitizing insoluble carriers having the same average grain size within a range of greater than 0.20 μm but 0.40 μm or less using two types of anti-PSA monoclonal antibodies having different epitopes that are anti-PSA monoclonal antibodies that will react with both free PSA and PSA-ACT, which is a complex of free PSA and α1-antichymotrypsin, and bringing the carriers into contact with a sample in the presence of an aggregation promoter. | 03-20-2014 |
20140080144 | METHOD FOR DETERMINING PLATELET-ASSOCIATED ANALYTES - The present invention relates to a routine in vitro method for determining platelet-associated analytes, for example VWF, factor XIII, fibrinogen or D-dimer, in a sample of platelet-rich plasma. | 03-20-2014 |
20140087392 | GLYCOSYL TRANSFERASE FROM CHINESE HAMSTER AND RELATED METHODS - A glycosyl transferase from Chinese hamster and related methods are described. | 03-27-2014 |
20140093888 | HIGHLY PURE PLASMID DNA PREPARATIONS - The present disclosure generally relates to highly pure plasmid compositions having low, or undetectable, levels of colanic acid and other contaminants made by a process that includes the steps of obtaining a crude lysate of a plasmid DNA from a bacteria that makes colanic acid; treating the partially purified or purified plasmid DNA with a polypeptide that digests colanic acid under conditions that digest the colanic acid; and purifying the plasmid DNA from the digested colanic acid and the colanic acid degrading enzyme by one or more chromatography steps. | 04-03-2014 |
20140099650 | MONOCLONAL ANTIBODIES AND DETECTION METHODS FOR ENZYMES THAT CONFER RESISTANCE TO PHOSPHINOTHRICIN-N-ACETYL-TRANSFERASE - Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of a phosphinothricin-N-acetyl-transferase enzyme. The claimed antibodies and methods are particularly useful for identifying and quantitating the presence of phosphinothricin-N-acetyl-transferase expressed in trangenic plants. | 04-10-2014 |
20140106369 | BIOMARKERS FOR AGGRESSIVE PROSTATE CANCER - The present invention relates to the field of biomarkers and, more specifically, to biomarkers useful in diagnosing aggressive prostate cancer. In specific embodiments, a method for diagnosing aggressive prostate cancer in a patient comprises (a) measuring the levels of one or more biomarkers in a sample collected from the patient; and (b) comparing the levels of the one or more biomarkers with predefined levels of the same biomarkers that correlate to a patient having aggressive prostate cancer and predefined levels of the same biomarkers that correlate to a patient not having aggressive prostate cancer, wherein a correlation to one of the predefined levels provides the diagnosis. In a specific embodiment, the one or more biomarkers may comprise cathepsin-L (CTSL), periostin, microfibrillar-associated protein 4 (MFAP4), collagen XII, neprilysin, clusterin, neutrophil gelatinase associated lipocalin (NGAL), epithelial cell activating molecule (EpCAM), prostate specific antigen (PSA), membrane metallo-endopeptidase (MME) and asporin (ASPN). | 04-17-2014 |
20140106370 | BIOMAKERS USEFUL IN LIVER FIBROSIS DIAGNOSIS - Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and β-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis. | 04-17-2014 |
20140113310 | CANCER DETECTION MARKERS - Methods and compositions involving molecular markers for the detection and characterization of cancer in a patient are provided. | 04-24-2014 |
20140113311 | AGGLUTINATION ENHANCER - The purpose of the present invention is to provide an agglutination enhancer which shows superior agglutination enhancing effect to those of conventional immunoagglutination enhancers, and the present invention relates to an agglutination enhancer for an immunoagglutination measurement method which comprises a polymer having a monomer unit shown by the following general formula [1]: | 04-24-2014 |
20140120551 | METHODS OF DIAGNOSING, PREDICTING AND TREATING CARDIOVASCULAR DISEASE - Methods for determining an increased risk of developing a cardiovascular event excluding stable angina in a subject are disclosed. Also disclosed are methods for diagnosing a human subject's myocardial infarction (MI) and/or acute coronary syndrome (ACS) state or identifying a human subject's risk of MI and/or ACS. | 05-01-2014 |
20140127711 | Method And System For Detecting Lymphosarcoma in Cats Using Biomarkers - The invention provides a method and system for developing and using diagnoses of lymphosarcoma in feline subjects using Thymidine kinase (TK) and haptoglobin (HP) as biomarkers. The invention provides a method for obtaining the level of each biomarker and computing an index for a feline subject. The invention provides predefined index ranges to which the index value may be matched in order to determine whether the subject has a high probability of being affected by lymphosarcoma, even when the subject shows apparent symptoms that may be common with inflammatory bowel disease. | 05-08-2014 |
20140127712 | USE OF BACTERIAL BETA-LACTAMASE FOR IN VITRO DIAGNOSTICS AND IN VIVO IMAGING, DIAGNOSTICS AND THERAPEUTICS - Provided herein are assays and in vitro methods to determine susceptibility to a drug effective against a pathogenic bacteria, for example, a pathogenic Mycobacteria, that has a beta-lactamase activity. An excitation wavelength is delivered to a biological sample obtained from a subject having an infection from the pathogenic bacteria in the presence of a beta-lactamase substrate. The intensity of a signal, such as a fluorescent, luminescent or colorimetric signal, at an emission wavelength of a product of the beta-lactamase on the subject is correlated to drug susceptibility. Also provided is an assay system for monitoring drug susceptibility of a pathogenic bacteria comprising color-producing substrates for a beta-lactamase of the pathogenic bacteria, an assay device for visibly detecting a product of the beta-lactamase on the substrate thereof and a reader configured to quantify the visibly detected product. | 05-08-2014 |
20140127713 | MEANS FOR THE EXAMINATION OF BODY FLUIDS - The invention provides means for making examinations on a sample of body fluid, particularly a sample of blood. The presence of at least one characteristic protein is additionally detected, and the intended examinations are only executed and/or evaluated if said characteristic protein is present. The characteristic protein may for example be human serum albumin or hemoglobin if the body fluid is blood. Preferably, the characteristic protein is quantitatively detected in a competitive assay performed in a cartridge ( | 05-08-2014 |
20140127714 | METHOD AND ASSAY FOR DETERMINING FAS EXPRESSION - Methods and immunoassays for the determination of fatty acid synthase (FAS) expression in patients having or suspected of having a proliferative disorder, especially prostate cancer, are disclosed. The sensitive method and assay detect the level of expression of FAS in a biological sample using antibodies that are highly specific for FAS. The method and assay can be used to monitor the progression of cancer, and/or to predict the efficacy of certain treatments or the likelihood of recurrence of the cancer. | 05-08-2014 |
20140134640 | Gene Defects And Mutant ALK Kinase In Human Solid Tumors - Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The invention also provides methods for determining the presence of these mutant polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides. | 05-15-2014 |
20140141450 | Assays for Detecting Enzymatic Activity - The present invention relates to method of detecting activity of a sample. Some methods involve detecting a neo-binding-site created by the activity such as detecting an activity of a protease by detecting a neo-binding-site created by cleavage of a substrate by the protease. | 05-22-2014 |
20140141451 | ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE - Disclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinson's Disease, antibodies that specifically bind to said novel phosphorylation sites, and laboratory and clinical uses thereof. | 05-22-2014 |
20140154698 | METHODS FOR MEASURING CARCINOEMBRYONIC ANTIGEN - Disclosed herein are methods of accurately measuring carcinoembryonic antigen in a biological sample and methods of identifying and treating a mucinous cyst in a subject. | 06-05-2014 |
20140154699 | Monoclonal Antibodies which Specifically Recognize Human Liver-Carboxylesterase 1, Hybridoma Cell Lines which Produce Monoclonal Antibodies, and Uses Thereof - The present invention relates to monoclonal antibodies which specifically recognize human liver-carboxylesterase 1, hybridoma cell lines which produce monoclonal antibodies, and uses thereof. The invention can be used for the objective analysis of the expression amount of human liver-carboxylesterase 1 in tissues and blood, and the like, by being specifically bound to the human liver-carboxylesterase 1. Therefore, liver cancer can be conveniently and quickly diagnosed from urine or blood. | 06-05-2014 |
20140162285 | Methods of Modulating Vesicular Trafficking - Described are methods of identifying compounds useful for modulating vesicular trafficking, particularly those that disrupt the interactions between ARNO and the V-ATPase a2-subunit. Also described are peptides that modulate vesicular trafficking. | 06-12-2014 |
20140162286 | METHOD FOR THE DETECTION OF ENZYMATIC ACTIVITY WITH MAGNETICALLY FUNCTIONALIZED SUBSTRATES - The present invention provides methods for detecting an enzymatic activity, the method including combining at least one magnetic particle to an enzyme substrate to form a magnetically modified substrate, reacting the magnetically modified substrate with at least one enzyme; and detecting a change in a magnetic property of the magnetically modified substrate or its cleavage products, thereby detecting an activity of said at least one enzyme, wherein the method may be applied to a human subject to detect a disease selected from the group consisting of rheumatitis, arthritis, an injury, Dupuytren's disease, Peyronie's disease, a collagen related disease, steatosis, fibrosis, cirrhosis, metastasis, tissue regeneration, cancer, coronary disease, a liver disease, a metabolic condition, an infection and an inflammatory disease. | 06-12-2014 |
20140170674 | Membraine-Based Assay Devices Utilizing Time-Resolved Up-Converting Luminescence - This invention discloses an immunochromatographic assay device to detect and quantify analytes. The device utilizes up-converting luminescent probes to detect time-resolved luminescence signals. Because the unconverting luminescent probes can have relatively long emission lifetime, background interference from sample autofluorescence and light scattering from excitation source can be easily eliminated through delayed luminescence detection. Furthermore, the up-converting luminescent probes can be excited by near Infrared (IR) or IR light sources. In comparing with UV and visible lights, the near IR and IR lights can penetrate deeper into sample matrices and more effectively excite the probes, but not the sample matrices, resulting in less background and higher detection sensitivity. A simple and low cost reader can be designed to measure the delayed up-converting luminescence of long lifetime that does not use expensive optical filters and mirrors. | 06-19-2014 |
20140170675 | PROTEIN DETECTOR BASED ON MOLECULAR CONTROLLED SEMICONDUCTOR RESISTOR - The invention provides a semiconductor device for the detection of an active site-containing protein or a ligand thereof in a solution, said device comprising at least one insulating or semi-insulating layer; at least one conducting semiconductor layer, two conducting pads on top of the upper layer making electrical contact with said at least one conducting semi-conductor layer, such that electrical current can flow between them at a finite distance from the surface of the device; a protective molecular layer fabricated on top of said upper layer and protecting said layer from corrosion; and said ligand or active site-containing protein linked to said protective molecular layer. Exposure of said ligand or active site-containing protein to a solution containing said active site-containing protein or ligand, respectively, causes a current change through the device when a constant electric potential is applied between the two conducting pads. The semi-conductor device can be seen as a molecularly controlled semiconductor resistor (MOCSER) protein sensor based on doped and undoped GaAs stack structure. The GaAs is protected against etching in aqueous environments by the protective molecular layer. | 06-19-2014 |
20140178893 | NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS - Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzymes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of cancer, metastatic cancer, and obstructive and degenerative conditions. | 06-26-2014 |
20140178894 | CULTURE MEDIUM SUITABLE FOR THE CULTURE OF UNDIFFERENTIATED CELLS - The present application relates to a composition comprising the components listed in Table I in an amount that will lead to the respective concentration specified in Table I for each of said component when said composition is diluted with water into 1× medium, said composition being particularly suitable to generate a chemically-defined medium suitable for culturing cells, especially primary cells, maintaining their proliferation and differentiation potential. | 06-26-2014 |
20140186852 | BIOMARKERS FOR MYOCARDIAL ISCHEMIA - This invention relates, e.g., to a method for determining if a subject has myocardial ischemia, comprising (a) providing a blood sample obtained from a subject suspected of having myocardial ischemia; (b) determining in the sample the amount of one or more of the following proteins: (i) Lumican and/or (ii) Extracellular matrix protein 1 and/or (iii) Carboxypeptidase N; and (c) comparing the amount(s) of the protein(s) to a baseline value that is indicative of the amount of the protein in a subject that does not have myocardial ischemia, wherein a statistically significantly increased amount of the protein(s) compared to the baseline value is indicative of myocardial ischemia. Other proteins indicative of myocardial ischemia are also described, as are methods for treating a subject based on a diagnostic procedure of the invention, and kits for carrying out a method of the invention. | 07-03-2014 |
20140193831 | SEED TRAIT PREDICTION BY ACTIVITY-BASED PROTEIN PROFILING - The present invention relates to a method of predicting a plant seed trait, such as germination rate, vigour, aging and priming, by determining the presence of a target protein, i.e. diagnostic marker, in its active state in a protein sample derived from a plant seed or plant seed lot. Thereby, the quality of a plant seed or a plant seed lot can be predicted and/or diagnosed and seeds may be distinguished on basis of their characteristics and with respect to the traits described herein. Inter alia, seeds and seed lots having high germination quality may be distinguished from seeds and seed lots having low germination quality. In particular, the method comprises contacting the protein sample or the plant seed or plant seed lot with a chemical probe comprising a warhead being able to attach to an amino acid residue in or nearby an active site of the target protein under conditions allowing the formation of a conjugate of the target protein and the chemical probe, wherein the chemical probe further comprises a reporter tag which is used to detect the conjugate, and wherein detection of the conjugate indicates the presence of the target protein in the protein sample and is used to predict or diagnose the plant seed trait. The present invention further relates to the use of such chemical probes for the prediction of plant seed traits. | 07-10-2014 |
20140193832 | DETECTION OF PROSTATE CANCER USING PSA GLYCOSYLATION PATTERNS - The present invention features novel methods for determining if a subject has prostate cancer. The present invention is based on the development of lectin immunosorbant assays which analyze α2,6-linked sialylation of total serum PSA by | 07-10-2014 |
20140193833 | ISOLATION AND DETECTION OF CANCER CELLS - Provided are methods of using polycarbonate filters to isolate and detect cancer cells in a biological fluid, particularly biological fluids, such as urine, that contain very low concentrations of cancer cells. The characterization of the isolated cells for the presence or absence of cancer specific proteins is useful for cancer diagnosis and prognosis. | 07-10-2014 |
20140199705 | GLUCANASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - The invention relates to polypeptides having glucanase, e.g., endoglucanase, mannanase, xylanase activity or a combination of these activities, and polynucleotides encoding them. In one aspect, the glucanase activity is an endoglucanase activity (e.g., endo-1,4-beta-D-glucan 4-glucano hydrolase activity) and comprises hydrolysis of 1,4-beta-D-glycosidic linkages in cellulose, cellulose derivatives (e.g., carboxy methyl cellulose and hydroxy ethyl cellulose) lichenin, beta-1,4 bonds in mixed beta-1,3 glucans, such as cereal beta-D-glucans or xyloglucans and other plant material containing cellulosic parts. In addition, methods of designing new enzymes and methods of use thereof are also provided. In alternative aspects, the new glucanases e.g., endoglucanases, mannanases, xylanases have increased activity and stability at increased pH and temperature. | 07-17-2014 |
20140199706 | Methods and Compositions for Enhancing Proteasome Activity - This invention relates to methods and compositions for enhancing proteasome activity in a cell. The methods and compositions for enhancing the activity of the proteasome in cells modulate the activity of Ubp6 (yeast) or Usp14 (human), an endogenous inhibitor of the proteasome. The methods and compositions partially or completely reduce the inhibitory activity of Usp14 on a proteasome, thereby specifically enhancing the protein-degradation activity of the proteasome. The invention also provides methods of screening to identify inhibitors of Ubp6, Usp14, and/or both Ubp6 and Usp14. | 07-17-2014 |
20140199707 | METHOD FOR IDENTIFYING INHIBITORS OF STAPHYLOCOCCUS AUREUS - Provided are methods for identifying and/or designing inhibitors of | 07-17-2014 |
20140199708 | CELL-BASED METHODS FOR MEASURING ACTIVITY OF A PROTEIN INHIBITOR - The invention provides a method for determining the activity of an inhibitor of a target protein that has a deleterious effect on cell growth. The principle of the claimed method is that a compound that inhibits the function of an overexpressed protein will relieve the detrimental effect of such overexpression in a concentration-dependent manner, thereby allowing the determination of the activity of the compound in inhibiting its target protein in live cells. | 07-17-2014 |
20140199709 | METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The invention provides an ELISA assay for the determination of serum mast cell β-tryptase levels using rabbit anti-tryptase as the capture antibody and alkaline phosphatase conjugated G3 as the detecting antibody. Luminescent substrate CPSD was used to enhance the assay sensitivity. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of β-tryptase, histamine and/or prostaglandin E | 07-17-2014 |
20140206017 | LYSYL OXIDASE-LIKE 2 ASSAY AND METHODS OF USE THEREOF - The present disclosure provides an assay to detect and/or quantify circulating lysyl oxidase-like 2 (LOXL2) poly-peptides in an individual. The assay is useful in diagnostic and prognostic applications, which are also provided. | 07-24-2014 |
20140206018 | ANTIBODIES AGAINST FATTY ACID SYNTHASE - The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed. | 07-24-2014 |
20140212890 | METHODS, APPARATUSES, AND SYSTEMS FOR DETECTING AND QUANTIFYING PHOSPHOPROTEINS - Embodiments herein provide methods, apparatuses, and systems for detecting, monitoring, measuring, and/or characterizing the activity of phosphoproteins, such as tyrosine kinases (TKs) and downstream proteins in TK signal transduction pathways (e.g., TK pathway proteins). In various embodiments, the methods, apparatuses, and systems may use nanoparticles, such as quantum dots (QD), to detect and/or characterize the abnormally overactive TK signaling pathways that underlie tumorgenesis and tumor progression. In various embodiments, the QD-based methods, apparatuses, and systems may have a sufficiently high degree of sensitivity to enable the identification of new TK signaling pathway markers, for example for use in diagnosing, staging, monitoring, and/or prognosing cancers, or in evaluating the efficacy of cancer therapeutics. | 07-31-2014 |
20140212891 | Compositions and Methods Using NOX5 - Certain embodiments include methods of assessing male fertility. | 07-31-2014 |
20140220593 | INHIBITION OF PEROXIDASE ENZYMATIC ACTIVITY - The present invention deals with reagents and compositions capable of effectively inhibiting peroxidase activity. According to the invention, peroxidase enzymatic activity is blocked with an acidic aqueous solution of a protein denaturing agent. Preferred protein denaturing agents are detergents and chaotropic substances. | 08-07-2014 |
20140220594 | NMR METHODS FOR ENDOTOXIN ANALYSIS - The invention features a method of monitoring a clotting process by measuring a signal characteristic of the NMR relaxation of water in a sample undergoing endotoxi-induced clotting to produce NMR relaxation data and determining from the NMR relaxation data a magnetic resonance parameter of water in the sample characteristic of the level of endotoxin present in the sample. | 08-07-2014 |
20140234860 | MEASUREMENT OF PKA FOR CANCER CHARACTERIZATION - A method for characterizing a carcinoma in a subject. The method comprises assaying a sample of a bodily fluid derived from the subject for extracellular PKA activity and comparing the activity to a reference value. In the assay, a reaction mixture is prepared comprising the previously unfrozen sample, a PKA peptide substrate, a phosphorylation agent, the prepared mixture is incubated, and phosphorylated substrate formed in the incubated mixture is detected. The reference value is the amount of phosphorylated substrate formed in a mixture under equivalent redox conditions for a sample of bodily fluid derived from a population of normal subjects of the same species. | 08-21-2014 |
20140234861 | METHOD FOR DIAGNOSIS, PROGNOSIS OR TREATMENT OF ACUTE CORONARY SYNDROME (ACS) COMPRISING MEASUREMENT OF PLASMA CONCENTRATION OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) - A method for diagnosing acute coronary syndrome (ACS) in a subject, the method comprising measuring plasma macrophage migration inhibitory factor (MIF) concentration in a sample from the subject, and diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, wherein the sample is taken less than 4 hours after symptom onset. The invention also relates to a method for prognosing ACS in a subject, the method comprising measuring plasma MIF concentration in a sample from the subject, diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, and prognosing the magnitude of ACS from the subject plasma MIF concentration. Also provided is a method of treating ACS in a subject, a device, a kit, and a cardiac biomarker related to the methods of diagnosing and prognosing ACS. | 08-21-2014 |
20140242606 | PROBE FOR iFRET AND USE THEREOF - The present invention relates to a probe for iFRET and use thereof. Specifically, the present invention relates to a novel probe for iFRET, a method for preparing the probe for iFRET, a method for searching a target protein-specific binding site or a molecule having the binding site using the probe for iFRET, and a method for imaging the target protein using the probe for iFRET. The probe for iFRET according to the present invention utilizes an amino acid in a protein as a fluorescent donor, unlike the conventional FRET method. Therefore, only one fluorescent material is used, and its emission wavelength is distinct from the intrinsic fluorescence of the protein. Thus, high specificity and sensitivity are ensured, and the quantity, activity and mechanism of various proteins can be analyzed in an easy and accurate manner. | 08-28-2014 |
20140242607 | ANTIBODY FOR DETECTING EPITHELIAL OVARIAN CANCER MARKER AND METHOD FOR DIAGNOSING EPITHELIAL OVARIAN CANCER - It is intended to find a highly specific epithelial ovarian cancer marker and to provide an antibody capable of specifically recognizing and detecting the marker or a fragment of the antibody. The present invention provides an anti-β1,6-N-acetylglucosaminyltransferase 5B antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase β1,6-N-acetylglucosaminyltransferase 5B as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1. | 08-28-2014 |
20140248635 | ALPHA-TUBULIN ACETYLTRANSFERASE - Polypeptides with tubulin acetyltransferase activity are described, as are nucleic acids encoding said polypeptides, and methods of use. The invention further provides enhancers and inhibitors of tubulin acetyltransferase activity, as well as cells having altered tubulin transferase activity. | 09-04-2014 |
20140248636 | ASSAY FOR HISTIDINYL HYDROXYLASE ACTIVITY - The present invention relates to assays for monitoring activity of Mina53 and NO66 activities, in particular, to assays for identifying modulators of Mina53 and NO66 activities. The invention also relates to assays to monitor the histidinyl hydroxylase activity of Mina53 and NO66 on their substrates, the human ribosomal protein Rpl27a and Rpl8 respectively. The invention also enables the introduction of S-3-hydroxyhistidinyl residues into peptides and proteins. | 09-04-2014 |
20140248637 | COMPOSITION FOR DIAGNOSIS OF LUNG CANCER AND DIAGNOSIS KIT OF LUNG CANCER - Disclosed is as a biomarker useful in early diagnosis of lung cancer, at least one protein selected from the group including Quescin-sulfhydryl oxidase 1, Fibrillin-1, Isoform A of Lamin-A/C, Latent-transforming growth factor beta-binding protein 2, Galectin-1, highly similar to Dickkopf-related protein 3, Isoform A1-B of Heterogeneous nuclear ribonucleoprotein A1, 14-3-3 protein epsilon, Stanniocalcin-2, Cystatin-C, Isoform 1 of Connective tissue growth factor, Profilin-1, Isoform 1 of Extracellular matrix protein 1, Histone H2B type 2-E, Kinesin-like protein KIF26A, Zinc finger protein 516, and Isoform 1 of A-kinase anchor protein 9. | 09-04-2014 |
20140255951 | ANTIBODIES THAT BIND TO LYSYL OXIDASE-LIKE 2 (LOXL2) AND METHODS OF USE THEREFOR - The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided. | 09-11-2014 |
20140255952 | DEGRADABLE CARBON NANOTUBE-CONTAINING BIOSENSORS AND METHODS FOR TARGET CLINICAL MARKER DETECTION - The invention relates to carbon nanotube-containing composites as biosensors to detect the presence of target clinical markers, methods of their preparation and uses in the medical field. The invention is particularly suitable for the detection in patient biological specimens of bone markers and tissue markers. The biosensors of the invention include carbon nanotubes deposited on a substrate, gold nanoparticles deposited on the carbon nanotubes and, binder material and biomolecule deposited on the gold-coated carbon nanotubes. The biomolecule is selected to interact with the target clinical markers. The biosensor can be used as an in-situ or an ex-situ device to detect and measure the presence of the target clinical markers. | 09-11-2014 |
20140255953 | GRANZYME A AND GRANZYME B DIAGNOSTICS - A method for identifying a subject being at risk for or having a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin. | 09-11-2014 |
20140273007 | DEVICES AND METHODS FOR SCREENING NIPPLE ASPIRATE FOR MARKERS INDICATIVE OF RISK OF DEVELOPING BREAST CANCER - A diagnostic test system, apparatus and method for identifying individuals at risk for developing or having breast cancer by detection of at least one marker associated with increased breast cancer risk in nipple aspirate fluid is provided. A testing device for screening nipple aspirate fluid for the presence of biomarkers associated with breast cancer and methods of identifying individual biomarkers and biomarker panels for evaluating the risk that an individual has developed or will develop breast cancer by assaying nipple aspirate fluid is described. | 09-18-2014 |
20140273008 | METHODS TO ASSESS ENZYME ACTIVITY USING MASS SPECTROMETRIC IMMUNOASSAY - Methods to assess biological enzyme activity directly in a complex clinical sample. To such a sample, e.g., plasma, an exogenous synthetic peptide substrate for an enzyme present in the sample and to be assessed is added. The sample then undergoes mass spectrometric immunoassay (MSIA) to monitor the mass spectral profile of the immuno-purified exogenous synthetic peptide substrate directly from the sample. Using the resulting profile, parameters such as enzyme activity and effect of enzyme modulators, including therapeutics administered to an individual for a condition involving the enzyme, may be determined. | 09-18-2014 |
20140287432 | Diagnosis, Prevention and Treatment of Disorders Characterized by Undesirable Cell Proliferation - The present invention relates to methods for the diagnosis, prevention and treatment of heart disease or heart failure in a subject. The present invention also relates to methods for the diagnosis, prevention and treatment of atherosclerosis with vulnerable plaque in a subject. Furthermore, the present invention relates to methods for the diagnosis, prevention and treatment of cardiomyopathies resulting from Chagas disease. | 09-25-2014 |
20140287433 | MEANS AND METHODS FOR DETERMINING CLOSTRIDIAL NEUROTOXINS - This invention relates to a method of determining presence, amount and/or activity of a clostridial neurotoxin in a sample, the method comprising or consisting of the following steps: (a) bringing said sample into contact with a liposome, said liposome comprising (aa) at least one receptor on its outer surface, said receptor being capable of binding said neurotoxin and comprising or consisting of (i) a glycolipid and (ii) a peptide or protein; and (ab) a substrate in its interior, said substrate (i) being cleavable by the peptidase comprised in said neurotoxin and (ii) generating a detectable signal upon cleavage, said detectable signal preferably being generated by (1) the donor of a FRET pair, said donor exhibiting increased fluorescence upon cleavage by said peptidase, (2) a luminescent compound formed upon said cleavage, or (3) an enzyme formed upon said cleavage; and (b) determining whether an increase in signal occurs as compared to the absence of said sample, wherein such increase is indicative of the presence of said neurotoxin and/or the degree of such increase is indicative of the amount and/or activity of said neurotoxin in said sample. | 09-25-2014 |
20140287434 | METHODS OF SCREENING FOR AND IDENTIFYING COMPOSITIONS WHICH MODULATE CELLULAR KINASE ACTIVITIES - The present invention relates to drug screening assays, therapeutic protocols and pharmaceutical compositions designed to target non-receptor tyrosine family kinases and components of the tyrosine kinase family signal transduction pathways. This includes primarily diseases or conditions associated with immune responses and can include treatment for cancers as well as various immune disorders. The invention reports a novel substrate SH2 domain docking mechanism apart from the kinase active site that is required for appropriate tyrosine phosphorylation by these tyrosine kinases. | 09-25-2014 |
20140295455 | ANTIBODY FOR DETECTING EPITHELIAL OVARIAN CANCER MARKER AND METHOD FOR DIAGNOSING EPITHELIAL OVARIAN CANCER - The present invention provides an antibody capable of specifically recognizing and detecting the highly specific cancer marker with respect to the epithelial ovarian cancer, or a fragment of the antibody. The present invention provides an anti-β1,3-N-acetylglucosaminyltransferase 3 antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase β1,3-N-acetylglucosaminyltransferase 3 as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1. | 10-02-2014 |
20140295456 | RENAL CELL CARCINOMA BIOMARKERS - Disclosed herein is a method of identifying a tumor biomarker. In one example, a tumor biomarker is identified by obtaining a peripheral biological fluid sample from a subject with a tumor as well as a tumor sample and an adjacent non-tumor sample from such subject. A protein expression profile is detected in the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample. The protein expression profiles of the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample are then compared, wherein an increase in expression of a specific protein in the tumor sample and peripheral biological fluid sample but not in the adjacent non-tumor sample indicates that the specific protein is a biomarker of the tumor. Also disclosed herein is a gene profiling signature that can be used to diagnosis a subject with renal cell carcinoma (RCC) or to identify agents with therapeutic potential to treat RCC. Thus, methods of diagnosing a subject with RCC are disclosed. Methods are also provided for identifying agents that alter an activity of a RCC biomarker. | 10-02-2014 |
20140295457 | GENE CLUSTER FOR BIOSYNTHESIS OF GRISELIMYCIN AND METHYLGRISELIMYCIN - The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents. | 10-02-2014 |
20140302524 | ANTIBODIES THAT BIND TO LYSYL OXIDASE-LIKE 2 (LOXL2) AND METHODS OF USE THEREFOR - The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided. | 10-09-2014 |
20140302525 | METHODS OF IDENTIFYING SENP1 INHIBITORS - Provided herein are methods of detecting binding of an SENP1 polypeptide to a compound and methods for screening for inhibitors of SENP1. Further provided are aqueous compositions comprising SENP1 polypeptides and NMR apparatuses comprising the compositions for NMR analysis. | 10-09-2014 |
20140302526 | ZAP-70 DETECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA - Detection of ZAP-70 expression provides important information about disease progression and overall survival in patients with chronic lymphocytic leukemia (CLL). The invention provides methods for diagnosing CLL in a subject, as well as methods for clearly distinguishing CLL patients with aggressive form of the disease. A consistent number of B cells from patient blood is isolated and lysed to release all of the intracellular ZAP-70 protein. The released ZAP-70 protein is subsequently extracted by immunomagnetic separation followed by detection with fluorescence immunosandwich assay. The ZAP-70 fluorescence signal is measured with Signalyte™-II spectrofluorometer. The VeriZAP™ assay is a simple, reliable, and reproducible method for quantitative detection of ZAP-70 in patient leukemic cells, and can be used as a prognostic test to distinguish indolent versus aggressive CLL patients. | 10-09-2014 |
20140308679 | Fluorometry - The invention relates to fluorometry, and in particular to methods and apparatus for time-delayed detection of fluorescence in a sample, for example for use in a clinical setting. Exemplary embodiments disclosed relate to a fluorometer ( | 10-16-2014 |
20140308680 | METHOD FOR DETECTION OF COAGULATION ACTIVITY AND BIOMARKERS - The present invention relates to a method for simultaneous detection of the coagulation activity of a blood sample and of the presence and/or amount of at least one target molecule within said blood sample, comprising the steps of: i) introducing a blood sample into a sample container comprising magnetic particles and a sensor surface, wherein said magnetic particles are functionalized with a first binding molecule, wherein said first binding molecule is attached to said magnetic particles, wherein the first binding molecule is capable of specifically binding to the at least one target molecule within said blood sample, and wherein a second binding molecule is attached to a sensor surface at the bottom of said sample container, and wherein said second binding molecule of the sensor surface is capable of specifically binding to the at least one target molecule within said blood sample; ii) measuring the presence and/or amount of said target molecule by detecting the number of magnetic particles bound to said sensor surface; wherein the number of bound magnetic particles is directly or inversely related to the amount of said at least one target molecule present in the sample; iii) at the same time or at different times measuring the co-agulation activity of said blood sample, wherein said magnetic particles are magnetically actuated; and wherein the loss of mobility of said magnetic particles is detected by measuring the light reflected from said immobilized magnetic particles near or at said sensor surface; and wherein the change of detected light signal is indicative of an increase of viscosity and/or a clotting of the blood sample; and wherein the magnetic particles in steps i) to iii) are magnetically actuated using a magnetic field generator. | 10-16-2014 |
20140315214 | CHAPERONE INTERACTION ASSAYS AND USES THEREOF - In some aspects, the invention provides methods of identifying, detecting, and/or measuring protein-protein interactions. In some aspects, the invention provides methods of identifying and/or characterizing modulators of protein-protein interactions. In some aspects, the invention provides methods of identifying and/or characterizing modulators of protein activity, wherein the methods are based at least in part on measuring interaction between a chaperone and client protein. In some aspects, the invention provides methods for identifying and/or characterizing compounds and/or for assessing compound specificity, wherein the methods are based at least in part on measuring interaction between a chaperone and client protein. In some embodiments, a client protein is a kinase. In some embodiments, a compound is a kinase inhibitor. In some aspects, the invention provides methods of profiling kinase inhibitor specificity. In some aspects, the invention provides assay systems and/or reagents useful for performing one or more of the inventive methods. In some aspects, the invention provides newly identified targets of a variety of kinase inhibitors. In some aspect, the invention provides methods of inhibiting kinases identified herein as targets of certain kinase inhibitors. In some aspects, the invention provides methods of treating a disease, e.g., cancer, by inhibiting one or more kinase(s) newly identified as targets of certain kinase inhibitors. | 10-23-2014 |
20140315215 | THERMOSTABLE ASSAY REAGENTS - There is provided a single-chain fusion protein comprising: (i) a thermostable kinase and (ii) a single-domain antibody or single-domain antibody fragment. There is also provided a method of preparing a single-domain antibody or single-domain antibody fragment, the method comprising: (i) expressing the single-domain antibody or antibody fragment as a single-chain fusion protein with a thermostable kinase, in a host cell such as | 10-23-2014 |
20140315216 | Immunoassay Test Slide - An immunoassay test slide for use in a dry chemistry analytical instrument includes a slide housing or case formed from two matable sections—a slide cover piece and a slide bottom piece. The slide housing defines an interior cavity in which is situated a sheet-like porous carrier matrix. The slide cover piece has an opening formed through the thickness thereof to expose a central portion of the fluid flow matrix so that a precise volume of fluid sample of blood, serum or the like, preferably pre-mixed with a conjugate reagent, and precise volumes of a wash reagent and a substrate (detector reagent), may be deposited on the matrix through the cover opening by a metering device of the analytical instrument. The bottom piece of the immunoassay test slide is transparent, and the slide is moved by a transport mechanism of the analytical instrument over a reflectometer or a fluorometer for performing reflectance or fluorescence measurements. | 10-23-2014 |
20140322725 | SENSORS AND ASSAYS FOR UBIQUITIN OR UBIQUITIN-LIKE PROTEINS - The present invention provides compositions comprising chimeric polypeptides that bind to free ubiquitin proteins or free ubiquitin-like proteins with high affinity, as well as chimeric polypeptides that bind to both free and conjugated ubiquitin proteins or free and conjugated ubiquitin-like proteins, and methods of using the chimeric polypeptides to determine the amount of free or total ubiquitin or free or total ubiquitin-like proteins in various types of samples. | 10-30-2014 |
20140322726 | MONOCLONAL ANTIBODY SPECIFICALLY RECOGNIZING ASPARAGINE SYNTHETASE - It is an object of the present invention to provide a monoclonal antibody, which is suitable for the quantitative analysis of asparagine synthetase in a cell. The present invention provides a monoclonal antibody which specifically recognizes asparagine synthetase that is present in a cell. | 10-30-2014 |
20140329252 | METHODS AND KITS FOR DIAGNOSING AND/OR PROGNOSING OSTEOARTHRITIS - A method of determining whether a subject is at risk of developing osteoarthritis (OA), said method comprising: determining the cellular localization of a Prohibitin-1 (PHB1) polypeptide and/or Small Ubiquitin-like Modifier (SUMO) polypeptide and/or UBC9, in a cell sample from said subject; and determining whether said subject is at risk of developing OA based on the cellular localization of a PHB1 polypeptide and/or SUMO and/or UBC9 polypeptide, is described. | 11-06-2014 |
20140329253 | Monoclonal Antibody For The Detection of SNAP/CLIP Tag - A monoclonal antibody that binds specifically to the SNAP motif and to the CLIP tag comprising CDRs with the amino acid sequences SEQ ID Nos. 3, 4, 5, and 8, 9, 10. | 11-06-2014 |
20140335537 | DEVICES FOR PERFORMING COLORIMETRIC ASSAY WITH PLUCKED HUMAN HAIR - Apparatuses are disclosed for performing calorimetric assays with plucked human hair using a device adapted for that purpose. This device may include a transparent reaction vessel connected via a capillary tube to a burst pack, and connected via another capillary tube to a funnel, into which a plucked human hair may be placed. | 11-13-2014 |
20140335538 | METHODS OF DIAGNOSING ALS - The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof. | 11-13-2014 |
20140342373 | MICROFLUIDIC SYSTEM - The present invention concerns a microfluidic system comprising: a microchannel containing several elements of two non-miscible fluids, the microchannel comprising a droplet ( | 11-20-2014 |
20140349309 | METHODS AND COMPOSITIONS FOR TREATMENT AND DIAGNOSIS OF FIBROSIS, TUMOR INVASION, ANGIOGENESIS, AND METASTASIS - The present disclosure provides innovative methodology and related compositions and kits for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an inhibitor of processed forms of lysyl oxidase or lysyl oxidase-like proteins, an inhibitor of LOX and an inhibitor of a LOXL, or a synergistic combination of an inhibitor of LOX or LOXL combined with other therapeutic agents. Also provided are innovative methods for selecting agents that prevent or inhibit tumor invasion, angiogenesis and metastasis, by contacting cells that are in an epithelial-mesenchymal transition (EMT) state with a candidate agent and detecting a change in the EMT state of the cells. Methods and related compositions and kits for diagnosing or monitoring various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using molecules or agents that specifically recognize processed forms of LOX or LOXL are also provided. Also provided herein are methods and related compositions, medical devices, systems and kits for preventing or treating various diseases and conditions associated with fibrosis with compositions comprising inhibitors of LOX or LOXL. Such diseases or conditions include pathological cardiovascular conditions and diseases such as hypertension, hypertensive heart disease, myocardial infarction, atherosclerosis, and restenosis, liver fibrosis, kidney fibrosis, lung fibrosis, dermal scaring, keloid formation, and Alzheimer's disease. | 11-27-2014 |
20140349310 | Anti-c-Met Antibodies - Provided is a monoclonal antibody, or antigen-binding fragment thereof that binds to c-Met. Such antibodies, or antigen-binding fragments thereof, are useful in in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting cell surface c-Met receptor levels for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients harboring tumors in which c-Met is implicated in pathogenesis. | 11-27-2014 |
20140356882 | NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS - Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzyme complexes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of metastatic cancer by the identification of high molecular weight enzyme complexes comprising MMPs. | 12-04-2014 |
20140356883 | METHOD FOR EVALUATING THE SENSITIVITY AND SPECIFICITY OF FAST MALARIA- DIAGNOSIS TEST KITS - The invention relates to a method for evaluating kits for rapid diagnosis of malaria, in order to determine or to test the sensitivity and specificity thereof. To that end, the reactive strips of the diagnostic kits are exposed to different concentrations of the malaria parasite in a method that allows data on sensitivity and specificity indicated on the technical sheet of the kit to be ascertained. | 12-04-2014 |
20140370520 | METHODS AND COMPOUNDS FOR DETECTING CANCER - The invention relates to a method for diagnosing cancer, particularly bladder or prostate cancer using compounds of general formula (I): | 12-18-2014 |
20140370521 | IDENTIFICATION OF TWO NOVEL BIOMARKERS FOR NIEMANN-PICK DISEASE TYPE C - This invention provides novel biomarkers for Niemann-Pick disease, type C (NPC). In an exemplary embodiment, the invention provides methods for identifying a subject as having NPC. In embodiments, the methods involve detecting the level of biomarker selected from the group comprising i) galectin-3 (LGALS3); ii) cathepsin D (CTSD); iii) LGALS3 and CTSD; and iv) LGALS3 and/or CTSD in combination at least one additional NPC associated biomarker in a sample obtained from the subject. In embodiments, the methods involve comparing the level of biomarker to a reference. | 12-18-2014 |
20140377773 | Detection Marker for Anticancer Effects by Selenomethionine as an Inhibitor of Environmental Toxicity - The present invention relates to specific markers capable of detecting the development of colorectal cancer and the colorectal cancer inhibitory effect of SeMet (selenomethionine) having a chemopreventive effect against colorectal cancer. When the expressions of the biomarkers according to the present invention are measured and the expression levels thereof are analyzed in combination, whether SeMet (selenomethionine) is to be administered to prevent colorectal cancer can be determined and the development of colorectal cancer and the inhibitory effect of SeMet (selenomethionine) against the development of colorectal cancer can be monitored. Thus, these markers can be effectively used to observe the colorectal cancer inhibitory effect of SeMet (selenomethionine) and the prognosis of colorectal cancer resulting from the intake of SeMet (selenomethionine). | 12-25-2014 |
20140377774 | PAS KINASE ASSAYS - The present invention is directed towards methods for measuring and assaying PAS Kinase activity. The methods are useful, for example, for detecting PASK activity in a cell, and for screening for small molecule regulators of PAS kinase activity, as well as characterizing endogenous factors and stimuli that modulate PAS kinase activity, and identifying and optimizing the activity of potential PAS kinase inhibitors. | 12-25-2014 |
20150010920 | Enzyme Sensors, Methods For Preparing And Using Such Sensors, And Methods Of Detecting Protease Activity - Embodiments of the present disclosure provide for enzyme sensors, protease sensors, methods for producing and using the enzyme and protease sensors, methods of detecting and/or measuring protease activity, methods for characterizing protease cellular activity, fusion proteins, polynucleotides, and vectors corresponding to the enzyme and protease sensors, kits, and the like. | 01-08-2015 |
20150017656 | Rapid Lateral Flow Assay Method for Detecting Low Quantity Liquid or Dry Samples - This invention describes a design of a lateral flow assay device that detects dried chemicals or trice volume aqueous sample solutions, applicable for detecting body fluids and dried or liquid chemicals. The dried or aqueous samples on the sample loading area will contact with a secondary aqueous solution in described manner and flow to the reaction area. This invention enables a complete lateral flow assay while the sample volume itself is too small to accomplish a complete lateral flow test. | 01-15-2015 |
20150024403 | METHOD FOR DETECTING REPLICATION OR COLONIZATION OF A BIOLOGICAL THERAPEUTIC - Methods for detecting replication in or colonization of a host by a biological therapeutic, such as an oncolytic virus, cells administered for cell therapy and gene therapy vectors, are provided. In the methods, a product produced by the biological therapeutic is detected in a sample of tissue or body fluid distinct from the administered therapy or locus thereof, thereby permitting assessment of the therapy and/or monitoring its progress. | 01-22-2015 |
20150031047 | Methods and Systems For the Rapid Characterization of Functional Biological Molecules - In one non-limiting aspect, the invention provides a method for detecting the quality of a biological molecule comprising forming a first mixture of ingredients comprising: (i) a first binding agent that specifically binds to a tag, wherein the first binding agent is attached to a solid support; (ii) a decoy comprising a first portion comprising the tag attached to a second portion comprising an anchor; (iii) a sensor attached to a second binding agent that specifically binds to the anchor; and (iv) a sample suspected of containing a high quality biological molecule comprising a tag, wherein the tag of the high quality biological molecule is accessible; allowing interaction of the ingredients such that the sensor provides an output signal | 01-29-2015 |
20150031048 | CITRULLINATED BRAIN AND NEUROLOGICAL PROTEINS AS BIOMARKERS OF BRAIN INJURY OR NEURODEGENERATION - The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing brain injury or neurodegeneration. In one embodiment, a method for diagnosing brain injury in a patient comprises the steps of (a) obtaining a sample from the patient; (b) determining the ratio of citrullinated to unmodified arginine residues at one or more arginine residues of one or more brain injury biomarker proteins; and (c) correlating the ratio to a patient having brain injury or to a patient not having brain injury, thereby providing the diagnosis. | 01-29-2015 |
20150031049 | METHOD OF PREDICTING ACUTE APPENDICITIS - Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich α-2-glycoprotein (LRG); S100-A8 (calgranulin); α-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-α-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and α-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals. | 01-29-2015 |
20150037814 | NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS - Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzymes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of cancer, metastatic cancer, and obstructive and degenerative conditions. | 02-05-2015 |
20150037815 | METHOD FOR THE TOPOGRAPHICALLY-SELECTIVE PASSIVATION OF MICRO- AND NANOSCALE DEVICES - Disclosed is a method of preparing a biosensor that involves providing a substrate including a surface having a topographical pattern formed at one or more sites on or in the surface, coating the substrate with a solution including hydrogel particles, wherein the hydrogel particles self-assemble on the surface to mask the surface except at the one or more sites, and binding one or more capture molecules to the one or more sites to form the biosensor. Systems that include the biosensor, as well as methods of using the biosensor, are also disclosed. | 02-05-2015 |
20150037816 | PCSK9 Function Assay - Methods and apparatuses for measuring the concentration of functional proprotein convertase subtilisin/kexin type 9 (PCSK9). A method of measuring functional PCSK9 in a sample is provided, by contacting the sample with a PCSK9-binding agent capable of binding to the LDL-R-binding region of a PCSK9; and measuring the amount of functional PCSK9 from the sample bound to the binding agent. Diagnostic methods, kits, and reagents for using the method are also provided. | 02-05-2015 |
20150044691 | BLOOD MARKER FOR RENAL CANCER - The present invention provides a blood marker for renal cancer, more specifically, a blood marker that can be practically used for clinical diagnosis of renal cancer. The present invention also provides a blood marker that can be practically used for follow-up after treatment such as surgery and during treatment such as medication for renal cancer. A blood marker for renal cancer selected from the group consisting of Galectin-1, Galectin-3, and α-enolase. Galectin-1 and/or Galectin-3 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging. α-Enolase as a blood marker for renal cancer for use in monitoring during and/or after treatment for renal cancer. | 02-12-2015 |
20150050664 | ENZYME CONCENTRATION AND ASSAYS - A method of preparing a sample for conducting an assay, the method including: providing an input sample including glycoproteins; capturing glycoproteins from the input sample on a solid support; and washing the sample support to remove unbound portions of the input sample. | 02-19-2015 |
20150050665 | PREDICTIVE BIOMARKERS FOR BREAST CANCER - The invention relates to compositions and methods for detecting, screening, diagnosing or determining the progression of, regression of and/or survival from a proliferative disease or condition, specifically breast cancer. The invention also provides new assays and kits for the staging or stratifying breast cancer patients or patients suspected of having breast cancer. | 02-19-2015 |
20150050666 | NON-SPECIFIC REACTION INHIBITOR - Disclosed is a non-specific reaction inhibitor for use in an immunological measurement, comprising a complex of an antibody or a fragment of the antibody capable of specifically binding to a non-specific reaction factor, and a polymer. The non-specific reaction inhibitor can inhibit a non-specific reaction which may interfere with the accurate detection or quantification of a trace substance in an immunological measurement method. | 02-19-2015 |
20150056633 | DETECTION OF GLUTATHIONYLATED PROTEINS - The present invention, in some aspects, relates to systems and methods for determining oxidized proteins, including glutathionylated proteins such as S-glutathionylated proteins. The systems and methods of the invention can be used in vitro (e.g., in cell or tissue culture) or in vivo, for example, to diagnose a person having an oxidative stress condition. For instance, in some cases, the invention can be used to spatially determine the location and/or concentration of oxidized proteins within cells and/or tissues (e.g., through visual detection). In one set of embodiments, a glutathionylated or otherwise oxidized moiety on a protein may be reacted with a detection entity, which may be, for example, fluorescent, radioactive, electron-dense, able to bind to a signaling entity or a binding partner in order to produce a signal, etc. As a specific example, a glutathionylated moiety on a glutathionylated protein may be reacted with an alkylating agent to form an alkylthio moiety; the alkylthio moiety may include a detection entity or otherwise be able to interact with a signaling entity. In some embodiments, other moieties on the protein may be altered or blocked before reaction of the protein with the detection entity. Such moieties on the protein may be, for instance, non-oxidized or non-glutathionylated moieties able to react with the detection entity. As a particular example, in a protein containing a glutathionylated moiety and non-glutathionylated thiol moieties, the thiol moieties may first be altered or blocked prior to reaction of the protein with the detection entity. Also provided in certain aspects of the present invention are kits for determining oxidized proteins, which may include components such as detection entities, alkylating agents, blocking agents, reducing agents, signaling entities, binding partners, antibodies, instructions, and the like. | 02-26-2015 |
20150064714 | Polypeptides containing a modified fragment of the peptide IF1 - Labelled polypeptide constituted by:
| 03-05-2015 |
20150064716 | Goodpasture Antigen Binding Protein and Its Detection - The present invention provides native Goodpasture antigen binding protein isoforms, monoclonal antibodies directed against such proteins, and methods for their use. | 03-05-2015 |
20150072355 | FLAP ENDONUCLEASE-1 AS A MARKER FOR CANCER - Methods aiding in the assessment of cancer comprising use of the Flap endonuclease-1 protein (=FEN1) as a universal marker of different cancer types are provided. In particular, methods for assessing cancer from a liquid sample derived from an individual, which comprise measuring FEN1 in the sample are disclosed. Measurement of FEN1 is useful for the early detection of cancer or in the monitoring of patients who undergo surgery for tumor removal. | 03-12-2015 |
20150079607 | METHODS FOR MONITORING NEUROINFLAMMATORY DESTRUCTION OF NEURONS AND FOR TREATING DISEASES HAVING AN INFLAMMATORY COMPONENT RELATED TO PHOSPHOLIPASE A2 - The present invention relates to methods useful to monitor central and peripheral nervous system neuron/axon destruction resulting from an increase in acute phase inflammatory enzymes. The methods have applicability to monitoring the progress of neurological diseases, including multiple sclerosis and Alzheimer's disease, as well as neuroinflammatory damage that results from sports injuries, vigorous physical activity or any form of physical abuse. The invention further relates to methods of treating multiple sclerosis or other diseases with an inflammatory component related to phospholipase A2. | 03-19-2015 |
20150086998 | VALUE-ASSIGNED SOLUTIONS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 HAVING A LONG SHELF-LIFE - Value-assigned solutions having predetermined concentrations of recombinant Lp-PLA2 are described herein. In particular, described herein are solutions of rLp-PLA2 that are stable for an extended period of time. Kits and assays include these calibration solutions, as well as methods of making and using them are described. | 03-26-2015 |
20150086999 | LONG SHELF-LIFE KITS AND METHODS FOR STANDARDIZING, VERIFYING, CALIBRATING OR RECALIBRATING DETECTION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 - Long shelf-life kits, value-assigned solutions, and methods for standardizing, verifying, calibrating or recalibrating detection of lipoprotein-associated phospholipase A2 having using them are described herein. In particular, described herein are methods of using solutions of rLp-PLA2 that are stable for an extended period of time to standardize, verify, calibrate or recalibrate assays for Lp-PLA2. | 03-26-2015 |
20150093758 | PSA CAPTURE AGENTS, COMPOSITIONS, METHODS AND PREPARATION THEREOF - Disclosed herein are novel synthetic prostate specific antigen (PSA)-targeted capture agents that specifically bind PSA. In certain embodiments, these PSA capture agents are biligand or triligand capture agents containing two or three target-binding moieties, respectively. | 04-02-2015 |
20150093759 | COMPOSITIONS AND METHODS FOR DETECTING NITRATION OF PKG-1a AND METHODS OF USE THEREOF - Antibodies for detecting nitration of nitrotyrosine 247 PKG-1α and antibodies for detecting nitrotyrosine 425 of PKG-1α are disclosed. Methods of detecting nitrotyrosine 247 PKG-1α and nitrotyrosine 425 of PKG-1α, and uses thereof are also disclosed for identification and diagnosis or phenotypes, pathologies, diseases and disorders associated with protein nitration of PKG-1α are also disclosed. In a preferred embodiment, one or more of the disclosed antibodies is used in the disclosed methods. | 04-02-2015 |
20150099270 | METHOD OF SCREENING PHARMACEUTICALS FOR DRUG INTERACTIONS AND NEPHROTOXICITY - A method of determining nephrotoxicity of pharmaceuticals by conducting a metabolite formation study in cells using PAH in a control group; measuring metabolite formation; exposing cells to pharmaceuticals in the treatment group; conducting the metabolite formation study using PAH; measuring the metabolite formation in the treatment group; comparing the metabolite formation in the control and treatment group, and making a determination as to the nephrotoxicity of pharmaceutical. | 04-09-2015 |
20150104806 | Parkinson's Disease Biomarker - The present invention relates to a biomarker for Parkinson's disease. The biomarker and products associated with the biomarker may be used to assist diagnosis or to assess onset and/or development of Parkinson's disease. The invention also relates to use of the biomarker in clinical screening, assessment of prognosis, evaluation of drug treatments, drug screening or drug development in the field of Parkinson's disease and Parkinson's disease related disorders. | 04-16-2015 |
20150104807 | KITS FOR DIAGNOSTIC AND THERAPEUTIC USES OF AUGMENTER OF LIVER REGENERATION IN INFLAMMATORY CONDITIONS - The present invention provides for methods and kits for detecting sepsis, trauma/hemorrhage or inflammation in a subject. It is based, at least in part, on the discovery that Augmenter of Liver Regeneration (“ALR”) is an early marker of these conditions. Accordingly, in other embodiments, the present invention provides for a method of treating sepsis, traumatic/hemorrhagic shock and inflammation by inhibiting ALR. | 04-16-2015 |
20150111223 | METHOD FOR EVALUATION OF PRESENCE OF OR RISK OF COLON TUMORS - The disclosed methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management. The methodology provided herein is intended to detect technical variations and to allow for data normalization and enhance signal detection and build predictive proteins profiles of disease status and response. | 04-23-2015 |
20150118690 | BIOLOGICAL ASSAY SAMPLE ANALYZER - A sample analyzer has an illuminator for illuminating an assay sample to cause luminescence, and a support for a sample vessel containing the assay sample. The support is adapted to position the assay sample proximate the illuminator. A detector is positioned along an optical axis extending from the illuminator, through the positioned assay sample, to the detector, so as to detect the luminescence from the assay sample. A reflector is removably disposed between the illuminator and the assay sample so as to reflect a portion of the luminescence back through the positioned assay sample toward the detector. | 04-30-2015 |
20150118691 | SIMULTANEOUS MEASUREMENT OF THROMBIN GENERATION AND CLOT STRENGTH IN PLASMA AND WHOLE BLOOD - A method for the simultaneous measurement of proteolylic enzyme generation and clot strength in plasma or whole blood or any appropriate biological sample derived from blood. The measurement method encompasses the use of a detectable substrate which includes a moiety that can be released upon reaction with the targeted proteolytic enzyme, and elements for measurement of an increase in viscosity of clot strength. | 04-30-2015 |
20150125876 | BIOMARKER FOR COGNITIVE DYSFUNCTION DISEASES, AND METHOD FOR DETECTION OF COGNITIVE DYSFUNCTION DISEASES USING THE BIOMARKER - The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27. And further aims to provide diagnostic method using these biomarker. | 05-07-2015 |
20150132769 | BIOMARKER FOR DETERMINING MITOCHONDRIAL DAMAGE IN FRIEDREICH'S ATAXIA - Compositions and methods for screening for a disease or a disorder associated with a deficiency in frataxin in a subject using biomarkers for diseases or disorders associated with a deficiency in frataxin are disclosed. The compositions and methods include determining the acetylation status of mito-chondrial proteins. Also disclosed are methods of detecting progression of a disease or a disorder associated with a deficiency in frataxin in a subject and methods of monitoring effectiveness of a therapy for diseases or disorders associated with a deficiency in frataxin. | 05-14-2015 |
20150132770 | PREGNANCY-ASSOCIATED PLASMA PROTEIN-A2 (PAPP-A2) POLYNUCLEOTIDES - The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described. | 05-14-2015 |
20150132771 | COMBINATION OF SPLA2 ACTIVITY AND LP(A) CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT - The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) s PLA2 activity and b) Lipoprotein(a), —combining said measurements, the combined value of s PLA2 activity and Lp(a) being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event. | 05-14-2015 |
20150132772 | Determination of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Diagnostic Marker for Renal Disorders - Methods for diagnosing renal disorders by measuring human neutrophil gelatinase-associated lipocalin (NGAL) are provided. | 05-14-2015 |
20150140573 | ASSAYS FOR DETECTING GLUCOSIDASE ACTIVITY - The present invention relates to a method of detecting α-(1→6)-glucosidase activity in a sample. The method is for example useful for determining the limit dextrinase activity in a sample. The method involves use of an oligosaccharide substrate of the formula X-(glucoside)n-*(glucoside)m-Z—Y, where X is a blocking group, -* is a α-(1→6)-glucosidic linkage and Y is a detectable label. Upon cleavage of the α-(1→6)-glucosidic linkage, the detectable label is released and thus the α-(1→6)-glucosidase activity can be determined. The invention also relates to the oligosaccharide substrate per se. | 05-21-2015 |
20150147762 | METHOD FOR DETECTING CANCER, AND ANTIBODY CAPABLE OF RECOGNIZING PANCREATIC RIBONUCLEASE 1 - Pancreatic cancer can be detected using a monoclonal antibody which binds to pancreatic RNase 1 when a site in pancreatic RNase 1 capable of being modified with an N-glycan chain is not linked to a glycan chain, but which does not bind to pancreatic RNase 1 when an N-glycan chain is linked to the site. Also provided is a monoclonal antibody which can bind to pancreatic RNase 1 simultaneously with the binding of the aforementioned antibody to pancreatic RNase 1, and determining the ratio of A to B using the antibodies, wherein A represents the amount of the site located in the pancreatic RNase 1 capable of being modified with an N-glycan chain, wherein an N-glycan chain is linked or not linked to the site; and B represents the amount of the site located in the pancreatic RNase 1 capable of being modified with an N-glycan chain. | 05-28-2015 |
20150293104 | EPITHELIAL OVARIAN CANCER DIFFERENTIATION MARKER - An object of the present invention is to develop and provide an epithelial ovarian cancer diagnosis marker with which epithelial ovarian cancer can be detected inexpensively, conveniently, and low invasively with high accuracy, and a method for determining the presence or absence of epithelial ovarian cancer using the marker. The present invention provides a glycoprotein having a glycan-linked asparagine residue at a particular site of the glycoprotein secreted from an epithelial ovarian cancer cell, or a fragment thereof having the glycan as an epithelial ovarian cancer diagnosis marker. The present invention also provides a method for determining the presence or absence of epithelial ovarian cancer using the glycoprotein. | 10-15-2015 |
20150301050 | IMMUNO-BASED RETARGETED ENDOPEPTIDASE ACTIVITY ASSAYS - The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed. | 10-22-2015 |
20150323535 | METHOD FOR DIAGNOSING NEURODEGENERATIVE DISEASES - The present invention relates to a method for diagnosing, in vitro, a neurodegenerative disease in an individual, in which: the level of the double-stranded RNA-dependent protein kinase (PKR) in a sample of cerebrospinal fluid from the individual is determined; it is deduced therefrom whether the individual is suffering from a neurodegenerative disease. | 11-12-2015 |
20150329896 | N-END RULE PROTEASE ACTIVITY INDICATION METHODS AND USES THEREOF - A cell based assay for detection for protease activity is disclosed. In the assay a cell is engineered to express a protease substrate with at least one label, preferably on its C-terminus. Cleavage of the substrate by the protease that recognizes it results in a C-terminal fragment and a N-terminal fragment, where the fragment having the label is subject to ubiquitin proteasome degradation. The assay measures the disappearance of the label due to degradation of the fragment to which it is attached. A cell free assay is also described for detection of protease activity. In the cell free assay, the protease substrate is expressed in a solution that includes the elements of the ubiquitin proteasome pathway for degradation of the fragment. The assay measures the disappearance of the label attached to the fragment that results from cleavage by the protease. | 11-19-2015 |
20150330976 | METHOD FOR THE DETECTION AND QUANTITATION OF BIOMARKERS - The invention provides a method for detecting the presence or absence of a biomarker in a biological sample at a very low concentration comprising the steps of (a) contacting the biological sample with a capture binding sequence immobilized on a surface, (b) providing a conjugate comprising a detection binding sequence-glucose oxidase, (c) contacting the surface with the detection binding sequence-glucose oxidase conjugate, (d) separating any unbound detection binding sequence-glucose oxidase conjugate from the surface, (e) incubating the resulting surface with a glucose solution and a mixture comprising gold nanoparticles and a gold salt, wherein the gold nanoparticles have an initial particle size of about 5 nm, and (f) observing any change in color of the mixture. The invention also provides a method for diagnosing the presence of a prostate cancer biomarker in a subject and a kit for detecting or quantifying a biomarker in a biological sample. | 11-19-2015 |
20150338409 | Markers for Abnormal Cells - The present invention relates to methods of determining the presence or absence of abnormal lymphoid cells or abnormal myeloid cells in a cell sample, with the methods comprising subjecting the cell sample to conditions that will activate any inactive matriptase present in the cell sample and measuring the levels of activated matriptase in the cell sample. Once measured, these levels can then be compared to control levels of active matriptase to determine if the cell sample has elevated levels of activated matriptase over control levels of active matriptase. An elevation in the levels of activated matriptase in the cell sample is indicative that the cell sample contains abnormal lymphoid cells or abnormal myeloid cells. | 11-26-2015 |
20150355176 | IMMUNOASSAY METHOD LESS AFFECTED BY IMPURITIES - An object of the present invention is to provide a method of measuring the amount of a compound containing a sugar chain in a biological sample by a sandwich immunoassay method using a labeled lectin, which method is suitable for reduction of noise originating from impurities and determination of the exact amount of a target compound. | 12-10-2015 |
20150361405 | HIGH LEVEL EXPRESSION OF RECOMBINANT TOXIN PROTEINS - The present invention relates to the field of recombinant toxin protein production in bacterial hosts. In particular, the present invention relates to production processes for obtaining high levels of a recombinant CRM197, Diphtheria Toxin, Pertussis Toxin, Tetanus Toxoid Fragment C, Cholera Toxin B, Cholera holotoxin, and | 12-17-2015 |
20150369809 | TARGETING PHOSPHOFRUCTOKINASE AND ITS GLYCOSYLATION FORM FOR CANCER - The present invention relates to methods of treating cancer, suppressing or inhibiting tumorigenesis, tumor growth or cancer progression, and suppressing or inhibiting cancer cells from altering cellular metabolism in favor of cancerous growth. Also provided are compositions comprising an agent that decreases glycosylation of phosphofructokinase 1 or increases phosphofructokinase 1 expression or activity. | 12-24-2015 |
20160011196 | ASSAY TO DETERMINE LRRK2 ACTIVITY IN PARKINSON'S DISEASE | 01-14-2016 |
20160018411 | USE OF SEPRASE FOR DIFFERENTIAL DIAGNOSIS OF ACUTE DYSPNEA - The present invention relates to a method for differentiating in a patient who suffers from acute shortness of breath (acute dyspnea) between pulmonary disease and cardiac disease. The method is based on measuring the levels of seprase and of a cardiac marker in a sample from said patient. Further envisaged are kits and devices adapted to carry out the method of the present invention. | 01-21-2016 |
20160032264 | PREPARATIONS AND METHODS FOR TREATING MALIGNANCIES - Disclosed are therapeutic formulations comprising antibodies against the PEKRAEKIWK (SEQ ID NO:1) epitope of the monomeric isoform of A-protein and a physiologically acceptable carrier. Methods for the treatment of subjects using these therapeutic formulations are also disclosed. | 02-04-2016 |
20160033490 | Linked Peptide Fluorogenic Biosensors - Biosensors, compositions comprising biosensors, methods of producing biosensors, and methods of using biosensors are disclosed. The biosensors comprise a fluorogen-activating peptide and a blocking peptide. The blocking peptide associates with the fluorogen-activating peptide thereby blocking an active domain of the fluorogen-activating peptide. The fluorogen-activating peptide and blocking peptide are covalently linked in certain embodiments through a peptide linker. The peptide linker may contain an amino acid sequence that is specifically recognized as a modification substrate by a cognate enzyme. The fluorogen-activating peptide and the blocking peptide at least partially disassociate when the linker is modified by a cognate enzyme, thereby allowing the fluorogen-activating peptide to bind a cognate fluorogen and modulate a fluorescence signal. | 02-04-2016 |
20160047810 | METHODS TO OBTAIN A NOVEL CLASS OF GRAM NEGATIVE BACTERIA ANTIBIOTICS WHICH TARGET AN UNKNOWN CELL DIVISION ASSOCIATED PROTEIN LOP1 - The present invention relates to methods to identify substances which affect bacterial cell division by interfering with the function of LOP1, comprising bringing into contact a purified protein selected from the group: FtsZ, FtsQ, FtsL, FtsI and FtsN; with purified LOP1 protein and then assaying the formation of complexes between LOP1 and the selected purified protein in the presence and absence of a substance to be tested and then selecting substances from step b) which affect the formation of complexes when present. The present invention also relates to inhibitors of the activity and expression of LOP 1. | 02-18-2016 |
20160053283 | Methods and Compositions for Generating Stable Transfected Cells - Methods and compositions are provided involving high producing cell lines. Embodiments concern efficient methods for screening for such cell lines and for creating such cell lines. These cell lines can be used to create large amounts of protein. To quickly generate large quantity of recombinant proteins or vaccines for both pre-clinical study and clinical trials, almost all drug development will face the same challenging obstacle of rapidly generating a high stable producer. Developing and identifying a stable cell line is a critical part of biopharmaceutical development. | 02-25-2016 |
20160054319 | METHOD FOR DETECTING TRICHOPHYTONS AND ASSOCIATED DISEASES - A method is described for detecting the presence of at least one | 02-25-2016 |
20160077098 | RECOVERY OF ASPARTYL (ASPARAGINYL) BETA HYDROXYLASE (HAAH) FROM AN EXOSOMAL FRACTION OF HUMAN SERA FROM CANCER PATIENTS - The present invention encompasses methods of detecting exosomes comprising Aspartyl-[Asparaginyl]-β-hydroxylase (HAAH). The present invention contemplates is further directed to methods diagnosing cancer by identifying exosomes comprising HAAH. | 03-17-2016 |
20160077099 | NONLINEAR OPTICAL DETECTION OF MOLECULES COMPRISING AN UNNATURAL AMINO ACID POSSESSING A HYPERPOLARIZABILITY - A system for making molecules, and proteins in particular, suitable for detection by a surface-selective nonlinear optical technique. A first use of the invention is for determining a protein's structure in real space and real time. A second use of the invention is to detect a protein or its activity (conformational change). A third use of the invention is for drug screening. A further aspect of the present invention is measuring probe tilt angle orientation in an oriented protein. | 03-17-2016 |
20160083712 | CSN5 POLYPEPTIDES AND USES THEREOF FOR SCREENING THERAPEUTIC AGENTS - The present invention relates to mutated CSN5 polypeptides and their use in a method of screening modulators of CSN5 activity that could be used as therapeutic agents. | 03-24-2016 |
20160097775 | METHODS AND KITS FOR DETECTING MISFOLDED PROTEINS - Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia. | 04-07-2016 |
20160103133 | METHOD FOR DETERMINING PROGNOSIS OF CANCER - The present invention relates to a method for determining prognosis of cancer in a subject, which comprises the step of detecting phosphorylation of a tyrosine residue at position 2681 of TRIO in a sample obtained from the subject. | 04-14-2016 |
20160109430 | METHODS FOR DRUG DISCOVERY - The present invention provides assays for identifying drug candidates that regulate cellular senescence. In particular, the present invention relates to the use of ATRX foci as a biomarker for determining whether one or more drug candidates regulate senescence in a cell line. In one non-limiting embodiment, the present invention provides assays to identify compounds that can be used in a combinatorial cancer treatment. The present invention is based, at least in part, on the discovery that the number of ATRX foci increases in cells that undergo senescence. Accordingly, in non-limiting embodiments, the present invention provides for assays and kits for identifying drug combinations that may be useful in treating subject that have cancer and for identifying compounds that may be useful in treating age-related diseases. | 04-21-2016 |
20160116472 | BIOMARKERS FOR STROKE DIAGNOSIS - Disclosed herein are assays and methods of diagnosing strokes using glycogen phosphorylase-BB (GPBB) as the biomarker. Specifically, assays and methods are described herein for distinguishing an ischemic brain condition from myocardial infarction, or distinguishing an ischemic brain condition from stroke mimics, or distinguishing an ischemic stroke from a hemorrhagic stroke. The diagnostic results offered by these assays and methods allow early and appropriate treatment for the specific condition. Also disclosed is a method to identify whether a subject having an ischemic stroke exhibits salvageable brain tissue. | 04-28-2016 |
20160123982 | METHODS FOR ASSAYING JAK2 ACTIVITY IN RED BLOOD CELLS AND USES THEREOF - The present invention relates to methods for assaying JAK2 activity in a red blood cell. The present invention also relates to methods for diagnosing myeloproliferative neoplasm. | 05-05-2016 |
20160131666 | BIOMARKERS FOR INFLAMMATORY RESPONSE - An in-vitro method for the prediction, prognosis and/or diagnosis of an inflammatory response associated with a condition or disease such as schizophrenia in a subject, the method comprising determining in a sample of a subject the level of 25-hydroxy vitamin D3, preferably in combination with the level of least one biomarker wherein the at least one biomarker is selected from innate chemokine (IL-8) and matrix metalloproteinase (MMP-9); and comparing the levels of said 25-hydroxy vitamin D3 and at least one biomarker to a control level of 25-hydroxy vitamin D3 and the at least one biomarker respectively in order to determine a positive or negative prediction, prognosis and/or diagnosis of said inflammatory response indicating an associated condition or disease, such as schizophrenia. | 05-12-2016 |
20160146817 | DOT1L PROBES - The present invention relates to compound that bind Histone H3-lysine79 (H3K79) methyl transferase (DOTIL). The disclosed compounds are useful as for assessing the activity of DOTIL and for identifying inhibitors of DOTIL. Described herein are probes useful for both assessing the activity of DOTIL and identifying inhibitors of DOTIL. These probes can be used in various assays, including Amplified Luminescent Proximity Homogeneous Assays (“ALPHA” assays), Differential Scanning Fluorimetry (DFS) Assay, and Fluorescence Polarization (FP) assays used for high-throughput screening (HTS) for small molecule drug discovery. The compounds can also be used as a pull down agent for target identification. | 05-26-2016 |
20160153878 | Device and Methods | 06-02-2016 |
20160165878 | SEMINAL PLASMA COMPLEX QUALITY CONTROL MATERIAL, PREPARATION METHOD AND KIT THEREOF | 06-16-2016 |
20160169892 | MONOCLONAL ANTIBODIES, HYBRIDOMA CELL LINES, METHODS AND ASSAYS FOR DETECTING FUNGAL PHYTASE | 06-16-2016 |
20160169893 | PCSK9 Function Assay | 06-16-2016 |
20160178627 | System and Method for Identification and Characterization of Transglutaminase Species | 06-23-2016 |
20160195534 | Enzyme Detection Device | 07-07-2016 |
20160200832 | ASSAY TO DETECT HUMAN DPP-4 | 07-14-2016 |
20160377617 | DETECTION OF THE DEGREE OF EXPOSURE TO CHEMICAL WARFARE NERVE AGENTS AND ORGANOPHOSPHATE PESTICIDES WITH LATERAL FLOW ASSAYS - A sample analysis device used to detect a level of exposure of organophosphorus within a sample comprising a sample collection pad, at least one conjugate zone comprising an anti-analyte antibody that is conjugated with a reporter label, and a control antibody that is conjugated with a reporter label, a blocking and/or test zone comprising an immobilized nanoparticle or other molecule that captures the Organophosphate-bound analyte, a second blocking and/or test zone comprising an immobilized antibody that binds to the unbound analyte and an optional third blocking and/or control zone comprising an immobilized antibody that binds to the control molecule wherein, when the analyte is bound by the Organophosphate in the sample it will bind to the first test line, and if the analyte is “free’ from the Organophosphate it will bind to the second test line, and the control antibody will bind to the control line. | 12-29-2016 |
20160377618 | PCSK9 QUANTIFICATION BY IMMUNODETECTION - The present disclosure relates to, among other things, systems for detecting the level of specific lipoprotein-bound level of PCSK9, and optionally free PCSK9, lipoprotein or portions thereof and/or PCSK9 unbound lipoproteins present in a biological sample. The present invention also relates to methods of assessing the level of specific lipoprotein-bound level of PCSK9, and optionally free PCSK9, Apo B and/or PCSK9 unbound lipoproteins present in a biological sample, determining whether a subject is at increased risk for cardiovascular disease and monitoring the risk for developing cardiovascular disease. | 12-29-2016 |
20160377619 | ANTI-KRS MONOCLONAL ANTIBODY AND USE THEREOF - The present invention relates to an anti-lysyl-tRNA synthetase (KRS) antibody selectively binding to KRS, and a use thereof and, more specifically, to an antibody binding to human KRS or a fragment thereof, a method for producing the same, and a composition containing the same for diagnosing cancer, autoimmune diseases or inflammatory diseases. The antibody or fragment thereof of the present invention specifically binds to human KRS, and enables KRS detection and inhibition due to the absence of cross-linkage reactivity with the other proteins including the same ARS family, and thus the antibody or fragment thereof can be used to detect KRS and diagnose KRS-related diseases, i.e., cancer, autoimmune diseases or inflammatory diseases. | 12-29-2016 |
20170234894 | Noninvasive Body Fluid Stress Sensing | 08-17-2017 |
20190145974 | COMPOSITIONS AND METHODS FOR IMPROVED CELL-BASED BOTULINUM NEUROTOXIN ASSAYS | 05-16-2019 |
20090263866 | Industrial-scale Serum-free Production of Recombinant Factor VII in Mammalian Cells - The invention provides a method for industrial-scale production of FVII polypeptides in mammalian cell culture free of animal-derived components. | 10-22-2009 |
20110171689 | ARTIFICIAL IMMUNE SYSTEM: METHODS FOR MAKING AND USE - The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system. | 07-14-2011 |
20150376293 | Methods of Producing Antibodies Specific for p95 - The invention provides methods of measuring and/or quantifying the presence and/or amount of p95 and/or p95 complex in a sample. The invention also provides antibodies specific for p95, and methods of making such antibodies. | 12-31-2015 |
20160039925 | CELL CULTURE METHODS TO REDUCE ACIDIC SPECIES - The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of acidic species expressed by host cells, as well as to compositions and processes for controlling the amount of acidic species present in purified preparations. | 02-11-2016 |
20160160258 | MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS - A method for producing a clone of an immortalised human B memory lymphocyte, comprising the step of transforming human B memory lymphocytes using Epstein Barr virus (EBV) in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an immortalised human B memory lymphocyte capable of producing a human monoclonal antibody with a desired antigen specificity, comprising the steps of: (i) selecting and isolating a human memory B lymphocyte subpopulation; (ii) transforming the subpopulation with Epstein Barr virus (EBV) in the presence of a polyclonal B cell activator; (iii) screening the culture supernatant for antigen specificity; and (iv) isolating an immortalised human B memory lymphocyte clone capable of producing a human monoclonal antibody having the desired antigen specificity. | 06-09-2016 |